

# EVER 2011

## Crete Oct 5-8

[www.ever.be](http://www.ever.be)

*Programme book*



*Partner in  
Concordia*

*Join  
EVER*



21 CME credits





Lene MARTIN  
EVER President 2011

Dear EVER members, fellow scientists, friends and colleagues!

It is with great pride I welcome you to the 14th annual meeting of the European Association for Vision and Eye Research.

As in previous years EVER offers numerous free papers and posters, with opportunities for discussions and exchanges of ideas. We also have really distinguished keynote speakers, providing updates regarding genetics, immunology, electrophysiology and ocular surface properties.

The numerous special interest symposia (SIS) deal with many topics in the wide field of ophthalmology. In addition, courses and workshops, with many prominent invited speakers, will serve as valuable sources of information for scientists and clinicians alike.

As usual, the dedicated work of section chairs and secretaries, under the wise guidance of our experienced program secretary, have managed to create a rich content and make this meeting a high quality environment for professional and scientific development.

For the second year EVER profits from the superb conference facilities at Creta Maris Convention Center by the beautiful coastline of the Aegean sea.

This agreeable venue certainly adds to the positive EVER experience.

On behalf of the EVER organization I thank you all for coming - and for your contributions to knowledge development in our important field.



# COURSES OVERVIEW

The 14 courses throughout the EVER 2011 congress:

## Wednesday, October 5, 12:00 - 14:15

1. NSPH: The swollen optic disc: Is it true swelling .....	25
2. ACB: In vitro techniques for ocular cell biology and tissue engineering.....	25
3. COS: Common corneal procedures .....	26
4. IM: EBO review course : Intraocular inflammation and infection (Part I).....	26
5. PO: EBO review course : Diagnostic of ophthalmic tumours .....	27

## Wednesday, October 5, 14:30 - 16:45

6. COS: Facial nerve palsy: anatomy .....	28
7. COS: Corneal infectious diseases update .....	28
8. COS: Basic keratoprotheses.....	29
9. IM: EBO review course: Intraocular inflammation and infection (Part II).....	29

## Thursday, October 6, 8:15 - 9:45

10. COS: Corneal ulcerations: from bench to slit lamp .....	36
---	----

## Thursday, October 6, 17:30 - 19:00

11. G: EBO review course: How to begin with the glaucomas? .....	54
12. PO: Crash course in ophthalmic pathology.....	54

## Saturday, October 8, 8:15 - 9:45

13. COS: Optical coherence tomography applications in anterior segment eye diseases .....	89
---	----

## Saturday, October 8, 11:00 - 12:30

14. IM: Angiography and fundus imaging in uveitis: principles & practice.....	95
---	----

# TABLE OF CONTENT

Word from the President .....	1
Courses overview .....	2
EVER Office.....	4
About EVER .....	5
Board Members 2011 .....	7
General Information .....	8
Guidelines.....	11
Grants .....	12
Partnership.....	14
Floor plan .....	16
About the Programme Book.....	17
Programme Committee 2011 .....	18
<b>Monday - Tuesday, October 3-4.....</b>	<b>19</b>
ICO Residency Program Directors Course .....	21
<b>Wednesday, October 5.....</b>	<b>23</b>
Courses.....	25
Opening Ceremony .....	31
<b>Thursday, October 6.....</b>	<b>33</b>
First morning session .....	35
Keynote Lecture: Elias Traboulsi.....	39
Second morning session .....	40
Lunchtime CIS Théa .....	45
First afternoon session.....	47
European Vision Award Lecture: Carlos Belmonte .....	51
Second afternoon session .....	52
Poster session 1.....	57
<b>Friday, October 7 .....</b>	<b>63</b>
First morning session .....	65
EVER-Acta lecture: Per Söderberg .....	68
Second morning session .....	69
Business Meetings of scientific sections .....	73
First afternoon session.....	74
Ophthalmic Research Lecture: Andrew D. Dick .....	78
Second afternoon session .....	79
Poster session 2.....	83
<b>Saturday, October 8.....</b>	<b>87</b>
First morning session .....	88
Keynote Lecture: Rando Allikmets .....	93
Second morning session .....	94
Uveitis Award Ceremony .....	98
Lunchtime CIS Croma.....	99
First afternoon session.....	100
Second afternoon session .....	104
EVER General Assembly and Prize Giving.....	109
Poster session 3.....	111
Presenting first authors .....	119
Presenting authors by country .....	123
Congress Time Schedule .....	124
Sponsors .....	back cover



Marlene Verlaeckt  
Executive Officer



Lies Van Eycken  
Executive Assistant

## Address

Kapucijnenvoer 33, 3000 Leuven, Belgium  
ever@ever.be  
tel +32 16 233 849  
fax +32 16 234 097



IT and website support by RESILION

EVER is a non-profit organisation. The aims of the association are to encourage research and the dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information.

EVER is the largest European scientific organization which covers all subspecialties of ophthalmology and visual sciences. It provides an umbrella for other ophthalmological societies to meet during its annual congress.

## Membership

Membership is open to individuals of any nationality, engaging in or with an interest in ophthalmic and vision research.

Applications for membership - available on [www.ever.be](http://www.ever.be) - may be submitted at any time, membership is on calendar year basis and starts on January 1.

Every member must select one of the 11 Scientific Sections that best represents his or her primary area of interest.

The benefits of EVER membership are:

- submission of abstracts to EVER annual meeting
- reduced registration fee for EVER annual meeting
- organizing Special Interest Symposia (SIS) and courses during the EVER annual meeting
- participating in the EBO review courses
- EACCME granted 21 European CME credits (ECMEC) recognized by the American Medical Association- for the EVER annual meetings
- voting rights for the election of the Board Members (except members-in-training and emeritus members)
- 25 travel grants for best papers to attend the EVER annual meeting
- free electronic subscription to the EVER journal, Acta Ophthalmologica (IF2,909)
- quarterly E-Newsletter
- e-alerts
- member of CONCORDIA

## Elections

This year new representatives of the scientific sections Immunology/Microbiology and Physiology/Biochemistry/ Pharmacology will be elected through electronic voting. Voting 2011 will close on October 7, midnight.

The result of the elections will be announced at the General Assembly on Saturday October 8, 2011.

The scientific sections will hold their Business Meetings on Friday, October 7, 2011 from 12:35 - 13:35. Sandwiches and refreshments are provided. The agenda is available on page 73.


The following 2 sections will nominate at least 2 candidates for the succession of their representatives in the Board of EVER for elections in 2012:

- Cornea / Ocular Surface
- Glaucoma

The term of Secretary General is coming to an end. Elections for a new Secretary General will be open to all full members from 2012 on. The list of candidates will be available on the member's web page.

The statutes and by-laws are available on the website: [www.ever.be](http://www.ever.be) » about » statutes.


## Participants:




Clinical with or without research: 73 %  
Research only: 27 %

## MEMBERS ACCORDING TO SCIENTIFIC SECTIONS

### Main targets



### Full coverage







## Executive committee



Lene MARTIN  
President



Bahram BODAGHI  
Secretary General



Jean-Jacques GICQUEL  
Treasurer



Tero KIVELÄ  
Programme Secretary  
Vice-President



Leopold SCHMETTERER,  
President Elect



Carl HERBERT  
Vice-President Elect



Graham HOLDER  
Past President

## Section chairs



Nadja KNOP  
ACB



Philippe KESTELYN  
COS



Thierry ZEYEN  
G



Carl HERBERT  
IM



Alfred WEGENER  
LC



Bart LEROY  
MBGE



Aki KAWASAKI  
NSPH



Leopold SCHMETTERER  
PBP



Laurence DESJARDINS  
PO



Constantin POURNARAS  
RV



Werner SPILEERS  
VEP

## Regional representatives



Francesco BANDELLO  
Italy



Rimvydas ASOKLIS  
East Europe

## Local representative



Ioannis PALLIKARIS  
Greece, Crete

## Co-opted



Martine JAGER  
Advocacy



## Venue

EVER 2011 will be held at the Creta Maris Convention Center in Hersonissos, Crete, Greece.

⇒ visit the website on [www.maris.gr](http://www.maris.gr)

The scientific programme of the EVER congress starts on Wednesday, October 5 at 12:00 and concludes on Saturday, October 8 at 19:30.



## Cancellation policy

Refunds – up to 75% of the advance registration fee will be granted for cancellation received in writing prior to September 20, 2011. Refunds will not be granted for later cancellations or no-shows.

## Website

The EVER website [www.ever.be](http://www.ever.be) has a central role in the EVER organisation. At this website, you can

- obtain up-to-date information about the scientific programme and the EVER 2011 meeting and view the status (session, hour, place) of your presentation
- pay on-line and obtain an overview of past payments
- look for other EVER members
- access general information about EVER
- access Acta Ophthalmologica, the EVER journal
- [cast your vote for officers](#)
- print your CME certificate after the congress

## Registration

Everyone attending the scientific sessions - whether or not an EVER member, invited speaker, accompanying person or presenter - must register and pay the registration fee.

On-site registration starts on Wednesday, October 5, 09:00.

### Please note that:

- being or becoming an EVER member – or having an abstract accepted – does not imply that you are registered
- if you register as a member-in-training, you need to prove your traineeship with a document signed by the Head of your Department
- registering as an accompanying person entitles you to attend the EVER social events, but not the scientific programme

## Housing / Travel



SUMMERLAND Travel S.A. has negotiated special rates for accommodation in several categories of hotels in the congress venue area.

## Registration fees on-site

	EUR	EUR
EVER member	350	275 *
SIS-invited speaker	350	275 *
Member-in-training	175	140 *
Non-member	570	460 *
Non-member-in-training	280	220 *
Course	50	30 *
Accompanying person	115	115 *

\* Citizens of these listed countries only: Albania, Algeria, Armenia, Belarus, Bosnia and Herzegovina, Bulgaria, Congo, Croatia, Czech Republic, Egypt, Estonia, Georgia, Hungary, India, Iran, Latvia, Libya, Lithuania, Macedonia, Moldova, Montenegro, Morocco, North Korea, Ouzbekistan, Pakistan, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Tunisia, Turkey, Ukraine. The list of countries will be updated annually and is based on the membership roster.

Creta Maris can be reached from Heraklion airport. Transfer from Heraklion airport to your hotel can be booked through the EVER housing bureau SUMMERLAND Travel S.A.: [www.evercrete.gr](http://www.evercrete.gr)

Round trip transfer from/to the airport 30 EUR (per person).

By arrival at Heraklion airport, you will find the SUMMERLAND hospitality desk in the arrival hall.

The transfer takes about twenty minutes.

## Weather

In October, the temperature remains friendly, averaging around 25°C.



## Tourist information

Crete - the largest island in Greece - is an island with an exquisite 1.000 kilometer-long coastline dotted with numerous coves, bays and peninsulas, which afford a multitude of soft, sandy beaches along the beautifully blue Mediterranean Sea. After all, it's among the finest in the world and has established Crete as one of Europe's most popular holiday destinations. And, of course, the island's historic importance in today's world as the home of the Minoan civilization with important archeological finds at Knossos, Phaistos and Gortys, is evidenced by the tens of thousands of visitors to these sites each year.

## Social programme

The social programme is open for all participants and registered accompanying persons:

### Wednesday 19:00

EVER welcome reception at Zeus Terrace

### Saturday 20:00

EVER Farewell dinner in Creta Maris

## Coffee

Included in the registration fee are the coffee and soft drinks throughout the meeting from 09:45 until 11:00 and from 15:30 until 17:25 and the sandwiches and refreshments at the time of section business meetings on Friday 12:35-13:35.

## Internet access

Wi-Fi internet access will be provided in the Convention Center.

## Photographs



It is strictly forbidden to take photographs or videos of the presentations in the lecture Halls.

## Publication of the abstracts

The abstracts of the EVER 2011 congress is published on-line in a special issue of Acta Ophthalmologica, the EVER journal. Access through EVER homepage.

## Business Meetings

EVER Business Meetings of the scientific sections  
Friday, 12:35 - 13:35

- ACB/VEP ..... Athena
- COS ..... Minos 2
- G ..... Minos 1
- IM/NSHP ..... Europa
- LC/PO ..... Danae
- MBGE/PBP ..... Artemis
- RV ..... Zeus

Agenda see page 73

## EVER General Assembly and Prize Giving

Saturday, 18:00 - 19:30 in Zeus

Agenda see page 109

## EVER 2011 congress App for iPhone / iPad



Available on iTunes store



# GENERAL INFORMATION



## Withdrawals

First authors unable to attend EVER for reasons beyond their control, may request permission of the Programme Secretary to have another author present the paper. Alternatively, they should send a written notice of withdrawal to the EVER Office before September 20, 2011.

## No-shows

Please note that any first author, whose paper or poster, once it has been accepted, is not presented without a valid excuse, will be prohibited from presenting papers at EVER for the next two years.

## CME - Continued Medical Education credits

The European Accreditation Council for Continuing Medical Education Institution of the UEMS, EACCME has granted 21 European CME credits (ECMEC) to the EVER 2011 congress on Oct 5-8 in Creta Maris, Crete, Greece.

CME credits certificate can be printed from the EVER website after the congress.

## Liability

The organisers cannot accept liability for personal accidents, loss of or damage to private property of participants and accompanying persons either during, or directly arising from the Meeting. Participants should make their own arrangements with respect to health and travel insurance.



## Poster Prizes

A poster prize of 200 EUR will be awarded for the best poster in each section. An additional VEP poster prize will be generously sponsored by the Alta Eficacia Tecnologia, SL, Spain.

The winners will be chosen by the moderators and will be announced in the General Assembly followed by the prize giving ceremony on Saturday October 8.

Please make sure to attend. No prize will be given after the congress.



## EVER supported SIS

EVER supports the following SIS with 1.000 EUR each:

- Ionizing radiation and cataract, organized by Jochen GRAW
- Doctor I can't see in the dark, organized by Graham HOLDER
- Ocular Rigidity and Hydrodynamics of the Human Eye, organized by Anna DASTIRIDOU and Ioannis G. PALLIKARIS



## Guidelines for speakers and handling presentations

EVER 2011 offers a high-performance network between all the different presentation rooms.

All presenters must read the following instructions:

- Uploading of presentation in [Speakers room](#) starts from Wednesday, October 5, at 11:00.
- The supported software for presentation is PowerPoint, Keynote is not allowed. All presentations will be presented at a resolution of 1024 by 768 pixels. When using videos, WMV and AVI are the most used video formats. Save the videos used in your presentation on your CD/USB memory stick.
- Read the Guidelines for preparation of a Powerpoint presentation.
- [Include your conflict of interest statement in the first slide.](#)
- Oral presentations in the free paper sessions are limited to eight minutes, followed by four minutes of discussion. The session chairman will strictly enforce this schedule.
- Rapid fire presentations should last no longer than 3-4 minutes with a 2 further minutes for questions from the audience. We strongly recommend that you do not use more than 2-3 PowerPoint slides for the rapid fire presentations.
- In the Speakers room, a technician helps the speaker to transfer his or her presentation into the central congress network. When the transfer is complete, the technician performs a quick run of the presentation so the speaker can check whether the presentation runs correctly and all parts of the presentation are copied. Desktop computers will be available at the Speakers room for last minute changes and reviewing your presentation, if needed.
- Inside each presentation room, a technical assistant starts each presentation at the right time using one of our fixed computers connected to the central congress network. When the presentation is launched, the speaker has control and can navigate with a remote device.
- We do not allow the use of personal laptops for presentations. If you bring your laptop to the congress, the technician will copy the files on your hard disk of the laptop into the central congress network, so the laptop will no longer be needed. Of course, the easiest way is to bring your presentation on CD, DVD or memory stick. E-mailing or up-loading of presentations is not encouraged but can be used in special circumstances.
- Download the EVER 2011 Master Slide freely available for your presentations.

At the end of the congress, all presentations will be deleted so that no copyright issues will arise.

## Guidelines for posters

Posters must be brought to the congress by the presenting author and should not be mailed in advance. The required dimensions are 190 cm (width) by 95 cm (height).

[NOTE: Landscape shape. Include your conflict of interest statement in your poster.](#)

Each printed poster is exhibited for one day only. All posters should be erected between 08:00 and 09:00 on the day of presentation and must not be removed until 19:00. EVER is not responsible for any poster left behind at the end of the day.

You are required to stand beside your poster during the poster session. On Thursday and Friday from 16:15 to 17:25, on Saturday from 15:20 to 16:25. During this time, moderators will be voting which poster should win the poster prize.

Some authors of posters, selected by the programme committee, will be invited to give a brief rapid fire oral presentation.

[All posters have to be presented in printed form. You have an option of submitting your poster also electronically. The e-posters will be display throughout the meeting.](#)



## EVER listed countries travel grants

We are pleased to announce that the following 15 members younger than 40 year in age from listed countries will receive a travel grant for the amount of 400 EUR:

- **ACB - Réka ALBERT - Hungary**  
3136 - Mesenchymal-like stem cells from human corneal stroma grown in medium containing human serum as the only supplement
- **RV - Adrienne CSUTAK - Hungary**  
357 - Diabetic retinopathy screening with computational support
- **COS - Dariusz DOBROWOLSKI - Poland**  
4374 - Cultivated oral mucosa epithelium transplantation (COMET) in bilateral limbal stem cell deficiency
- **LC - Marie KALFERTOVA - Czech Republic**  
254 - Evaluation of posterior capsule opacification after cataract surgery using liquifaction method
- **MBGE - Gergely LOSONCZY - Hungary**  
261 - Identification of novel germline mutations in the VHL gene in Hungarian von Hippel-Lindau patients
- **RV - Anna MACHALIŃSKA - Poland**  
3216 - AMD and atherosclerosis coincidence: the role of complement system activation and endothelial dysfunction
- **MBGE - Ireneusz MAJSTEREK - Poland**  
265 - Evaluation of MMP-1 gene expression variants as a risk factor of primary open-angle glaucoma
- **MBGE - Dorota NOWAK - Poland**  
260 - Analysis of locus 2q13 in Ecuadorian family with keratoconus
- **PO - Mykolas PAJAUJIS - Lithuania**  
437 - Anterior segment OCT and histopathologic data in conjunctival, limbal and subconjunctival tumours
- **VEP - Przemyslaw PAWLOWSKI - Poland**  
464 - Electrophysiological assessment of fundus albipunctatus
- **G - Donatas PETROSKA - Lithuania**  
235 - Digital analysis of the trabecular pigmentation using positive pixel count algorithm
- **RV - Simona STECH - Lithuania**  
340 - Responce to intravitreal bevacizumab for macular edema following central retinal vein occlusion in patients with pseudoexfoliation syndrome
- **RV - Katalin TOTH-KOVACS - Hungary**  
3211 - Association of Alzheimer's disease and age-related macular degeneration
- **NSPH - Magdalena WASIK - Poland**  
309 - Relationship between optical coherence tomography and visual evoked potentials in patients with parasellar tumours without chiasmal compression
- **RV - Olesya ZIYATDINOVA - Russia**  
3217 - Ranibizumab for the treatment of exudative age-related macular degeneration associated with retinal pigment epithelial detachment







## EVER travel grants

We are pleased to announce that the following 11 members have received a travel grant of 500 EUR each from the EVER Sections:

- **ACB - Goran PETROVSKI - Hungary**  
2132 - Resveratrol, rapamycin and MG-132 as inducers of autophagy in ARPE-19 cells
- **COS - Claudia CURCIO - Italy**  
4372 - CREB is involved in growth of pterygia
- **G - Omar MAHROO - UK**  
4151 - Outcomes of trabeculectomy with transconjunctival application of mitomycin C
- **IM - Magdalena BAZEWCZ - Belgium**  
429 - Effect of SOCS1 overexpression on RPE cells activated by cytokines
- **LC - Marzieh KOHANDANI TAFRESHI - France**  
2365 - Semi-automatic 3D reconstruction of the anterior segment from high frequency ultrasound scans
- **MBGE - Pete WILLIAMS - UK**  
2121 - Changes in retinal neuronal connectivity in a mouse model of dominant optic atrophy
- **NSPH - Hafid KHAYI - France**  
306 - Association between non-arteritic anterior ischaemic optic neuropathy and sleep apnoea syndrome
- **PBP - Sarah VAN DE VELDE - Belgium**  
3323 - Topical application of AMA0076, a locally acting rho kinase (ROCK) inhibitor, results in a robust IOP control in a hypertensive rabbit model
- **PO - Mieke VERSLUIS - The Netherlands**  
3362 - ERK activation and monosomy 3 are associated with Src expression in uveal melanoma and may serve as biomarkers for dasatinib treatment
- **RV - Matus REHAK - Germany**  
4112 - The effect of anti-VEGF treatment and triamcinolone in experimental retinal vein occlusion
- **VEP - Guillermo PEREZ - Spain**  
4325 - Assessing the wavelength dependence of intraocular scattering by a new optical approach



## Alta Eficacia Tecnología SL, Spain, travel grant

Alta Eficacia Tecnología is pleased to announce a travel grant of 400 EUR for the best paper in the VEP section

- **Christian CASANOVA - Montreal**  
4321 - Spatio-temporal responses in the visual cortex evoked from first and higher order thalamic nuclei in tree shrews: a voltage sensitive dyes study



## In CONCORDIA pro VISU

The following societies collaborate with EVER to unify European ophthalmology by promoting quality education in ophthalmology and its scientific foundations:



**EBO - European Board of Ophthalmology**

The European Board was founded in 1992 to guarantee the highest standards of care in ophthalmology in the countries of the European Union by ensuring that the training is raised to the best possible level. It makes recommendations regarding the standards and syllabus for training ophthalmologists, assesses the content and quality of training by site visits and the annual EBO Diploma Examination, facilitates the exchange of trainees and teachers, and promotes CME in ophthalmology. EBO works under the Section of Ophthalmology of the European Union of Medical Specialists (UEMS). During the EVER meeting, EBO organises review courses open to all delegates since 2007, see pages 26, 27, 29 and 53.

[ebo-online.org](http://ebo-online.org)



**EUPO - European University Professors of Ophthalmology**

EUPO is the organiser of the annual structured subspecialty course for residents in training in Europe since 1988. Most of the ophthalmology curriculum is covered over a 4 year period to allow residents to get an overview of theoretical knowledge during their residency rotation. EUPO courses are held in different places in Europe. The EUPO 2012 course will be on neuro-ophthalmology and strabismus and will take place in Leuven, Belgium.

[www.eupo.eu](http://www.eupo.eu)



**EVER - European Association for Vision and Eye Research**

We aim to encourage research and the dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information. EVER is the leading ophthalmological research association in Europe which covers all areas of ophthalmology and the visual sciences. EVER currently has members from over 50 countries and is represented by 11 scientific sections. One of the main activities of EVER is the organizing of a high quality research meeting every October at a location chosen for its access and its agreeable autumn climate. EVER collaborates closely with other societies and encourages them to convene annually with EVER.

In 2010, the EVER Foundation was created to raise money to promote these goals, [www.ever-f.eu](http://www.ever-f.eu).

[www.ever.be](http://www.ever.be)



**SOE - Societas Ophthalmologica Europea**

SOE aims to promote ophthalmology in Europe and to stimulate co-operation between European ophthalmologists and between their National Societies. Today, its mission is to become a central point in European ophthalmology through education and by fostering collaboration with subspecialty societies and supranational organisations both within Europe and beyond.

[www.soevision.org](http://www.soevision.org)

## Long time partners

The following societies are long time partners in the EVER programme



### ARVO - Association for Research in Vision and Ophthalmology

In many senses the counterpart of EVER in North America, the purposes of ARVO are to encourage and assist research, training, publication, and dissemination of knowledge in vision and ophthalmology. EVER and ARVO are collaborating in many fields, including an ARVO symposium held every year in EVER and an EVER symposium held in ARVO since 2005, see page 36.

[www.arvo.org](http://www.arvo.org)



### FRO - Belgian Fund for Research in Ophthalmology

The aim of the FRO association is to stimulate research in ophthalmology and in visual function by awarding grants to research projects carried out under order of Belgian institutions. The FRO candidates have presented their research work to an international jury during the EVER congress since 2002, see pages 75 and 79.

[www.fro-online.org](http://www.fro-online.org)



### ISCEV - International Society for Clinical Electrophysiology of Vision

ISCEV was founded in 1958 to promote co-operation and communication amongst workers in the field of clinical and basic electrophysiology. There are about 400 members who are physicians, scientists, engineers, optometrists and other professional personnel. Its major symposium is held annually at different venues throughout the world. The European Chapter of ISCEV has met with EVER since 1998, see page 104.

[www.iscev.org](http://www.iscev.org)



### IUSG - International Uveitis Study Group

The International Uveitis Study Group (IUSG) was formed in 1978 by a small number of clinicians who shared a common interest in uveitis. Over the next 30 years the group has increased in size to over 80 uveitis specialists from all over the world. The IUSG comprises researchers and clinicians who are committed to stimulate, encourage, and intensify a concerted effort in research and clinical management of uveitis, with the goal of developing new methods for the diagnosis, treatment, and prevention of the blinding complications of uveitis, see pages 97 and 105.

[www.iusg.net](http://www.iusg.net)



### KPro Study Group

The KPro Study Group was established in 1990 to foster clinical and basic research on keratoprosthesis, synthetic corneas and artificial corneal implants. This International Group aims to foster the development and improvement of keratoprosthesis worldwide for the benefit of eyecare and patients. The KPro Study Group is collaborating with EVER since 2004. See page 96.

[www.kpro.org](http://www.kpro.org)



### OOG - The Ophthalmic Oncology Group

OOG is an independent scientific workgroup devoted to basic and clinical ophthalmic oncology. It has convened with EVER since 1998. The aims of the OOG are to improve the practice of ophthalmic oncology in Europe, develop internet-based databases to share scientific information, organise multicenter studies and quality control studies, and meetings and other activities with the aim of improving the treatment of eye tumours and knowledge about them. OOG encourages all EVER delegates to take part in its sessions, see pages 97, 102 and 107.




### SOIE - Society for Ophthalmology-Immunoinfectiology in Europe


The aims are to form an association of ophthalmologists and other doctors or scientists having an interest in the field of ophthalmology-Immunology and to share mutual experiences in order to contribute to the progress of each member in this field, to promote education by organising or sponsoring symposia or courses or by contributing to publications in this field and to promote contacts between clinical centres in order to realise collaborative studies. SOIE is collaborating with EVER since 2008. See page 41.

[www.soie-soif.org](http://www.soie-soif.org)

## Level 0





## Level -1



- 1 Pre-registration
- 2 Onsite-registration
- 3 Housing/Travel desk

## This programme book is organised chronologically



## The sessions are colour-coded

Special Interest Symposium (SIS)

Keynote Lecture

Workshop

Free Papers (FP)

General Assembly & Business Meeting

Poster Session

Joint Meeting

Course

Social

Commercial Interest Symposium (CIS)

FP = Free Paper session

SIS = Special Interest Symposium

CIS = Commercial Interest Symposium

 = EVER travel grant recipient

 = EVER listed countries travel grant recipient

 = Alta Eficacia Tecnología SL, Spain, travel grant recipient

*rf* = Rapid Fire presentation

★ Conflict of interest disclosed

## Scientific sections

ACB = Anatomy/Cell Biology

COS = Cornea/Ocular Surface

G = Glaucoma

IM = Immunology/Microbiology

LC = Lens and Cataract

MBGE = Molecular Biology/Genetics/ Epidemiology

NSPH = Neuro-ophthalmology/Strabismology/Paediatric Ophthalmology/History of Ophthalmology

PBP = Physiology/Biochemistry/Pharmacology

PO = Pathology/Oncology

RV = Retina/Vitreous

VEP = Vision Sciences/Electrophysiology/Physiological Optics



Programme Committee meeting, July 2011


## Section programme secretaries

ACB	Anatomy/Cell Biology	Ulla AAPOLA
COS	Cornea/Ocular Surface	Jean-Jacques GICQUEL
G	Glaucoma	Sayeh POURJAVAN
IM	Immunology/Microbiology	Piergiorgio NERI
LC	Lens and Cataract	Ralph MICHAEL
MBGE	Molecular Biology/Genetics/Epidemiology	Marzena GAJECKA
NSPH	Neuro-ophthalmology/Strabismus/Paediatric Ophthalmology/ History of Ophthalmology	Andrzej GRZYBOWSKI
PBP	Physiology/Biochemistry/Pharmacology	Neville OSBORNE
PO	Pathology/Oncology	Karin LÖFFLER
RV	Retina/Vitreous	Catherine CREUZOT-GARCHER
VEP	Vision Sciences/Electrophysiology/Physiological Optics	Miguel CASTELO-BRANCO
Programme secretary		Tero KIVELÄ
Programme secretary elect		Marcela VOTRUBA





Monday Oct 3  
Tuesday Oct 4







## Two Days Ophthalmology Residency Program Directors Course in Crete, Greece

The International Council of Ophthalmology (ICO) has a long experience in Residency Programs Directors Educational Courses all over the world. The interactive approach of these courses has allowed participants to acquire practical information and skills, and it improves their residency-training program. Several countries have formed residency program directors' groups to continue efforts in enhancing resident education.

The first course of this kind in Greece will take place at Hersonissos, Heraklion, Crete, Greece, on October 3-4, 2011 at Terra Maris Hotel, [www.maris.gr](http://www.maris.gr), just prior to the EVER Meeting. The Course is organized by the ICO with the support of the University Eye Clinic of Heraklion, Crete and the Confederation of the Greek Ophthalmological Societies.

The Residency Program Director's Course is designed to improve the participants' teaching and assessing effectiveness. There will be valuable presentations and resources related to new methodologies of residency training.

The meeting is based on active participation. Teaching methods include lecture (25%), small group discussion (35%), and large group discussion (40%). Major topics include adult learning principles, curriculum design, resident assessment and improving teaching skills.

Participants should possess the following qualities:

1. Speak and understand English
2. Be involved with residency education
3. Be interested in improving the quality of their educational program
4. Enthusiastically participate in discussion groups

We encourage all ophthalmologists involved in training programs to participate. We are confident that by attending this course they will benefit through the presentations, resources and discussions with colleagues.

Thanks to the support of the ICO, the University Ophthalmological Clinic of Crete and the EVER, the participants will be able to attend the Course with no registration fees. Moreover, participants who will attend the Course will be able to register in the EVER meeting with a reduced fee.

Looking forward to seeing you in Crete

I G Pallikaris, M K Tsilimbaris, B Spivey, K Golnik



*Science for Sight*



# Wednesday Oct 5







## COURSE 1 THE SWOLLEN OPTIC DISC: IS IT TRUE SWELLING, WHAT CAUSES IT AND HOW TO INVESTIGATE IT

Zeus

NSPH

Aki KAWASAKI

Intermediate

This course will provide the attendee the information necessary for evaluating and investigating the patient with unilateral or bilateral optic disc swelling. A series of didactic lectures will review the important points of the history, examination, differential diagnosis and investigative approach. Thereafter, a series of unknown cases will be presented to the audience who will use the information given in the preceding lectures to discuss and solve the case. Each case will emphasize a specific aspect of the evaluation that is important to the differential diagnosis or will highlight a particularly urgent diagnosis that should not be missed. The cases will progress in increasing difficulty so that the attendee learns to use the clues from the history and examination to decide the best approach for determining the cause.

The aim of this course is to give the attendee a practical, updated and multilevel approach to the swollen optic disc in a format that includes both formal teaching and interactive case discussion with experienced experts in the field of neuro-ophthalmology.

12:00	★	1211	Unilateral optic disc swelling: history and examination KAWASAKI A–Lausanne
12:40		1212	Unilateral optic disc swelling: differential diagnosis and evaluation GOLNIK K–Cincinnati
13:20			Break
13:35		1213	Bilateral optic disc swelling: differential diagnosis and approach to investigation LEE AG–Houston

## COURSE 2 IN VITRO TECHNIQUES FOR OCULAR CELL BIOLOGY AND TISSUE ENGINEERING

Artemis

ACB

Hannu UUSITALO, Ulla AAPOLA

Intermediate

In vitro methods like cell and tissue cultures are an essential part of basic and translational eye research. These techniques can be used as tools in ocular cell and molecular biology. They have, however an increasing role in disease modeling and tissue engineering. The course will give an overview of vitro techniques used in modern cell and molecular biology. The use of various ocular immortalized cell lines and differentiated pluripotent stem cells in cell biological research, ocular pharmacology, toxicology and tissue engineering will be covered.

12:00		1221	In vitro techniques for ocular cell biology and tissue engineering UUSITALO H–Tampere
12:30		1222	In vitro methods, biomarkers and proteomics in eye research BEUERMAN RW, WEON SR, CHEW J, ZHOU L, ZHU HY, RIAU AK–Singapore
13:00			Break
13:15		1223	How to study autophagy in RPE cells? KAARNIRANTA K–Kuopio
13:45		1224	In vitro techniques for assessing differentiation and functionality of human pluripotent stem cell -derived RPE cells JUUTI-UUSITALO K–Tampere

### COURSE 3 COMMON CORNEAL PROCEDURES COS

Harminder S DUA, Jean-Jacques GICQUEL

Athena

Intermediate

The cornea is the first part of the eye that light passes through and is responsible for the majority of the focusing power of the eye (even more than the lens). Just like any other tissue in the body, the cornea is susceptible to inflammation, infections, degenerations, inherited diseases and trauma. Some common cornea procedures include pterygium removal, superficial keratectomy (polishing the superficial part of the cornea to remove diseased tissue) and various forms of corneal transplantation.

12:00	1231	Modern pterygium surgery DUA H–Nottingham
12:24	1232	Limbal stem cell transplantation techniques GICQUEL JJ–Poitiers
12:48	1233	Penetrating keratoplasty DIGHIRO P–Poitiers
13:12		Break
13:27	1234	Anterior and posterior lamellar keratoplasty NUBILE M–Chieti
13:51	1235	Indications and limitations of amniotic membrane transplantation DUA H–Nottingham

### COURSE 4 EBO REVIEW COURSE: INTRAOCULAR INFLAMMATION AND INFECTION (PART I)

Bahram BODAGHI, Carl P HERBORT

Europa

Intermediate



The aim of this course is to review major topics of intraocular inflammations and infections. A paper composed of multiple choice questions will evaluate the basic knowledge of the participants initially. The test will be followed by 6 consecutive general presentations for the understanding of different uveitis features. The pathophysiology will be described and different classifications will be presented. Clinical characteristics are highlighted. Diagnostic tests are discussed and imaging techniques will revisit the

pathophysiology of different entities involving the retina and the choroid. Important points will be discussed during each practical situation. The course will be interactive allowing general discussion and the participation of the audience. It will be basic and aimed at pathologies that are frequent.

12:00		Pre-test (MCQs)
12:30	1241	Pathophysiology of uveitis DICK A–Bristol
12:45	1242	Classification of uveitis ANDROUDI S–Thessaloniki
13:00	1243	Symptoms and signs of anterior uveitis NERI P, ARAPI I–Ancona
13:15	1244	Symptoms and signs of posterior uveitis KHAIRALLAH M, KAHLOUN R–Monastir
13:30	1245	Laboratory work-up and specialized investigations PLEYER U–Berlin
13:45	1246	Imaging: techniques and indications HERBORT C–Lausanne

**COURSE 5 EBO REVIEW COURSE: DIAGNOSTICS OF OPHTHALMIC TUMOURS**  
**PO**

Laurence DESJARDINS, Bertil DAMATO

Danae

Advanced



The aim of the course is provide a practical guide to the diagnosis of ophthalmic tumours by clinical examination and judicious use of ancillary tests. Most intraocular tumours can usually be diagnosed by ophthalmoscopy, with the aid of investigations such as ICG and fluorescein angiography, ultrasonography and OCT. Biopsy of intraocular tumours is valuable in selected cases, but special measures are necessary to obtain the best results. Diagnostic algorithms that are specific for adnexal (lid, conjunctiva, orbit) tumours will

be presented. Strategies for the diagnosis of retinoblastoma and phakomatoses will be described. Consideration of the differential diagnosis is especially important and this aspect of patient management will also be considered.

12:00	1261	Diagnosics of adult ophthalmic tumours: role of clinical history, symptoms and signs KIVELÄ T–Helsinki
12:20	1262	Diagnostic tools for adult intraocular tumours ZOGRAFOS L–Lausanne
12:40	1263	Technique and role of biopsies in intraocular tumours DAMATO BE, COUPLAND SE–Liverpool
13:00		Break
13:15	1264	Diagnostic techniques for adnexal tumours SEREGARD S–Stockholm
13:35	1265	Diagnosics of retinoblastoma DESJARDINS L–Paris
13:55	1266	Diagnosics of phakomatosis BECHRAKIS NE–Innsbruck

## COURSE 6 FACIAL NERVE PALSY: ANATOMY, ETIOLOGY, EVALUATION AND MANAGEMENT

Zeus

**COS** Ioannis MAVRIKAKIS

Intermediate

This course will present the facial nerve anatomy, etiology, ocular complications and treatment of facial nerve palsy. At the conclusion of the course, the attendee will be able to evaluate and provide comprehensive management for patients with facial nerve palsy. In addition, theoretical knowledge of surgical techniques will be obtained.

14:30	1311	Anatomy & etiology DETORAKIS ET—Heraklion
14:54	1312	History of disease, facial nerve grading systems & clinical evaluation MAVRIKAKIS I—Athens
15:18	1313	Management of corneal exposure & lagophthalmos BOBORIDIS K—Thessaloniki
15:42		Break
15:57	1314	Management of epiphora & facial synkinesis CHALVATZIS N—Bristol
16:21	1315	Periocular cosmesis & facial dynamic procedures PANTELIDIS E, LINARDOS EP, PANTELIDIS EMM—Athens

## COURSE 7 CORNEAL INFECTIOUS DISEASES UPDATE

Artemis

**COS** Jean-Jacques GICQUEL, Harminder S DUA

Intermediate

Acanthamoeba keratitis, infectious crystalline keratopathy, fungal keratitis and atypical mycobacterial keratitis have emerged as important types of infectious keratitis. These corneal infections have often been associated with contact lens wear, with corneal surgery such as radial keratotomy or penetrating keratoplasty and with the uncontrolled use of topical steroids. The clinical setting of each of these infections is important in alerting the clinician to the possible diagnosis. There have been improvements in rapid diagnostic techniques for such infections in the last years. Treatment has also improved, but remains a difficult problem, especially for Acanthamoeba. In this course, we'll give you an overview of recent developments in the clinical and histopathologic methods for diagnosis and treatment options of these corneal infections.

14:30	1321	Corneal bacterial infections GICQUEL JJ—Poitiers
14:54	1322	Herpes ans Zoster keratitis LABETOULLE M—Le Kremlin-Bicêtre
15:18	1323	Fungal infections KESTELYN P—Ghent
15:42		Break
15:57	1324	Can amniotic membrane help treating severe corneal infections DIGHIERO P—Poitiers
16:21	1325	Infectious crystalline keratopathy and its management DUA H—Nottingham

## COURSE 8 BASIC KERATOPROSTHESES

### COS

Christopher LIU

Athena

Intermediate

Keratoprostheses are artificial cornea. The subject is highly specialised but has entered mainstream clinical ophthalmology in the last few years. This course aims to introduce candidates to basics of the osteo-odonto-keratoprosthesis and the Boston Type 1 keratoprosthesis. Patient assessment, brief description of surgery, recognition and treatment of complications will be covered. After the course, a candidate should be able to refer suitable cases, and enter into shared care with a KPro centre.

14:30	1331	Introduction to KPros LIU CS—Brighton
14:45	1332	Patient assessment LAM FC—Brighton
15:00	1333	Psychological assessment BUSUTTIL A—Hastings
15:15	1334	Osteo-odonto-keratoprosthesis - surgical technique and complications LIU CS—Brighton
15:30		Break
15:45	1335	Boston Type 1 KPro - patient selection LAKE D—East Grinstead
16:00	1336	Boston Type 1 KPro - surgical technique CORTINA S—USA
16:15	1337	Management of Boston Type 1 KPro complications ETXEBARRIA J—Spain

## COURSE 9 EBO REVIEW COURSE: INTRAOCULAR INFLAMMATION AND INFECTION (PART II)

IM

Bahram BODAGHI, Carl P HERBORT

Europa

Intermediate



The first part on general aspects of uveitis will be followed by a quiz and case presentations in different basic or more challenging situations. Important points will be discussed during each practical situation. The course will be interactive allowing general discussion and the participation of the audience. It will be intermediate and present entities that are frequently observed in routine.

14:30	1341	Infectious anterior uveitis PLEYER U—Berlin
14:45	1342	Infectious posterior uveitis MARKOMICHELAKIS N—Athens
15:00	1343	Pediatric uveitis BODAGHI B—Paris
15:15	1344	B27-associated uveitis WILLERMAIN F—Brussels
15:30	1345	Behçet disease, sarcoidosis, VKH ABU EL ASRAR A—Riyadh
15:45	1346	White dot syndromes: from MEWDS to serpiginous choroiditis HERBORT C—Lausanne
16:00	1347	Complications of uveitis and their management NERI P, ARAPI I—Ancona
16:15	1348	Immunosuppression and biologic agents DICK A—Bristol
16:30		Take home messages BODAGHI B—Paris





17:00 - 17:15    Welcome by the President EVER 2011    Zeus  
**Lene MARTIN - President 2011**



17:20 - 18:00    EVER Lecture    Zeus  
 Spot the difference! The electrophysiological differentiation of retinal  
 fleck and spot disorders  
**Graham HOLDER - Past-President**  
 Introduction by Lene MARTIN



18:05 - 18:20    European Ophthalmologic Heritage Lecture    Zeus  
 The development of microkeratomes from the very early ages, with handmade  
 and mechanical systems, until the fempto - laser technology today  
**Ioannis PALLIKARIS - Heraklion, Crete**  
 Introduction by Tero KIVELÄ



18:25 - 19:00    Keynote lecture    Zeus  
 Ocular surface and refractive surgery  
**Béatrice COCHENER - Brest**  
 Introduction by Jean-Jacques GICQUEL



19:00 - 21:00    **Welcome Reception**    Zeus Terrace






*Science for Sight*



# Thursday Oct 6





SIS  
RV**CHOLESTEROL AND RETINA: NEWS AND VIEWS**

Lionel BRETILLON

Zeus



08:15	2111	Cholesterol from diet to the retina LECERF JM–Lille
08:37	2112	Metabolism of cholesterol in health and disease of the retina BRETILLON L–Dijon
08:59	2113	Cholesterol, drusen and AMD RUDOLF M
09:21	2114	Cholesterol and neurodegeneration PFRIEGER FW–Strasbourg

FP  
MBGE**FUNCTIONAL STUDIES OF CELLULAR & MOLECULAR DYSFUNCTION**

Seang-Mei SAW, Graeme C M BLACK

Artemis

08:15	2121	Changes in retinal neuronal connectivity in a mouse model of dominant optic atrophy WILLIAMS P, VON RUHLAND C, MORGAN J, VOTRUBA M–Cardiff
08:27	2122	Visual impairment in Leber hereditary optic neuropathy carriers of the same family REIS A, MATEUS C, SILVA ED, CASTELO-BRANCO M–Coimbra
08:39	2123	Retinal ganglion cell neurodegeneration in mitochondrial optic neuropathies: a comparative structural study MATEUS C, REIS A, SILVA ED, CASTELO-BRANCO M–Coimbra
08:51	★ <i>rf</i> 2124	Pupillometric quantification of residual rod and cone activity in patients with visual loss due to Leber congenital amaurosis KAWASAKI A, MUNIER FL, LEON L, KARDON RH–Lausanne, Nantes, Iowa City
08:57	2125	Functional aspects of hyperautofluorescent ring in retinal dystrophies HAWLINA M, LENASSI E, FAKIN A, JARC VIDMAR M, BRECELJ J–Ljubljana
09:09	2126	Beijing Eye Public Health Care Project JONAS JB, XU L, CUI TT, YOU QS, WANG YX, YANG H, LI JJ, WEI WB, LIANG QF, WANG S, YANG XH, ZHANG L–Mannheim, Beijing

FP  
ACB**RETINAL CELL GROWTH, DEATH AND SURVIVAL**

Arto URTTI, Neville OSBORNE

Athena

08:15	2131	Inhibition of mitochondrial complex IV in cell death and the influence of light OSBORNE N–Oviedo
08:27	2132	Resveratrol, rapamycin and MG-132 as inducers of autophagy in ARPE-19 cells PETROVSKI G, BERENYI E, ALBERT R, MOE MC, FESUS L, BERTA A–Debrecen, Oslo
08:39	2133	Quantification of GFAP and NF-200+ retinal ganglion cells in contralateral mice retina to experimental glaucoma ROJAS B, DE HOZ R, SALAZAR JJ, RAMIREZ AI, GALLEGO BI, RAMIREZ JM, SALINAS-NAVARRO M, ORTIN-MARTINEZ A, TRIVINO A–Madrid, Murcia
08:51	2134	MHC-II glial upregulation in contralateral mice retina to experimental glaucoma GALLEGO BI, DE HOZ R, RAMIREZ AI, SALAZAR JJ, ROJAS B, TRIVINO A, VALIENTE-SORIANO FJ, SALINAS-NAVARRO M, RAMIREZ JM–Madrid, Murcia
09:03	2135	A hypothesis about structural changes of the posterior pole based on scleral deformation during ocular movements THEOCHARIS IP–Athens
09:15	<i>rf</i> 2136	AICAR induces autophagy in ARPE-19 cells KAARNIRANTA K, VIIRI J, AMADIO M, HYTTINEN J, PAIMELA T, RYHÄNEN T, MARCHESI N, AKHTAR S, PASCALE A, PETROVSKI G, SALMINEN A–Kuopio, Pavia, Riyadh, Debrecen
09:21	<i>rf</i> 2137	BDNF-deficiency upregulates SIRT2 expression but does not affect cellular metabolism in mouse retina PODRACKA L, VEHANEN K, TUULOS T, RÖNKKO S, KAARNIRANTA K, UUSITALO H, KALESNYKAS G–Kuopio, Tampere

**JOINT M. IM EVER/ARVO: ANTIGEN PRESENTING CELLS IN THE EYE IN HEALTH AND DISEASE**

Europa

Sally ATHERTON



08:15	2141	T Cells and the eye DICK A—Bristol
08:37	2142	Macrophages and the eye JAGER MJ—Leiden
08:59	2143	Conjunctival antigen presenting cells: sentinels for ocular surface inflammation NIEDERKORN J—Dallas
09:21	2144	PMNs and the eye ATHERTON S, ZHENG M—Augusta

**COURSE 10 CORNEAL ULCERATIONS: FROM BENCH TO SLIT LAMP**

Minos 1

Eric GABISON, Serge DOAN

Intermediate

A corneal ulceration is defined as a disruption of the epithelial layer with involvement of the corneal stroma. A common initiating event in corneal ulcerations of various etiologies including tear film anomalies, toxic reactions, neurotrophic or inflammatory disorders is a delay in epithelial closure leading to a persistent epithelial defect (PED). In the absence of healing, PED progresses toward basement membrane disruption which is a prerequisite for stromal thinning. Proteinases such as the matrix metalloproteinases are known to be overexpressed and have been implicated as mediators in the pathogenesis of this corneal disorder, tilting the ECM remodeling towards proteolysis. The management of corneal ulcerations requires the precise recognition of all the different risk factors involved in delayed corneal healing. Medical and surgical management of this ocular surface disorder may involve the exclusion of any potential iatrogenic treatment, anti-infective agents, epithelial debridement, autologous serum application, inlay or overlay amniotic membrane grafting and lamellar or penetrating keratoplasties. This interactive course will provide updates on the pathogenesis and the therapeutic management of corneal ulcerations.

08:15	2151	From persistent epithelial defect to corneal ulceration: induction of proteases and epithelial-stromal interactions MENASHI S—Paris
08:39	2152	Corneal ulcerations associated with allergy and meibomian gland dysfunctions DOAN S—Paris
09:03	2153	Infectious corneal ulcers: pathogenesis and management BOURCIER T—Strasbourg
09:27		Break
09:42	2154	Herpes simplex and Herpes zoster - associated corneal ulcerations LABETOULLE M—Le Kremlin-Bicêtre
10:06	2155	Therapeutic approach in sterile corneal melts GABISON EE—Paris



SIS  
LC

## IONIZING RADIATION AND CATARACT

Jochen GRAW

Danae



The lens of the eye is recognized as one of the most radio-sensitive tissues in the human body and cataracts are known to be initiated by exposures to relatively low doses of ionising radiation. Recent work on survivors of the Hiroshima atomic bomb and the Chernobyl atomic power plant together with epidemiological work on radiation technologists suggests that the question of the threshold dose for cataract development is open again. In the past, a threshold of approximately 2 Gy was fixed. In this session recent findings on human cataracts will be discussed together with genetically modified mouse models.

08:15	2161	Radiation cataracts: epidemiology and biology KLEIMAN N—New York
08:40	2162	Monitoring the eye lens BEHRENS R—Braunschweig
09:00	2163	Lens opacities among physicians occupationally exposed to ionizing radiation—a pilot study in Finland KIVELÄ T, MRENA S, KURTIO P, AUVINEN A—Tampere
09:20	2164	Occupational Cataracts and Lens Opacities in interventional Cardiology (O'CLOC Study) JACOB S, LAURIER D, JOURDAIN JR, BERNIER MO—Fontenay-aux-Roses
09:40		Concluding remarks by Jochen GRAW

FP  
COS

## REFRACTIVE SURGERY AND QUALITY OF VISION

Ioannis G. PALLIKARIS, Béatrice COCHENER

Minos 2

08:15	2171	Novel methods to maintain corneal transparency while increasing the strength of LASIK flaps KAMMA-LORGER CS, DOOLEY EP, DU Y, DAVIES L, MI S, FUNDERBURGH JL, STEPHENS P, MEEK KM—Cardiff, Pittsburgh, PA
08:27	2172	A new method of the eye refraction correction under non-ablative laser radiation BOLSHUNOV A, SOBOL E, AVETISOV S, BAUM O, SIPLIVY VLAD, OMELCHENKO A, FEDOROV A—Moscow, Troitsk
08:39	2173	I-LASIK retreatment of residual refractive errors after microkeratome and femtosecond assisted LASIK MENICACCI F, FRUSCHELLI M, MENICACCI C, SANGIUOLO M, HADIJUSTILIANOU T—Siena
08:51	2174	Comparative evaluation of photorefractive keratectomy with the use of an excimer laser and a solid state laser system KONTADAKIS G, KOUNIS G, KYMIONIS G, PLAKA A, STRATOS A, DIAKONIS V, PALLIKARIS IG—Heraklion
09:03	2175	Evaluation of tear film osmolarity after mechanical LASIK, femtosecond laser-assisted sub-Bowman keratomileusis and LASEK CANADAS SUAREZ P, GARCIA-GONZALEZ M, ORTEGA MARIA, TEUS M—Madrid
09:15	2176	Dynamic corneal wavefront aberrations and quality of vision in patients with dry eye disease DENOYER A, RABUT G, BAUDOIN C—Paris
09:27	2177 <i>rf</i>	Long-term results of simultaneous topo-guided photorefractive keratectomy followed by corneal collagen cross-linking for keratoconus DIAKONIS V, GRENTZELOS M, PORTALIOU D, KOUNIS G, LIMNOPOULOU A, KYMIONIS G—Heraklion




**KEYNOTE LECTURE - Elias TRABOULSI**

Zeus

- |       |  |
|-------|--|
| 10:00 | Introduction by Aki KAWASAKI   |
| 10:10 | Clinical and molecular genetic aspects of optic nerve hypoplasia<br><b>TRABOULSI E-Cleveland</b> |
| 10:40 | Award of the EVER certificate of honour  |

FP RV	DIABETIC RETINOPATHY		Zeus
	Jost B JONAS, Anat LOEWENSTEIN		
11:00	2211	High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy ABU EL ASRAR A, NAWAZ MI, KANGAVE D, GEBOES K, OLA MS, AHMAD S, AL-SHABRAWAY M—Riyadh, Leuven, Augusta	
11:12	2212	Alteration of plasmalogens in erythrocytes of patients with diabetic retinopathy ACAR N, SAAB S, BERDEAUX O, BRON AM, CREUZOT C, BRETILLON L—Dijon	
11:24	2213	Health related quality of life in patients with diabetic retinopathy TADROS C, KONTODIMOPOULOS N, FERETIS E, KABANAROU SA, PETO T—Athens, Patra, London	
11:36	★ 2214	Treatment accuracy and patient pain compared in retinal navigated laser (Navilas®) versus conventional laser in diabetic macular edema KERNT M, ULBIG MW, KAMPIK A, NEUBAUER AS—Munich	
11:48	2215	Diabetic retinopathy macular edema: treatment by series of 3 ranibizumab injections after 3 years follow-up GONZALEZ C—Toulouse	
12:00	2216 <i>rf</i>	The distribution of retinal thickness in healthy eyes and its use in the objective analysis of optical coherence tomography (OCT) scans HALDAR S, DAVIES N—London	
12:06	2217 <i>rf</i>	Cytokine concentration in aqueous humor of eyes with diabetic macular edema JONAS JB, JONAS R, NEUMAIER M, FINDEISEN P—Mannheim	
12:12	2218 <i>rf</i>	Experimental study of distinguishing small retinal haemorrhages from dust artefacts using HLS colour space SUZUKI N, YAMANE K—Higashi-Hiroshima, Hiroshima	

FP MBGE	NEW DISEASE GENES & MUTATIONS		Artemis
	Bart LEROY, Marcela VOTRUBA		
11:00	2221	Mutation in Pxdn encoding peroxidase causes small lenses and kinky tails in the mouse GRAW J, WAGNER S, FUCHS H, HRABE DE ANGELIS M—Neuherberg	
11:12	2222	CTNND2 is a genetic variant for high myopia SAW SM, FAN Q, YOSHIMURA N, KHOR CC, TAI ES, GOH LK, YOUNG T, LI YL—Singapore, Kyoto, Durham	
11:24	2223	A meta-analysis of studies on the heritability of myopia MORGAN I—Canberra	
11:36	2224 <i>rf</i>	Analysis of locus 2q13 in Ecuadorian family with keratoconus NOWAK DM, KAROLAK JA, KUBIAK J, MOLINARI A, PITARQUE JA, BEJJANI BA, GAJECKA M—Poznan, Quito, Spokane	
11:42	2225 <i>rf</i>	Identification of novel germline mutations in the VHL gene in Hungarian von Hippel-Lindau patients LOSONCZY G, FAZAKAS F, PFLIEGLER G, KOMAROMI I, BERTA A—Debrecen	

SIS ACB	CELL BIOLOGY OF RETINAL PIGMENT EPITHELIUM		Athena
	Hannu UUSITALO, Kai KAARNIRANTA		
11:00	2231	iPS cells - an alternative source of RPE? CARR A—London	
11:30	2232	Towards xeno-free differentiation of RPE cells ILMARINEN T, VAAJASAARI H, JUUTI-UUSITALO K, NARKILAHTI S, SUURONEN R, UUSITALO H, SKOTTMAN H—Tampere	
12:00	2233	The role of RPE in the regulation of VEGF KLETTNER A—Kiel	

**JOINT M. IM** **UVEITIS: FROM PRACTICE TO PRINCIPLES**

Carl P HERBORT

Europa



11:00	2241	Behçet's uveitis: why biologicals are predestined to become the first line treatments ONAL S—Istanbul
11:12	2242	Laser flare photometry: why is it going to be the gold standard for the assessment of intraocular inflammation KHAIRALLAH M, KHOCHTALI S—Monastir
11:24	2243	How OCT changed the appraisal of macular inflammatory disease MARKOMICHELAKIS N—Athens
11:36	2244	Birdshot chorioretinopathy: why is sustained immunosuppression going to be the standard of therapy in most cases PAPADIA M—Genova
11:48	2245	Vogt-Koyanagi-Harada disease: why indocyanine green angiography-assisted therapy is going to become the standard of care BOUCHENAKI N, HERBORT C—Geneva, Lausanne
12:00	2246	Choriocapillaritis: why is ICGA due to become the standard to monitor evolution and response to therapy HERBORT C—Lausanne
12:12	2247	Inflammatory choroidal neovascularization: how combined anti-VEGF and inflammation suppressive therapy is going to become the treatment of choice NERI P, ARAPI I—Ancona

**FP G** **VISUAL FIELDS AND RISK FACTORS**

Ananth VISWANATHAN, Thierry ZEYEN

Minos 1

11:00	2251	Agreement between structural and functional classifications in glaucoma diagnosis OTIN S, FERRANDEZ ARENAS B, CALVO P, GIL-ARRIBAS L, GÜERRI N, ALTEMIR I, FERRERAS A—Zaragoza
11:12	2252	Rates of visual field progression before and after trabeculectomy BERTRAND V, FIEUWS S, STALMANS I, ZEYEN T—Leuven
11:24	2253	Location of visual field defect and optic disc assessment by confocal scanning laser ophthalmoscope in early normal tension glaucoma JUNG KI, PARK CK—Seoul
11:36	2254	Correlation of the rate of progression of visual field loss between guided progression analysis (GPA II) and PeriData® program in glaucoma patients: pilot study POURJAVAN S, PEETERS H, DETRY-MOREL M—Brussels
11:48	2255	Increased hydrostatic pressure does not cause loss of retinal ganglion cell viability in human organotypic retinal cultures SANDERSON J, RHODES J, OSBORNE A, BROADWAY D—Norwich
12:00	2256	Mitigation of the IOP elevation associated with non-supine sleep positions FLATAU A—College Park
12:12	2257	Posture-induced IOP changes in treated and untreated primary open angle glaucoma patients KATSANOS A, DASTIRIDOU A, RUSSO A, RIVA I, DIMASI B, TSIRONI E, QUARANTA L—Brescia, Larissa





FP  
NSPH

## FREE PAPERS

Andrzej GRZYBOWSKI, Aki KAWASAKI

Danae

11:00	2261	Emil von Behring, the first Nobel prize laureate in medicine or physiology, and his ophthalmic interests GRZYBOWSKI A, WILHELM H—Poznan, Tuebingen
11:12	2262	Detection of retinal nerve fibre layer defects in Alzheimer's dementia using SD-OCT BEUTELSPACHER SC, SERBECIC N, HAUSNER L, KROHMER R, ABOUL-ENEIN F, FROELICH L, JONAS JB—Mannheim, Vienna
11:24	2263	Dyschromatopsy and visual alliesthesia in a glioblastoma multiforme patient ALMALIOTIS D, REPTISIS A, DEMIRTZOGLU I, NIKOLAKOPOULOS A, KARAMPATAKIS V—Thessaloniki
11:36	2264	The pupil in pupillometry - to dilate or not to dilate NISSEN C, SANDER B, LUND-ANDERSEN H—Copenhagen
11:48	2265	Toxic optic neuropathy secondary to disulfiram: a case series LUCAS RS, LEROY BP—Ghent
12:00	2266 <i>rf</i>	Endothelin-1 (ET-1) plasma levels in multiple sclerosis (MS) patients JANKOWSKA-LECH I, BIK Z, WOLINSKA E, TERELAK-BORYS B, GRABSKA-LIBEREK I, PALASIK W—Warsaw
12:06	2267 <i>rf</i>	Anisometropia and amblyopia in children BOGDANICI C, BOGDANICI T—Iasi
12:12	2268 <i>rf</i>	Retinal nerve fiber layer thickness measured by optical coherence tomography correlates with Expanded Disability Status Scale (EDSS) in multiple sclerosis (MS) CARZOLI A, LATARCHE C, BERROD JP, DEBOUVERIE M, ANGIOI K—Cannes, Nancy

SIS  
COS

## REFRACTIVE SURGERY FOR EVER

Béatrice COCHENER, Jean-Jacques GICQUEL

Minos 2

11:00	2271	Spectacle independence and subjective satisfaction of multifocal intraocular lens after cataract or presbyopia surgery COCHENER B—Brest
11:22	2272	Wavefront guided or topo-link? Which one and when? GICQUEL JJ—Poitiers
11:44	2273	Would you recommend PresbyLASIK to your best friend? PISELLA PJ—Tours
12:06	2274	Spherical aberration: friend or foe? NOCHEZ Y, MAJZOUB S, PISELLA PJ—Tours



Lunchtime CIS



**LUNCHTIME CIS - THEA: WHAT'S NEW IN 2011 IN ANTIBIOTHERAPY?**

Zeus

12:35	★	Azithromycin clinical efficacy and safety in infants BREMOND-GIGNAC D–Amiens
12:50		Management of the infectious risks in cataract surgery
13:05		Antibiotic prophylaxis in cataract surgery: what about the guidelines ? ROBERT PY–Limoges



FP RV	<b>SURGICAL RETINA</b>		Zeus
	Catherine CREUZOT, Constantin POURNARAS		
13:45	2311	Characterization of neuroepithelial progenitor cells in patients with proliferative vitreoretinopathy MOE MC, JOHNSEN EO, FROEN R, ALBERT R, BERTA A, PETROVSKI G, NICOLAISSEN B—Oslo, Debrecen	
13:57	2312	Compared effectiveness of brilliant blue G for internal limiting membrane peeling in idiopathic epiretinal membrane in novice and experimented surgeons CREUZOT C, KOEHRER P, DUGAS B, PASSEMARD M, BRON AM—Dijon	
14:09	2313	Customized intraocular telescope implanted in high myopic patients with advanced maculopathy NAVEA TEJERINA A, MORALES J, FELIPE A, ARTIGAS VERDE JM—Valencia	
14:21	2314	Reasons for reduced vision after anatomically successful retinal detachment surgery CHALKIA A, TSIKA C, CHARISSIS SK, AGOROGIANNIS GI, TSILIMBARIS MK—Heraklion	
14:33	2315	Transferrin and prealbumin: indicators of PVR and risk of recurrence in retinal detachment ARNDT C, RAMONT L, DUCASSE ALAIN, BONNAY G—Reims	
14:45	2316	Measurement of scleral rigidity in patients with age-related macular degeneration KAYA S, KNOGLER K, WEIGERT G, SACU S, GARHOFER G, SCHMETTERER L—Vienna	
14:57	2317 <i>rf</i>	New cyanine dye for ILM staining LAUBICHLER P, VARJA A, LANGHALS H, EIBL K, KERNT M, HARITOGLOU C—Munich	
15:03	2318 <i>rf</i>	Acute intraocular pressure after intravitreal injections, what is the mechanism? DOT C, EL CHEHAB H, LE CORRE A, RACT-MADOUX G, COSTE O, SALVANY P, MOURGUES G, SWALDUZ B, GIRAUD JM—Lyon	

SIS MBGE	<b>UPDATE ON OCULAR GENETICS - PART 1</b>		Artemis
	Bart LEROY, Graeme C M BLACK		
13:45	2321	Principles of genetic counseling HALL G—Manchester	
14:07	2322	Molecular ophthalmic genetics tools DE BAERE E—Ghent	
14:29	2323	Inherited ocular developmental disease BLACK GCM—Manchester	
14:51	2324	Electrodiagnosis in inherited retinal disease HOLDER GE—London	

SIS ACB	<b>THE EYELID MARGIN – A FRESH VIEW ON AN IMPORTANT STRUCTURE</b>		Athena
	Erich KNOP, Nadja KNOP, Johannes NEPP		
13:45	2331	Morphology and function of the inner lid margin – history and recent findings KNOP E, KNOP N—Berlin	
14:00	2332	Goblet cells in the conjunctival lid wiper elevation provide a built-in lubrication system KNOP N, KORB DR, BLACKIE CA, KNOP E—Berlin, Boston	
14:15	2333	A grading system for alterations of the lid wiper zone in ocular surface disease NEPP J, MUNK M—Vienna	
14:30	2334	Prevalence of MGD in a clinical dry eye population HORWATH-WINTER J, RABENSTEINER DF, SCHWANTZER G, BOLDIN I, WACHSWENDER C, SCHMUT O—Graz	
14:45	2335	The relation of lipid layer structure to meibum - results from a new high resolution microscope KING-SMITH PE, BRAUN RJ, NICHOLS JJ, NICHOLS KK—Columbus, Ohio, Newark, Delaware	
15:00	2336	Correlation of non-contact meibography to dry eye symptoms and signs in Sjögren's syndrome and graft-versus-host disease RABENSTEINER DF, HORWATH-WINTER J, BOLDIN I, BAUER H, NITSCHKE M, SCHMUT O—Graz	

**SIS  
IM****APPLICATIONS OF PCR IN INFECTIOUS OCULAR DISEASE**

Christophe CHIQUET, Marc LABETOULLE

Europa




13:45	2341	PCR, principles, advantages and pitfalls: focus in some viral infections of the anterior segment of the eye LABETOULLE M—Le Kremlin-Bicêtre
14:07	2342	PCR in posterior segment viral diseases BODAGHI B—Paris
14:29	2343	New test for rapid Acanthamoeba diagnosis GOLDSCHMIDT P, DEGORGE S, BENALLAOUA D, BORSALI E, LE BOUTER A, BATELLIER L, BORDERIE V, LAROCHE L, CHAUMEIL C—Paris
14:51	2344	PCR in acute bacterial endophthalmitis CHIQUET C—Grenoble

**SIS  
G****CONTROVERSIES IN GLAUCOMA**

Sayeh POURJAVAN, Veva DE GROOT, Andrzej GRZYBOWSKI

Minos 1

13:45	2351	CSF pressure and glaucoma: pro JONAS JB—Mannheim
14:03	2352	CSF pressure and glaucoma: contra GRZYBOWSKI A—Poznan
14:21	2353	Deep sclerectomy: pro COLLIGNON NJ—Liège
14:39	2354	Deep sclerectomy: contra ZEYEN T—Leuven
14:57	2355	Trend versus event analysis in glaucoma progression VISWANATHAN A—London

FP LC	LENS		Danae
13:45	2361	Kinetics of TP53, CASP3 and GADD45 genes expression in the rat lens after in vivo exposure to subthreshold dose of UV-B radiation GALICHANIN K, TALEBIZADEH N, YU Z, SÖDERBERG P—Stockholm, Uppsala	
13:57	2362	Ocular temperature rise and light scattering development in the lens correlating with exposure time after in vivo exposure to 1090 nm infrared radiation YU Z, SCHULMEISTER K, GALICHANIN K, SÖDERBERG P—Uppsala, Seibersdorf, Stockholm	
14:09	2363	Comparison between 2 recent optical biometry devices DJABAROUTI M, BADAT I, MERCIÉ M, BOISSONNOT M, DIGHIÉRO P, GICQUEL JJ—Poitiers	
14:21	2364	Characteristics of the anterior eye segment in patients affected by Ehlers-Danlos Syndrome WEGENER A, HOLTZ FG, FINGER R, WEISSBACH A—Bonn	
14:33	★  2365	Semi-automatic 3D reconstruction of the anterior segment from high frequency ultrasound scans KOHANDANI TAFRESHI M, LAMARD M, COCHENER B—Brest	
14:45	2366	Age-specific changes of the crystalline lens' physical characteristics KUDRYAVTSEVA YV, CHUPROV AD—Kirov	
14:57	2367 <i>rf</i>	On the impact of multifocal IOL decentration and tilt on retinal image quality PALLIKARIS IG, KONTADAKIS G, GINIS H—Heraklion	

FP COS	KERATOCONUS AND CORNEAL GRAFTING		Minos 2
13:45	2371	Creating endothelial lenticules with femtosecond laser: the double layer technique BOURGÉS JL, ROUSSEAU A, SARAGOUSSI JJ, RENARD G, BEHAR-COHEN F—Paris	
13:57	2372	Riboflavin's time dependent degradation rate induced by ultra violet – an irradiation at 370 nm wavelength DIAKONIS V, GRENTZELOS M, KANKARYIA V, TZATZARAKIS E, KARAVITAKI A, KYMIONIS G—Heraklion	
14:09	2373	Corneal biomechanical characterization from in vitro eye inflation, optical coherence tomography and finite element modeling KLING S, PEREZ P, ORTIZ S, MARCOS S—Madrid	
14:21	2374	Proteases and proteolysis in the tears of people with keratoconus BALASUBRAMANIAN SIVA, PYE DAVID, WILLCOX MARK—Sydney	
14:33	2375	Theoretical basis for estimating the elastic characteristics of individual living human eyes STEIN AA, MOISEEVA IN—Moscow	
14:45	★ 2376	A biocornea of fish scales – first results of a research model VAN ESSEN TH, LIN CC, LAI HJ, HUSSAIN AK, LUYTEN GPM, JAGER MJ—Leiden, Taipei	
14:57	2377 <i>rf</i>	Mechanical reinforcement of the cornea with an intrastromal in-situ photo-polymerised implant PENNOS A, PENTARI IG, GINIS H, KARIOTAKIS N, KYMIONIS G, PALLIKARIS IG—Heraklion	







**EUROPEAN VISION AWARD 2011 LECTURE**

Zeus



**EVA Awardee 2011**

**Carlos BELMONTE**

University Miguel Hernandez, Instituto de Neurociencias, Alicante, Spain

Introduction by Eberhart ZRENNER

**15:30**

From comfort to pain: neural basis of ocular surface sensations  
**BELMONTE C**–Alicante

**SIS  
RV****MACULAR EDEMA IN VEIN OCCLUSION**

Catherine CREUZOT

**Zeus**

17:30	2411	Oxygen and VEGF in venous occlusion STEFANSSON E–Reykjavik
17:52	2412	Mechanisms involved in vein occlusion related macular edema POURNARAS JAC–Lausanne
18:14	★ 2413	Clinical presentations in venous occlusion JONAS JB–Mannheim
18:36	★ 2414	Treatment of macular edema in vein occlusion CREUZOT C–Dijon

**SIS  
MBGE****UPDATE ON OCULAR GENETICS - PART 2**

Bart LEROY, Graeme C M BLACK

**Artemis**

17:30	2421	Genetics and diagnostics of retinitis pigmentosa CREMERS FPM, NEVELING K, ESTRADA-CUZCANO A, VELTMAN JA, SCHEFFER H, KLEVERING BJ, DEN HOLLANDER AI, COLLIN RWJ–Nijmegen
17:52	2422	The bestrophinopathies LEROY BP–Ghent
18:14	2423	Genetics of Leber congenital amaurosis DEN HOLLANDER AI, ROEPMAN R, KOENEKOOP RK, CREMERS FPM–Nijmegen, Montreal
18:36	2424	Gene therapy & pharmacotherapy for inherited retinal disease: current status HAMEL C–Montpellier

**SIS** **IMMUNOLOGY AND INFLAMMATION AT THE OCULAR SURFACE** **Athena**  
**ACB** Erich KNOP, Robert A SACK, Nadja KNOP

17:30	2431	The eye-associated lymphoid tissue (EALT) - a basis of the anatomy and immunology at the ocular surface KNOP E, KNOP N-Berlin
17:48	2432	Overview of the spectrum and therapy of inflammatory ocular surface disease PLEYER U-Berlin
18:06	2433	The immunology of allergic ocular surface disease LEONARDI A-Padua
18:24	★ 2434	Inflammatory events in trachoma HUGUET P-Clermont Ferrand
18:42	2435	Differential control and selective downregulation of cytokines but not chemokines in the normal and pathological tear fluid SACK RA, ISEROVICH P, SATHE S, BEATON A-New York

**SIS** **CONTROVERSIES IN NEURO-OPHTHALMOLOGY AND PEDIATRICS** **Europa**  
**NSPH** Andrzej GRZYBOWSKI, Dominique BREMOND-GIGNAC

17:30	2441	Why electrophysiology in children? HOLDER GE-London
17:45	2442	Pros of treatment of NA-ION LEE A-Houston
18:00	2443	Cons of treatment of NA-ION GRZYBOWSKI A-Poznan
18:15	2444	Pros of steroids use in optic neuritis LEE A-Houston
18:30	2445	Cons of steroids use in optic neuritis GRZYBOWSKI A-Poznan
18:45	2446	Why pulley surgery in strabismus? BREMOND-GIGNAC D-Amiens

**COURSE 11 EBO REVIEW COURSE: HOW TO BEGIN WITH THE GLAUCOMAS?**

Minos 1

G Alain BRON

Beginner



The glaucomas encompass many clinical presentations with different risk factors and various outcomes. However the clinical examination of a glaucoma patient or a glaucoma suspect follows the basic rules of medicine: collect the symptoms if any and search for signs before giving a diagnosis and/or prognosis. In this basic course, 3 glaucoma experts will give you some practical and very simple tips to enhance your clinical practice with daily tools you have at your fingertips. We strongly recommend reading of the European Glaucoma Society Guidelines ([http://www.eugs.org/eng/EGS\\_guidelines.asp](http://www.eugs.org/eng/EGS_guidelines.asp)) before attending the course.

17:30	2451	Your first best glaucoma friend, the slit-lamp BRON AM—Dijon
18:00	2452	Your second best glaucoma friend, function testing VISWANATHAN A—London
18:30	2453	Your third best glaucoma friend, structure evaluation SUNARIC MEGEVAND G—Geneva

**COURSE 12 CRASH COURSE IN OPHTHALMIC PATHOLOGY**

Danae

PO Sarah COUPLAND, Karin LOEFFLER, Steffen HEEGAARD

Intermediate

This course will be run by leading eye pathologists and will provide an overview of important disease processes occurring in the eye and the surrounding ocular adnexa, in both adults and in children. It will be an interactive and case-orientated course, with emphasis on the association between the clinical-pathological findings, and incorporating latest data in the literature. It will briefly outline new methodologies, which are applied in diagnosis establishment and in prognostication in ocular tumours. Comparative ocular pathology in our "furry" and "not-so-furry" friends will also be presented for interest. A fun quiz will conclude the course to highlight important take-home-messages. Participants will receive a course handbook for reference.

17:30	2461	Tips and tricks in grossing and processing ophthalmic specimens COUPLAND SE—Liverpool
17:45	2462	Overview of eyelid and conjunctival tumours LOEFFLER K—Bonn
18:00	2463	Anterior-to-posterior "tour" of ocular disease processes LOEFFLER K—Bonn
18:15	2464	Overview of orbital tumours HEEGAARD S—Copenhagen
18:30	2465	Incorporation of cytogenetic and molecular techniques in ocular pathology COUPLAND SE—Liverpool
18:45	2466	Comparative ocular pathology HEEGAARD S—Copenhagen

**SIS**      **MANAGEMENT OF CONJUNCTIVAL CICATRIZING DISEASES AND**      **Minos 2**  
**COS**      **SEVERE OCULAR SURFACE DYSFUNCTION**  
Harminder S DUA, Jean-Jacques GICQUEL

17:30	2471	The modern management of ocular surface burns GICQUEL JJ–Poitiers
17:52	2472	How anterior segment imaging helps in the management of ocular surface cicatrizing diseases NUBILE M–Chieti
18:14	2473	The amniotic membrane in conjunctival cicatrizing diseases DUA H–Nottingham
18:36	2474	An update on mucous membranes management CLAERHOUT I–Ghent



**Anatomy/Cell Biology****Moderators:****Nadja KNOP, Hannu UUSITALO, Roger BEUERMAN**

- 201 Optic vesicle-like neurospheres derived from the H9 and H1 human ES cell lines  
PINILLA I, WRIGHT LS, VERHOEVEN AD, WALLACE KA, CAPOWSKI EE, MEYER J, CUENCA N, GARCIA MARTIN E, GAMM DM—Zaragoza, Madison, Indianapolis, Alicante
- 202 Transduction of mesenchymal stem cells with an ecdysone inducible lentiviral vector expressing luciferase gene  
FAVARD A, BELLI CAUD D, NOCHEZ Y, COLLIN C, PISELLA PJ, GABISON EE, PAGES JC—Tours, Paris
- 203 Viral vectors for gene transfer into corneal endothelial cells  
FUCHSLUGER T—Boston
- 204 Evaluation of human retinal pigment epithelial cells growth on elastin-like recombinamers substrates  
SRIVASTAVA GK, MARTIN L, SINGH AK, RODRIGUEZ-CABELLO JC, PASTOR JC—Valladolid
- 205 Trypan blue staining method for quenching the autofluorescence of RPE cells for improving protein expression analysis  
SRIVASTAVA GK, REINOSO R, SINGH AK, CORELL A, FERNANDEZ-BUENO I, HILEETO D, PASTOR JC—Valladolid
- 206 *rf* AICAR induces autophagy in ARPE-19 cells  
KAARNIRANTA K, VIIRI J, AMADIO M, HYTTINEN J, PAIMELA T, RYHÄNEN T, MARCHESI N, AKHTAR S, PASCALE A, PETROVSKI G, SALMINEN A—Kuopio, Pavia, Riyadh, Debrecen
- 207 Aging and BDNF-deficiency upregulates heat shock protein expression in mouse retina  
PURANEN J, TUULOS T, VEHANEN K, RYHÄNEN T, UUSITALO H, KAARNIRANTA K, KALESNYKAS G—Kuopio, Tampere
- 208 *rf* BDNF-deficiency upregulates SIRT2 expression but does not affect cellular metabolism in mouse retina  
PODRACKA L, VEHANEN K, TUULOS T, RÖNKKO S, KAARNIRANTA K, UUSITALO H, KALESNYKAS G—Kuopio, Tampere
- 209 Interleukin-10 promotes macrophage infiltration in mouse retina  
MENDES-JORGE L, RAMOS D, VALENCA A, NACHER V, RODRIGUEZ-BAEZA A, ALMOLDA A, CAMPBELL IL, GONZALEZ B, CASTELLANO B, RUBERTE J—Barcelona, Lisbon, Sydney
- 210 Effect of autocrine vascular endothelial growth factor on the survival of retinal Müller cells under oxidative stress  
KIM NR, KIM CY, RHO SS, OH JH, MOON YS, CHIN HS, HONG S, SEONG GJ—Incheon, Seoul
- 211 Role of toll-like receptor 2 and 4 of keratocytes on corneal innate immunity  
CHOI HJ, LEE HJ, JEONG HJ, KIM MK, WEE WR—Seoul
- 212 The effects of thermal sources emitted infrared radiation (IR) on rabbit corneal and crystalline lens extracellular molecules and the influence of cyclooxygenase (COX) inhibition  
ALMALIOTIS D, DADOUKIS P, KARAMPATAKIS V, KARAKIOULAKIS G, PAPACONSTANTINO E, KOMNINO A—Thessaloniki
- 213 Differential effects of irradiation with X-rays and carbon ions on normal and tumoral uveal melanocytes  
CALIPEL A, LUX AL, MOURIAUX F—Caen
- 214 Effect of fixation and embedding methods on collagen fibril diameter and spacing  
AKHTAR S, ALMUBRAD T—Riyadh


- 215 Ultrastructural organisation of stingray and shark corneal stroma  
ALIBRAHIM A, ALMUBRAD T, AKHTAR S—Riyadh

- 216 Use of imaging techniques to reveal connectivity within the human fovea and to predict consequences of lesions.  
SJÖSTRAND J, POPOVIC Z—Gothenburg

**Glaucoma****Moderators:****Gordana SUNARIC MEGEVAND, Michèle DETRY-MOREL**

- 217 *rf* Outcome of trabeculectomy in uveitis patients with secondary glaucoma  
LEWKOWICZ D, WILLERMAIN F, JANSSENS S, MAKHOUL D, CASPERS L, JANSSENS X—Brussels
- 218 *rf* ★ Optic disc assessment using confocal scanning laser ophthalmoscope in normal tension glaucoma with disc hemorrhage  
LIM S—Seoul
- 219 *rf* GDx-VCC vs GDx-ECC in glaucoma diagnosis  
MILANO G, LOMBARDO S, BORDIN M, BOSSOLESI L, RAIMONDI M, LANTERI S, ROSSI GCM—Pavia
- 220 *rf* Anterior segment optical coherence tomography changes post laser peripheral iridotomy in primary angle closure suspects in an Asian population  
HOW A, AUNG T—Singapore
- 221 *rf* Evaluation of the efficacy of patterned laser trabeculoplasty: pilot study  
DENEYER J, POURJAVAN S, DETRY-MOREL M—Brussels
- 222 Nurse-led glaucoma clinics- the pros and cons  
ANSARI E, GAMBLE A—Maidstone, Gillingham
- 223 Usefulness of dynamic gonioscopy during systematic survey of glaucoma patient in a university hospital  
ROUSSEAU A, POGORZALEK N, KASWIN G, GENDRON G, M'GARRECH M, LABETOULLE M—Le Kremlin-Bicêtre
- 224 The role of Mas receptors in an experimental rat glaucoma model  
VAAJANEN A, KALESNYKAS G, VAPAATALO H, UUSITALO H—Tampere, Kuopio, Helsinki
- 225 Congenital glaucoma: from the diagnosis up to the surgery. About a case  
IBANEZ J, PEREZ GARCIA D, REMON L, JIMENEZ DEL RIO B, PEIRO C, CABEZON L, RAMIRO P, CRISTOBAL JA—Zaragoza
- 226 Closed angle glaucoma and myopia as an adverse effect of topiramate  
SATUE M, HERRERO LATORRE R, DE LA MATA G, FERNANDEZ-PEREZ S, GARCIA MARTIN E, POLO V—Zaragoza
- 227 *rf* ★ A phase 2, randomized study evaluating the safety and efficacy of Catioprost® (unpreserved latanoprost 0.005% emulsion) compared to Travatan Z® in subjects with glaucoma and ocular surface disease  
ISMAIL D, AMRANE M, GARRIGUE JS, BUGGAGE R—Evry
- 228 Relationship of intraocular pressure with risk factors of metabolic syndrome  
KIM SJ, LEE JE, LEE JS, LEE SU—Busan




- 229 Low pressure glaucoma: patients threatened of vision worsening and blindness  
VASSILEVA P–Sofia
- 230 Ocular response analyzer in pre-perimetric glaucoma  
MAY F, GIRAUD JM, HAMAM O, FENOLLAND JR, SENDON D, MOUINGA A, RENARD JP–Paris
- 231 The relationship between corneal biomechanical properties and intraocular pressure  
OGBUEHI K, ALMUBRAD T–Riyadh
- 232 Intraocular pressure after cataract surgery measured with Pascal dynamic contour tonometer, Goldmann applanation tonometer and pneumotonometer  
VILLAFRUELA I, PRIETO M, COLAS T, RIVAS O, FERNANDEZ A, CLARIANA A, BORREGO R–Madrid
- 233 Comparison of Ex-Press miniature implant with standard trabeculectomy after combined glaucoma surgery  
IBANEZ J, PEREZ GARCIA D, PEIRO C, JIMENEZ B, RAMIRO P, CABEZON L, MATEO A, CRISTOBAL JA–Zaragoza
- 234 Ahmed glaucoma valve implantation for neovascular glaucoma after vitrectomy for proliferative diabetic retinopathy  
CHO H–Seoul
- 235 Digital analysis of the trabecular pigmentation using positive pixel count algorithm  
 PETROSKA D, PAJAUJIS M, LEVINAITE G, RIAUKA R, ASOKLIS R–Vilnius
- 236 Relationship between retinal nerve fiber layer evaluation and visual field results in healthy and glaucoma individuals  
CALVO P, GIL-ARRIBAS L, GÜERRI N, OTIN S, FERRANDEZ ARENAS B, ALTEMIR I, GARCIA MARTIN E, FERRERAS A–Zaragoza
- 237 Effect of cataract in Fourier-domain OCT measurements using two optical coherence tomographers  
GARCIA MARTIN E, SANCHO MORO E, HERRERO LATORRE R, GIL-ARRIBAS L, IDOPE M, FERNANDEZ-PEREZ S, PINILLA I, PRIETO CALVO E, DE LA MATA G–Zaragoza
- 238 A formula to predict spectral-domain OCT retinal nerve fiber layer measurements based on time-domain OCT measurements  
KIM NR, KIM CY, RHO SS, OH JH, MOON YS, CHIN HS, HONG S, SEONG GJ–Incheon, Seoul
- 239 The effect of cataract on spatial and temporal contrast sensitivity tests in glaucoma  
KLEIN JO, ZLATKOVA M, PIERSCIONEK B, LAURITZEN JS–Coleraine, London
- 240 Relationship between time- and spectral-domain optical coherence tomography in glaucoma  
GIL ARRIBAS L, GÜERRI N, OTIN S, FERRANDEZ ARENAS B, CALVO P, GARCIA-MARTIN E, ALTEMIR I, FERRERAS A–Zaragoza
- 241 The relationship between RNFL thickness and rim thickness by Cirrus® HD OCT  
LEE MK–Seoul
- 242 Peripapillary retinal nerve fiber layer thickness measurement with 3 spectral domain OCT devices  
FENOLLAND JR, GIRAUD JM, MOUINGA A, SENDON D, ELASRI F, MAY F, RENARD JP–Paris
- 243 Applications of anterior segment OCT to glaucoma surgery  
GÜERRI N, OTIN S, FERRANDEZ ARENAS B, CALVO P, GIL-ARRIBAS L–Zaragoza

## Lens and Cataract

### Moderators:






Ralph MICHAEL, Per SÖDERBERG

- 244 Caspase-3 expression in rat lens after in vivo exposure to UVR-300 nm  
TALEBI ZADEH N, GALICHANIN K, HALLBÖÖK F, SÖDERBERG P–Uppsala, Stockholm
- 245 Evolution of protein concentration in the rat lens after in vivo exposure to close-to-threshold dose ultraviolet radiation  
JING W, ZHANG J, LÖFGREN S, GALICHANIN K, ZALEBIZADEH N, YU Z, SÖDERBERG P–Uppsala, Stockholm
- 246 Establishment of a lens epithelial cell line from cataract dog  
OCHIAI H–Sagamihara
- 247 Cadmium, copper and lead in cataractous and normal dog lenses  
DODI PL, QUINTAVALLA F–Parma
- 248 Unilateral pediatric cataract of uncertain cause  
PARK JH, LEE JJ, SONG SW–Seoul
- 249 Management of IOLs in pediatric cataracts  
DEL BUEY MA, CRISTOBAL JA, REMON L, LAVILLA L, MINGUEZ E, ASCASO J, CASAS P, JIMENEZ B, PALOMINO C–Zaragoza
- 250 Outcomes of phacoemulsification and intraocular lens implantation in cataracts secondary to uveitis  
JIMENEZ DEL RIO B, PEREZ GARCIA D, RAMIRO P, IBANEZ J, PINILLA I, MINGUEZ E, CRISTOBAL JA–Zaragoza
- 251 Surgery of ectopia lentis  
EGEA ESTOPINAN C, PRIETO CALVO E, IDOPE M, SATUE M, FERRERAS A, FERNANDEZ LARRIPA S, ABECIA MARTINEZ E–Zaragoza
- 252 On the impact of multifocal IOL decentration and tilt on retinal image quality  
*rf* PALLIKARIS IG, KONTADAKIS G, GINIS H–Heraklion
- 253 A comparison of remaining refractive error after cataract surgery using different monofocal intraocular lenses  
STRATOS A, PEONIS V, DRAKOS E, HALKIADAKIS I, SKOURIOTIS S, PARIKAKIS EA, KARAGIANNIS D, MITROPOULOS P–Athens
- 254 Evaluation of posterior capsule opacification after cataract surgery using liquifaction method  
 KALFERTOVA M, BUROVA M, NEKOLOVA J, JIRASKOVA N, ROZSIVAL P–Hradec Kralove
- 255 Light transmission of the human lens and its relation with aging  
FELIPE MARCET A, ARTIGAS VERDE JM, NAVEA TEJERINA A, FANDINO A, ARTIGAS C, GARCIA-DOMENE MC–Valencia
- 256 Age-induced change in the color of the human crystalline lens  
ARTIGAS VERDE JM, FELIPE MARCET A, NAVEA A, FANDINO A, ARTIGAS C, DIEZ-AJENJO A–Valencia
- 257 Near distance vision with aspherical intraocular lenses in a model eye  
LANGENBUCHER A, JANUNTS E, GILLNER M, EPPIG T–Homburg
- 258 Simulation platform for evaluation of geometrical and positional changes of lenses during accommodation  
GILLNER M, EPPIG T, ZORIC K, BRÜNNER H, LANGENBUCHER A–Erlangen, Homburg/Saar

## Molecular Biology / Genetics / Epidemiology

### Moderators:

Marcela VOTRUBA, Seang-Mei SAW

- 259  Pupillometric quantification of residual rod and cone activity in patients with visual loss due to Leber congenital amaurosis  
 KAWASAKI A, MUNIER FL, LEON L, KARDON RH—Lausanne, Nantes, Iowa City
- 260  Analysis of locus 2q13 in Ecuadorian family with keratoconus  
 NOWAK DM, KAROLAK JA, KUBIAK J, MOLINARI A, PITARQUE JA, BEJJANI BA, GAJECKA M—Poznan, Quito, Spokane
- 261  Identification of novel germline mutations in the VHL gene in Hungarian von Hippel-Lindau patients  
 LOSONCZY G, FAZAKAS F, PFLIEGLER G, KOMAROMI I, BERTA A—Debrecen
- 262 Anisometropia in population based study: The Mashhad Eye Study  
 OSTADIMOGHADDAM H, FOTOUHI A, HASHEMI H, HERAVIAN J, YEKTA AA, KHABAZKHOOB M—Mashhad, Tehran
- 263 Ocular phototoxicity and altitude among mountaineer guides  
 EL CHEHAB H, BLEIN JP, HERRY JP, GIRAUD JM, LE CORRE A, CHAVE N, RACTMADOUX G, SWALDUZ B, MOURGUES G, DOT C—Lyon, Chamonix Mont-Blanc
- 264 The -1562C/T MMP-9 and the -511C/T IL-1 $\beta$  gene polymorphisms in primary open-angle glaucoma patients  
 MAJSTEREK I, MARKIEWICZ L, PRZYBYLOWSKA K, GACEK M, WASZCZYK M, UDZIELA M, SZAFLIK JP, SZAFLIK J—Lodz, Warsaw
- 265  Evaluation of MMP-1 gene expression variants as a risk factors of primary open-angle glaucoma  
 MAJSTEREK I, MARKIEWICZ L, PRZYBYLOWSKA K, GACEK M, KAMINSKA A, SZAFLIK J, SZAFLIK JP—Lodz, Warsaw
- 266 Clinical assessment and molecular genetics of an autosomal dominant retinitis pigmentosa in a Bulgarian Roma family  
 KOEV K, CHERNINKOVA S, GEORGIEV R, KANEVA R—Sofia
- 267 Angioid streaks leading to the discovery of a new mutation in pseudoxanthoma elasticum  
 LOCATELLI A, ZUILY S, WAHL D, ANGIOI K—Vandoeuvre-Lès-Nancy
- 268 Multiple mtDNA deletions in Kearns-Sayre syndrome associated with macular dystrophy  
 ASCASO FJ, LOPEZ-GALLARDO E, DEL PRADO E, RUIZ-PESINI E, DEL BUEY MA, CRISTOBAL JA, SOUSA R, MONTOYA J—Zaragoza
- 269 Retinal dystrophy with macular hyperpigmentation in long chain 3-hydroxy-acyl-CoA dehydrogenase (LCHAD) deficiency  
 PEIRO C, PINILLA I, PEIRO B, JIMENEZ B, RAMIRO P, CASAS P, PEREZ-GARCIA D, IBANEZ J, AVENTIN MP, CABEZON L—Zaragoza, Barbastro - Huesca
- 270 Benign concentric annular macular dystrophy. Diagnosis in a pediatric case  
 DE LA MATA G, FERNANDEZ-PEREZ S, SATUE M, HERRERO LATORRE R, RUIZ O—Zaragoza
- 271 Electrophysiologic findings in Greek patients with Stargardt's disease  
 ANASTASAKIS A, PLAINIS S, KAMAKARI S, TSIKA C, DOUKA C, TSILIMBARIS MK—Heraklion

**EVER 2012**  
**Crete** Oct 3-6  
[www.ever.be](http://www.ever.be)

*Join EVER*



**EUPO**  
Leuven, Belgium  
June 29 - 30  
[www.eupo.eu](http://www.eupo.eu)



**2012**



**EB** 

**EBO 2012**  
Le Palais des Congrès,  
Paris, on 26-27 April 2012

Application  
opens from  
**October 2011**

For all further information log on to [www.ebo-online.org](http://www.ebo-online.org)

**SOE 2013** 


European Society of Ophthalmology  
8-11 June 2013, Copenhagen, Denmark



*Science for Sight*



Friday  
Oct 7







SIS  
RV

## ANTI-VEGF AGENTS FOR VARIOUS OCULAR PATHOLOGIES

Zeus

Constantin POURNARAS, Efstratios MENDRINOS



08:15	3111	Anti-VEGF for the treatment of retinal angiomatous proliferation DATSERIS I—Halandri-Athens
08:30	3112	Anti-VEGF for the treatment of serous and vascularized RPE detachment n exudative AMD KAPETANIOS A—Athens
08:45	3113	Anti-VEGF for the treatment of diabetic macular edema POURNARAS JAC, MASSIN P—Lausanne, Paris
09:00	3114	Anti-VEGF for treatment of macular edema secondary to retinal vein occlusions MENDRINOS E—Geneva
09:15	3115	Anti-VEGF for the treatment of CNV secondary to angoid streaks ROUVAS A—Athens
09:30	3116	Anti-VEGF treatment in ocular oncology ZOGRAFOS L—Lausanne

FP  
PBP

## ANTERIOR CHAMBER


Artemis

Nicholas DELAMERE, Gerhard GARHOFER

08:15		3121	Hyposmotic stress triggers ATP release from porcine lens via connexin and pannexin hemichannels DELAMERE NA, BEIMGRABEN C, MANDAL A, SHAHIDULLAH M—Tucson
08:27		3122	Stimulation of adrenergic $\beta$ -receptors enhances mydriasis in a porcine eye model JANBAZ CC, LUNDBERG B, BEHNDIG A—Umeå
08:39	★	3123	The discordance between objective signs and giant papillae improvement in patients with vernal kerato-conjunctivitis (VKC) participating in a randomized controlled clinical trial AMRANE M, BREMOND-GIGNAC D, LEONARDI A, ISMAIL D, BUGGAGE R, DENIAUD M, BAUDOUIN C—Evry, Amiens, Padova, Lyon, Paris
08:51		3124	Azithromycin: intrinsic cytotoxic effects on corneal epithelial cell cultures MENCUCCI R, PALADINI I, FAVUZZA E, SCARTABELLI T, MENCHINI U, PELLEGRINI GIAMPIETRO D—Florence
09:03		3125	Assessment of the efficacy of Cationorm® in patients with moderate dry eye compared with Optive® and Emustil® eye drops ARAGONA P, SPINELLA R, RANIA L, POSTORINO E, ROSZKOWSKA A, VERSURA P, PROFazio V, ROLANDO M—Messina, Bologna, Genova
09:15	★	3126	Cationic oil-in-water emulsions protect and restore function of the injured ocular surface DAULL P, LIANG H, BAUDOUIN C, GARRIGUE JS, BUGGAGE R, BRIGNOLE-BAUDOUIN F—Evry, Paris



**FP  
ACB**      **ANTERIOR SEGMENT ANATOMY AND THERAPY POSSIBILITIES**      **Athena**  
Erich KNOP, Tanja ILMARINEN

08:15	3131	Effect of swelling on the ultra structure of camel corneal stroma AKHTAR S, KHAN F, AHMED M, ALMUBRAD T—Riyadh
08:27	3132	Structure of solitary sebaceous glands in the sea lion eyelid – a Meibomian gland equivalent? KNOP E, KNOP N, KELLEHER DAVIS R—Berlin, Boston
08:39	3133	Characteristics of goblet cells in the conjunctival epithelium of the lid wiper explain the hydrodynamic type of ocular surface lubrication during the blink KNOP N, KORB DR, BLACKIE CA, KNOP E—Berlin, Boston
08:51	3134	Differential effects of various VEGF isoforms on endothelial cells and Tenon fibroblasts VAN BERGEN T, VANDEWALLE E, VAN DE VEIRE S, MOONS L, STALMANS I—Leuven
09:03	3135	Cis-urocanic acid inhibits SAPK/JNK signaling pathway in UV-B exposed human corneal epithelial cells in vitro PAIMELA T, JAUHONEN HM, KAUPPINEN A, LAIHIA JK, LEINO L, SALMINEN A, KAARNIRANTA K—Kuopio, Turku
09:15	 3136	Mesenchymal-like stem cells from human corneal stroma grown in medium containing human serum as the only supplement ALBERT R, VEREB Z, MOE MC, FESUS L, RAJNAVOLGYI E, FACSKO A, BERTA A, PETROVSKI G—Debrecen, Oslo

**SIS  
IM**      **IMMUNE MODULATION IN CORNEAL TRANSPLANTATION**      **Europa**  
Thomas FUCHSLUGER, Uwe PLEYER

08:15	3141	Immune modulation in the next decade PLEYER U—Berlin
08:33	3142	Roles of human antimicrobial peptides in innate immune defense at the ocular surface: arming and alarming corneal and conjunctival epithelial cells PAULSEN F, GARREIS F—Erlangen
08:51	3143	Novel therapeutic strategies for the induction of tolerance in corneal transplantation RITTER T, TREACY M, WILK M, MORCOS M, O'FLYNN L, RYAN A, NOSOV M—Galway
09:09	3144	Graft survival and cytokine production profile after limbal transplantation in the experimental mouse model LENCOVA A, FILIPEC M, HOLAN V—Prague
09:27	3145	Anti-apoptotic gene transfer to corneal epithelial grafts modulates immune response and leads to increased graft survival FUCHSLUGER T—Boston

SIS  
G**OCULAR RIGIDITY AND HYDRODYNAMICS OF THE HUMAN EYE**

Anna DASTIRIDOU, Ioannis G. PALLIKARIS

Minos 1



Ocular rigidity characterises the relationship between pressure and volume changes in the human eye and is expressed as a macroscopic coefficient. Ocular rigidity depends on the geometry of the globe as well as on the mechanical properties of its materials. Difficulties in the measurement of ocular rigidity in the living human eye have limited our knowledge on this parameter. However, the accurate assessment of ocular rigidity is important in tonometry, tonography and pulsatile ocular blood flow measurements. Moreover, ocular biomechanics have been implicated in the pathogenesis of glaucoma and age related macular degeneration. This symposium focuses on the techniques for the measurement of ocular rigidity in the human eye, its implications in aqueous humor dynamics and tonography and its clinical associations with ocular disease.

08:15	3151	Ocular rigidity: review of measurement methods and its implications in clinical practice PALLIKARIS IG—Heraklion
08:33	3152	Manometric measurement of the outflow facility in the human eye GINIS H, KARYOTAKIS NG, DASTIRIDOU A, TSILIMBARIS MK, PALLIKARIS IG—Heraklion, Larissa
08:51	3153	Ocular pulsatility and intraocular pressure DASTIRIDOU A—Larissa
09:09	3154	Ocular rigidity assessment in the decision making for glaucoma patients DETORAKIS ET—Heraklion
09:27	3155	Ocular rigidity and age-related macular degeneration TSILIMBARIS MK, KYMIONIS G, GINIS H, KOUNIS G, PALLIKARIS IG—Heraklion

SIS  
LC**OCULAR OXIDATIVE STRESS**

Per SÖDERBERG, Marjorie F LOU

Danae

08:15	3161	The physiological role of reactive oxygen species (ROS) in lens and corneal epithelial cells LOU M, XING KY, PAN Q, HUO YN, QIU WY, YAO YF—Lincoln, Hangzhou
08:33	★ 3162	Oxidative stress in the eye in diabetes OBROSOVA IG—Baton Rouge
08:51	3163	In vitro detection of uv-induced damage of the cornea, lens and RPE SIVAK JG, YOUN HY, MCCANNA DJ, JONES LW—Waterloo
09:09	3164	The evidence of oxidation in ultraviolet radiation cataract SÖDERBERG P—Uppsala
09:27	3165	Mouse models of accelerated lenticular aging by carbonyl and oxidant stress MONNIER VM, FAN X—Cleveland

SIS  
COS**WAVEFRONT ABERROMETRY AND QUALITY OF VISION SYMPOSIUM**

Jean-Jacques GICQUEL, Pierre Jean PISELLA

Minos 2

08:15	3171	From corneal topography to wavefront aberrometry GICQUEL JJ—Poitiers
08:33	3172	Wavefront aberration variations with multifocal intraocular lenses PISELLA PJ—Tours
08:51	3173	Professional sportsmen aiming for super vision DIGHIERO P—Poitiers
09:09	★ 3174	What are the implications of the straylight domain for the clinician VAN DEN BERG TJTP—Amsterdam
09:27	3175	An update on adaptive optics and the vision simulator CHATEAU N—Orsay



## Acta Ophthalmologica

### EVER-ACTA LECTURE - Per SÖDERBERG

Zeus

10:00 Introduction by Einar Stefansson

10:05 Clouding lens, swap or stop?  
SÖDERBERG P-Uppsala

FP RV	AMD		Zeus
11:00	3211	Association of Alzheimer's disease and age-related macular degeneration TOTH-KOVACS K, PAMER Z, RIDEG O, KOVACS A, FEKETE S, BIRO Z, KOVACS GL-Pecs	
11:12	3212	Evaluating the effectiveness of therapy with prospidin in patients with age-related macular degeneration CHUPROV AD, KULIGINA NA-Kirov	
11:24	3213	The effect of intravitreal injections of anti-VEGF on the pigment epithelial detachment (PED) in eyes with the exudative type of age related macular degeneration (AMD) KALOUDA P, TSIKA X, ANASTASAKIS A, TSILIMBARIS MK-Heraklion	
11:36	3214	Long-term visual acuity in patients with age-related macular degeneration treated with ranibizumab and persistence of subretinal fluid FERNANDEZ-PEREZ S, TORRON C, RUIZ-MORENO O, LECINENA J, PEREZ-INOIG A, DE LA MATA G, HERRERO LATORRE R, PABLO L-Zaragoza	
11:48	3215	Association between hypovitaminosis D and age-related macular degeneration: a case-control study MAUGET-FAYSSSE M, GRAFFE A, ANNWEILER C, BEAUCHET O, MILEA D-Lyon, Angers	
12:00	3216	AMD and atherosclerosis coincidence: the role of complement system activation and endothelial dysfunction MACHALINSKA A, MACHALINSKI B, KARCZEWICZ D-Szczecin	
12:12	3217	Ranibizumab for the treatment of exudative age-related macular degeneration associated with retinal pigment epithelial detachment ZIYATDINOVA O, SAFIULLINA L-Kazan	

SIS PBP	VASCULAR ASPECTS OF GLAUCOMA - WHAT TO LOOK AT?	Artemis
11:00	3221	Looking at the ONH - pros and cons of vascular involvement in glaucoma JONAS JB-Mannheim
11:22	3222	Looking into clinical studies - pros and cons of vascular involvement in glaucoma ORGUL S-Basel
11:44	3223	Vascular reactivity in glaucoma GARHOFER G-Austria
12:06	3224	The vascular aspect of glaucoma - what should we look at? SCHMETTERER L-Vienna

SIS ACB	CELL BIOLOGY OF OCULAR SURFACE	Athena
11:00	3231	Biomarkers and proteomics in corneal cell biology BEUERMAN RW, ZHOU L-Singapore
11:30	3232	Corneal epithelium in ocular pharmacology URTTI A-Helsinki
12:00	3233	Replacement of corneal epithelium ILMARINEN T, LAINE J, JUUTI-UUSITALO K, NUMMINEN J, SUURONEN R, UUSITALO H, SKOTTMAN H-Tampere



**JOINT M. CONCORDIA: STANDARDS AND CRITERIA IN ACADEMIC  
OPHTHALMOLOGY IN EUROPE**

Europa

Marko HAWLINA



Academic career in every branch of medicine as well as in ophthalmology typically consists of three components: professional expertise, research achievements and ability to teach. In European countries, however, criteria to qualify and progress in career are very different. One common requirement for academic career is to obtain a PhD title, yet the requirements to achieve this may be very different in European countries.

Likewise, achieving the level of professor can involve very different requirements across the European countries. This variation involves different numbers and requirements regarding IF of the papers or books published as well as "heraldic" aspects of the post. The aim of this symposium is to compare these standards and requirements across European countries and to see if any harmonization is feasible from both research and educational aspect with the aim to be able to achieve similar and comparable standards in academic ophthalmology throughout Europe.

**SIS BINOCULAR VISION & STEREOPSIS: WHY TWO EYES ARE BETTER  
THAN ONE!**

Minos 1

VEP Franziska RAUSCHER



11:00	3251	An introduction to binocular vision & stereopsis. why 2 eyes are better than 1! BARRETT BT–Bradford
11:22	3252	Development of binocular vision and implications for clinical testing MCGRAW P–Nottingham
11:39	3253	Assessment of BV & the more common anomalies of binocular vision VAKROU C–Athens
11:56	3254	The impact of binocular vision disorders on 3D display viewing STRANG NC–Glasgow
12:13	★ 3255	Clinical assessment of binocular vision with the ZEISS Polatest® KRESS C–Aalen

**SIS**      **COMPLICATIONS OF IRRADIATION TREATMENT OF INTRAOCULAR**      Danae  
**TUMOURS**  
**PO**      Leonidas ZOGRAFOS

11:00	3261	Radiation induced optic neuropathy. Clinical presentation and treatment GRAGOUDAS E–Boston
11:18	3262	Irradiation induced maculopathy and retinopathy. Diagnosis and treatment DAMATO BE, GROENEWALD C–Liverpool
11:36	3263	Neovascular glaucoma anti-VEGF treatment ZOGRAFOS L–Lausanne
11:54	3264	Inflammation and scleral defect following ocular radiotherapy. Therapeutic approach DESJARDINS L, LEVY C, LUMBROSO-LE ROUIC L, CASSOUX N, DENDALE R, PLANCHER C, ASSELAIN B–Paris
12:12	3265	The preservation of ocular surface following complete irradiation of the anterior segment SCHALENBOURG A, MAJO F, OTHENIN-GIRARD P, ZOGRAFOS L–Lausanne

**SIS**      **UPDATE ON TECHNIQUES IN CORNEAL AND OCULAR SURFACE**      Minos 2  
**SURGERY**  
**COS**      Mario NUBILE, Jean-Jacques GICQUEL

11:00	3271	Conjunctival autografts: indications and techniques GICQUEL JJ–Poitiers
11:15	3272	Corneal epithelial limbal stem cell transplantation for ocular surface reconstruction DUA H–Nottingham
11:30	3273	Corneal collagen cross linking: traditional vs transepithelial results with histopathological analysis MENCUCCI R, MARINI M, PALADINI I, FAVUZZA E, SARCHIELLI E, MENCHINI U, VANNELLI GB–Florence
11:45	3274	Amniotic membrane transplantation LANZINI M, CALIENNO R, CURCIO C, CIAFRÈ M, COLASANTE M, NUBILE M, MASTROPASQUA L–Chieti
12:00	3275	New trends in endothelial transplantation: DSAEK vs DMEK SCORCIA V–Catanzaro
12:15	3276	Refractive and therapeutic applications of femtosecond laser corneal surgery NUBILE M–Chieti



### BUSINESS MEETINGS OF THE SCIENTIFIC SECTIONS

- ACB - Anatomy / Cell Biology ..... Athena
- COS - Cornea / Ocular Surface ..... Minos 2
- Glaucoma ..... Minos 1
- IM - Immunology / Microbiology ..... Europa
- LC - Lens and Cataract ..... Danae
- MBGE - Molecular Biology / Genetics / Epidemiology ..... Artemis
- NSPH - Neuro-ophthalmology / Strabismology / Paediatric ophthalmology / History ..... Europa
- PO - Pathology / Oncology ..... Danae
- PBP - Physiology / Biochemistry / Pharmacology ..... Artemis
- RV - Retina / Vitreous ..... Zeus
- VEP - Vision Sciences / Electrophysiology / Physiological Optics ..... Athena

### AGENDA

1. Report of the chair of section
2. Report of the programme secretary
3. Next year's meeting:
  - nomination of the 2012 section programme secretary (different from the section chair)
  - proposals of Special Interest Symposia (SIS)
  - proposals of Courses
  - proposals for Keynote speakers
4. Comment on the EVER activities
5. Other business

**In addition to the agenda, the sections COS and G will nominate at least 2 candidates for section chair.**


**Sandwiches and refreshments will be served**



**SIS** **IMAGING RETINAL FLUOROPHORES: AUTOFLUORESCENCE AND BEYOND** **Zeus**  
**RV** Irene BARBAZETTO

13:45	3311	Isolation and structural studies of native RPE and BM fluorophores GAILLARD E, DILLON JP, MURDAUGH L–DeKalb
14:00	3312	Spectral properties of the anterior segment of primates DILLON JP, MERRIAM JC, GAILLARD E–DeKalb, New York
14:15	3313	Time resolved autofluorescence - a new diagnostic tool in ophthalmology SCHWEITZER D–Jena
14:30	3314	Quantitative autofluorescence measurements SMITH RT, GREENBERG J, DELORI F–Demarest
14:45	3315	Dual-wavelength “color” autofluorescence HAMMER M–Jena
15:00	3316	Differences in fundus autofluorescence in clinical practice BARBAZETTO I–New York

**FP** **INTRAVITREAL TREATMENT** **Artemis**  
**PBP** Miltiadis TSILIMBARIS, Neville OSBORNE

13:45	3321	Dhea analogue neuroprotection in an experimental model of retinal detachment TSOKA PA, CHARALAMPOPOULOS I, GRAVANIS A, TSILIMBARIS MK–Heraklion
13:57	3322	Retinal bioavailability of a DHEA synthetic analog after intraperitoneal administration in the Sprague Dawley rat TSIKA C, TSOKA PA, TZATZARAKIS M, CHARALAMPOPOULOS I, GRAVANIS A, TSILIMBARIS MK–Heraklion
14:09	 3323	Topical application of AMA0076, a locally acting rho kinase (ROCK) inhibitor, results in a robust IOP control in a hypertensive rabbit model VAN DE VELDE S, VAN BERGEN T, VANDEWALLE E, SIJNAVE D, HOLLANDERS K, LEYSEN D, MOONS L, STALMANS I–Leuven, Diepenbeek
14:21	3324	Effect of anti-VEGF drugs and steroids on the inner blood-retinal barrier, after experimental BRVO in rats: preliminary results BOUZIKA PS, GILODI N, CONTI A, TSILIMBARIS MK, POURNARAS CJ–Geneva, Crete
14:33	3325	Cytoarchitectonic and apoptotic consequences after intravitreal octreotide injection in an oxygen induced retinopathy mouse model AKKOYUN I, KAYA S, HABERAL N, DAGDEVIREN A, YILMAZ G, OTO S, AKOVA YA–Ankara
14:45	3326	Ghrelin and obestatin decreases the IOP in a acute glaucoma model ROCHA DE SOUSA AA, TAVARES-SILVA M, PEREIRA-SILVA P, AZEVEDO- PINTO S, RODRIGUES-ARAÚJO J, LEITE-MOREIRA AF–Porto

**JOINT M. FRO - BELGIAN FUND FOR RESEARCH IN OPHTHALMOLOGY 1**

Philippe KESTELYN

Athena



13:45	3331	SOCS1 gene overexpression in the retinal pigment epithelium during experimental autoimmune uveitis BAZEWICZ M-Brussels
14:03	3332	Glaucoma from eye to brain: are MMP-2 and MMP-14 involved? DE GROEF L-Leuven
14:21	3333	Regulation of adhesion molecules in EAU DEWISPELAERE R-Brussels
14:39	3334	Evaluation of Cyclosporine ocular dosage forms in an in vivo mouse model HERMANS K-Antwerp
14:57	3335	The role of local rock-inhibition in the pathogenesis of age-related macular degeneration HOLLANDERS K-Leuven

**SIS  
NSPH****UPDATE IN MANAGEMENT OF GRAVES' ORBITOPATHY**

Antonella BOSCHI, Aki KAWASAKI

Europa

13:45	3341	Management of thyroid dysfunction in Graves' orbitopathy ORGIAZZI J-Lyon
14:03	3342	Management of mild and moderate Graves' orbitopathy BOSCHI A-Brussels
14:21	3343	Dysthyroid optic neuropathy: diagnosis and treatment BORRUAT FX-Lausanne
14:39	3344	Radiologic features of inflammatory versus tumoral orbital diseases DE POTTER P-Brussels
14:57	★ 3345	Clinical cases KAWASAKI A-Lausanne


**SIS  
G****EYE AND BRAIN IN GLAUCOMA**

Georg MICHELSON, Doina GHERGHEL

Minos 1

13:45	3351	Glaucoma of the brain: a disease model for the study of transsynaptic neural degeneration GUPTA N-Toronto
14:00	3352	Abnormal retinal vascular function and cognitive loss in Alzheimer's disease patients GHERGHEL DOINA, BENAVENTE-PEREZ A, MROCKOWSKA S-Birmingham
14:15	3353	Quantitative assessment of the visual pathway by MRI-DTI ENGELHORN T-Erlangen
14:30	3354	Impairment of 4th neuron axons correlates with retinal nerve fiber loss in glaucoma MICHELSON G, WAERNTGES S, ENGELHORN T, EL-RAFEI A, HORNEGGER J, DOERFLER A-Erlangen
14:45	3355	Retinotopic organisation of primary visual cortex in glaucoma: a fMRI study ZANGWILL L-San Diego
15:00	3356	Neuroprotection of the visual pathway in glaucoma - is there a future role? CORDEIRO MF-London



FP PO	PATHOLOGY/ONCOLOGY 1		Danae
	Theodora HADJISTILIANOU, Martine J JAGER		
13:45	3361	Proteomic analysis of aqueous humor in retinoblastoma: a preliminary approach MICHELI L, HADJISTILIANOU D, GIGLIONI S, VANNONI D, BROGI E, CEVENINI G, CORTELAZZO A, DE FRANCESCO S, MENICACCI F, LEONCINI R—Siena	
13:57	 3362	ERK activation and monosomy 3 are associated with Src expression in uveal melanoma and may serve as biomarkers for dasatinib treatment VERSLUIS M, EL FILALI M, BRONKHORST IHG, BAGHAT A, LUYTEN GPM, JAGER MJ, VAN DER VELDEN PA—Leiden	
14:09	3363	C-met signaling and preclinical analysis of crizotinib in uveal melanoma VAN DER VELDEN PA, DE LANGE M, DA SILVA CG, VERSLUIS M, LUYTEN GPM, JAGER MJ—Leiden	
14:21	3364	Immunosuppressive inflammation is an inherent characteristic of prognostically bad uveal melanoma BRONKHORST IHG, VU THK, JORDANOVA ES, ONKEN MD, VERSLUIS M, VAN DER VELDEN PA, LUYTEN GPM, HARBOUR JW, VAN DER BURG SH, JAGER MJ—Leiden, St Louis	
14:33	3365	Inflammation in primarily and secondarily enucleated eyes with uveal melanoma VU THK, BRONKHORST IHG, VERSLUIS M, MARINKOVIC M, VAN DUINEN SG, VROLIJK J, LUYTEN GPM, JAGER MJ—Leiden	
14:45	3366 <i>rf</i>	Mutations in the BAP1 gene in uveal melanoma KOOPMANS AE, VAN DEN BOSCH T, VAARWATER J, KILIC E, PARIDAENS D, NAUS N, DE KLEIN A—Rotterdam	
14:51	3367 <i>rf</i>	Preclinical study of a glycoengineered anti-human CD20 antibody in murine models of primary cerebral and intraocular B-cell lymphomas BAGGA RYM—Courbevoie	

SIS COS	CELL THERAPY IN CORNEA - MOVING TOWARDS INDIVIDUALIZED TREATMENT		Minos 2
	Thomas FUCHSLUGER, Harminder S DUA		
13:45	3371	Autologous and allogeneic limbal stem cell therapy - where are the limits? DUA H—Nottingham	
14:05	3372	Keratin films for ocular surface reconstruction REICHL S, BORRELLI M, GEERLING G—Braunschweig, Wuerzburg	
14:25	3373	Nanoparticle-mediated transfer of therapeutics to corneal cells FUCHSLUGER T—Essen	
14:45	★ 3374	Corneal stromal mesenchymal stem cells for corneal stroma reconstruction GRIFFITH M, RAFAT M—Linköping	



## Ophthalmic Research

Journal for Research in Experimental and Clinical Ophthalmology

### OPHTHALMIC RESEARCH LECTURE - Andrew D DICK

Zeus

15:30 ☆

Road to fulfillment (not perdition): taming immune response to restore vision  
**DICK A**—Bristol

Introduction by Uwe PLEYER

**SIS** **RETINAL OXYGENATION AND BLOOD FLOW** **Artemis**  
**PBP** Sveinn HARDARSON, Gerhard GARHOFER

17:30		3421	The role of oxygen in ocular blood flow regulation GARHOFER G—Vienna
17:52	★	3422	Neurovascular coupling and retinal oxygenation HAMMER M—Jena
18:14		3423	Retinal vessel oximetry in glaucoma MCNAUGHT A, HARVEY A, MORDANT D, GORMAN A, RITCHIE P, RODMELL P, MORGAN S, CROWE J—Cheltenham, Edinburgh, Oxford, Nottingham
18:36	★	3424	The effect of intravitreal ranibizumab on retinal oxygenation in central retinal vein occlusion TRAUSTASON S, LA COUR M, LARSEN M—Copenhagen

**JOINT M. FRO - BELGIAN FUND FOR RESEARCH IN OPHTHALMOLOGY 2** **Athena**  
 Philippe KESTELYN



17:30		3431	Expression and role of aquaporins in proliferative vitreoretinopathy MOTULSKY E—Brussels
17:48		3432	A Th2-inducing dendritic cell vaccine targeting amyloid- as found in drusen of patients with age-related macular degeneration POSSEMIERS T—Antwerp
18:06		3433	The effect of local rock-inhibition on wound healing after glaucoma filtration surgery SIJNAVE D—Leuven
18:24		3434	Local rock-inhibition as a novel therapeutic approach for neuroprotection of retinal ganglion cells VAN BERGEN T—Leuven
18:42		3435	Local Rock inhibition as a novel IOP lowering strategy in the treatment of glaucoma VAN DE VELDE S—Leuven

**SIS** **THE NEW DECADE: IMMUNE MODULATION IN EYE DISEASES** **Europa**  
**IM** Uwe PLEYER, Andrew DICK

17:30	★	3441	Immune modulation in the next decade DICK A—Bristol
17:48		3442	Immune modulation in uveitis: biologicals - "golden calf" or "gold standard"? BODAGHI B—Paris
18:06		3443	Immune modulation in ocular allergy: update and future directions LEONARDI A—Padua
18:24		3444	Graft rejection in keratoplasty: is there a place for topical immune modulation? PLEYER U—Berlin
18:42		3445	Immune modulation in optic neuritis: "good news?" LAGREZE W—Freiburg



**SIS** **SECONDARY GLAUCOMAS** **Minos 1**  
**G** Sayeh POURJAVAN, K. Sheng LIM

17:30	3451	Intraocular tumours and glaucomas DE POTTER P–Brussels
17:48	3452	Thyroid and ocular hypertension BOSCHI A–Brussels
18:06	3453	Glaucoma after vitreoretinal surgery DETRY-MOREL M–Brussels
18:24	3454	Secondary glaucoma associated with congenital corneal abnormalities CLAERHOUT I–Ghent
18:42	3455	Management of secondary glaucoma LIM KS–London

**SIS** **MANAGEMENT OF SMALL CHOROIDAL MELANOCYTIC LESIONS** **Danae**  
**PO** Laurence DESJARDINS, Tero KIVELÄ

17:30	3461	Definition, clinical aspects and new imaging of small melanocytic lesions of the choroid CASSOUX N–Paris
17:45	3462	Genetic findings in small melanocytic lesions COUPLAND SE, DAMATO BE–Liverpool
18:00	3463	Metastasis from small melanocytic lesions: OOG experience and review of the literature KIVELÄ T–Helsinki
18:15	3464	Practical management of small melanocytic lesions ZOGRAFOS L–Lausanne
18:30	3465	Practical management of small melanocytic lesions DAMATO BE, HEIMANN H–Liverpool
18:45	3466	Practical management of small melanocytic lesions DESJARDINS L–Paris

**SIS** **CORNEAL BIOENGINEERING** **Minos 2**  
**COS** Thomas FUCHSLUGER, Christopher LIU

17:30	3471	Limitations of 'hard' keratoprosthesis in clinical practice - can 'soft' kps lead the way out? LIU CS, AVADHANAM V–Brighton
17:48	3472	Autologous versus allogeneic limbal stem cell therapy - challenges and pitfalls DUA H–Nottingham
18:06	3473	From lab to limbus and back to the lab! AHMADI-LARI S–Surrey
18:24	3474	Corneal cell and nerve regeneration promoted by biosynthetic implants LAGALI N, GRIFFITH M, FAGERHOLM P–Linköping
18:42	3475	Mesenchymal stem cell properties in the endothelium - bioengineered ec for lamellar keratoplasty? FUCHSLUGER T–Essen





## Neuro-ophthalmology / Strabismology / Paediatric / History

### Moderators:

**Dominique BREMOND-GIGNAC, François-Xavier BORRUAT**

- 301 Endothelin-1 (ET-1) plasma levels in multiple sclerosis (MS) patients  
*rf*  
JANKOWSKA-LECH I, BIK Z, WOLINSKA E, TERELAK-BORYS B, GRABSKA-LIBEREK I, PALASIK W—Warsaw
- 302 Anisometropia and amblyopia in children  
*rf*  
BOGDANICI C, BOGDANICI T—Iasi
- 303 Retinal nerve fiber layer thickness measured by optical coherence tomography correlates with Expanded Disability Status Scale (EDSS) in multiple sclerosis (MS)  
*rf*  
CARZOLI A, LATARCHE C, BERROD JP, DEBOUVERIE M, ANGIOI K—Cannes, Nancy
- 304 Simulation and psychosomatic events in ophthalmology  
CRETU I, BETERMIEZ P, MILAZZO S—Amiens
- 305 Frequency of anisocoria in patients with asthenopia  
BOYCHUK IM, KHRAMENKO NI, BUSHUYEVA NN—Odessa
- 306 Association between non-arteritic anterior ischaemic optic neuropathy and sleep apnoea syndrome  
  
KHAYI H, CHIQUET C, PEPIN JL, ARNOL N, RENARD E, PALOMBI K, LEVY P, ROMANET JP—Grenoble
- 307 Cyclomed 1% for diagnosis of disturbances of pupillary-accommodative system in patients  
BUSHUYEVA NN, MALIEVA E, DUKHAYER SH—Odessa
- 308 Effects of extreme altitude in retinal and optic nerve head parameters  
ASCASO FJ, NERIN MA, VILLEN L, MORANDEIRA JR, HUERVA V, PINILLA I, DEL BUEY MA, CRISTOBAL JA—Zaragoza, Lleida
- 309 Relationship between optical coherence tomography and visual evoked potentials in patients with parasellar tumours without chiasmal compression  
  
WASIK M, PILECKI W—Wroclaw
- 310 Abnormalities of optical coherence tomography and visual evoked potentials in patients with chiasmal compression syndrome  
WASIK M, PILECKI W—Wroclaw
- 311 Study of retinal nerve fiber layer in obstructive sleep apnea syndrome patients  
FERRANDEZ ARENAS B, CALVO P, GIL-ARRIBAS L, GÜERRI N, OTIN S, ALTEMIR I, GARCIA E, FERRERAS A—Zaragoza
- 312 Degeneration of retinal nerve fiber layer in patients with multiple sclerosis. Prospective study with three years follow-up  
HERRERO LATORRE R, GARCIA MARTIN E, SATUE M, SANCHO MORO E, FERNANDEZ TIRADO J—Zaragoza
- 313 Retinal evaluation by optical coherence tomography in adults with obstructive sleep apnea syndrome  
CASAS P, ASCASO FJ, ADIEGO MI, JIMENEZ B, CABEZON L, CRUZ N, TEJERO-GARCES G, CRISTOBAL JA—Zaragoza
- 314 Parkinson's disease and retinal optical coherence tomography  
JIMENEZ DEL RIO B, ASCASO FJ, LOPEZ DEL VAL J, CABEZON L, CASAS P, CRUZ N, PEIRO C, CRISTOBAL JA—Zaragoza
- 315 Retinal nerve fiber layer thickness measured by  
CABEZON L, ASCASO FJ, RAMIRO P, JIMENEZ B, PEREZ D, CASAS P, CRUZ N, CRISTOBAL JA—Zaragoza
- 316 Morphological changes in peripapillary nerve fiber in multiple sclerosis patients  
JANKOWSKA-LECH I, GRABSKA-LIBEREK I, WASYLUK J, TERELAK-BORYS B, PALASIK W—Warsaw
- 317 Frequency of glaucomatous optic neuropathy (GON) in multiple sclerosis patients  
JANKOWSKA-LECH I, GRABSKA-LIBEREK I, TERELAK-BORYS B, WASYLUK J, PALASIK W, TREDA A—Warsaw
- 318 Optical coherence tomography in the evaluation of patients with mild cognitive impairment of amnesic type  
CASAS P, CRUZ N, ASCASO FJ, PASCUAL LF, LOBO A, JIMENEZ B, CABEZON L, CRISTOBAL JA—Zaragoza
- 319 The role of suppression in amblyopia  
LI J, THOMPSON B, LAM CS, CHAN LY, MAEHARA G, WOO GC, YU M, HESS RF—Guangzhou, Auckland, Hong Kong SAR, Montreal
- 320 Prevalence and risk factors of near decompensated heterophoria in a population of university students  
YEKTA AA, GHASEMI MOGHADDAM S, KHABAZKHOOB M, OSTADI MOGHADDAM H, DERAKHSHAN A, HERAVIAN J, AZIMI A, YEKTA R—Mashhad, Tehran
- 321 Peculiarities of accommodative esotropia  
BUSHUYEVA NN, SENYAKINA A, MARTYNYUK S—Odessa, Ternopil
- 322 Strabismus and amblyopia in Iranian schoolchildren  
OSTADIMOGHADDAM H, HERAVIAN J, YEKTA AA, AZIMI A, KHABAZKHOOB M, MOHAMMADIAN M—Mashhad, Tehran
- 323 Entropion as a complication of the frontalis muscle flap direct advancement  
SATUE M, GARCIA-MARTIN E, HERRERO LATORRE R, EGEA MC, FUENTES JL, FERNANDEZ FJ—Zaragoza
- 324 Foreign body granulomas after fadenoperation: a review of seven cases  
ROBIN A, GEORGE JL, MAALOUF T, ANGIOI K—Vandoeuvre Les Nancy
- 325 Ocular manifestations in Duane radial ray syndrome  
GARCIA MARTIN E, ALMARCEGUI C, FERNANDEZ J, PINILLA I, SATUE M, CALVO P, FERRANDEZ ARENAS B, FUERTES I—Zaragoza
- 326 Unilateral mydriasis revealing a neurovascular conflict: a case report  
TRECHOT F, LEGOU F, BRAUN M, ANGIOI K—Nancy
- 327 Unilateral ischemic optic neuropathy by tacrolimus after liver transplantation  
RAMIRO P, MATEO J, CABEZON L, IBANEZ J, PEIRO C, JIMENEZ B, PADGETT E, CRISTOBAL JA—Zaragoza
- 328 Loss of visual acuity following bariatric surgery for morbid obesity in three sisters  
PEIRO C, PINILLA I, PEIRO B, AVENTIN MP, ASCASO J, PEREZ-GARCIA D, IBANEZ J, CAMELLO C, DEL BUEY MA, ZABADANI K—Zaragoza, Barbastro - Huesca
- 329 A case of chronic relapsing inflammatory optic neuropathy (CRION)  
HERRERO LATORRE R, FERNANDEZ PEREZ S, DE LA MATA G, IDOPE M, SATUE M, GARCIA MARTIN E—Zaragoza
- 330 Is tractography coupled with the retinotopy obtained by functional magnetic resonance imaging feasible at 1,5 Tesla to study the optic radiations?  
GEORGET M, DESTRIEUX C, ANDERSSON F, ZEMMOURA I, COTTIER JP, PISELLA PJ—Tours
- 331 An unusual optic neuropathy: interest of imaging and conservative treatment  
CRETU I, MILAZZO S, BREMOND-GIGNAC D—Amiens

## Retina / Vitreous

Moderators: Efstratios MENDRINOS, Carl ARNDT

- 332 The distribution of retinal thickness in healthy eyes and its use in the objective analysis of optical coherence tomography (OCT) scans  
*rf*  
HALDAR S, DAVIES N—London
- 333 Cytokine concentration in aqueous humor of eyes with diabetic macular edema  
*rf*  
JONAS JB, JONAS R, NEUMAIER M, FINDEISEN P—Mannheim
- 334 Experimental study of distinguishing small retinal haemorrhages from dust artefacts using HLS colour space  
*rf*  
SUZUKI N, YAMANE K—Higashi-Hiroshima, Hiroshima
- 335 New cyanine dye for ILM staining  
*rf*  
LAUBICHLER P, VARJA A, LANGHALS H, EIBL K, KERNT M, HARITOGLOU C—Munich
- 336 Acute intraocular pressure after intravitreal injections, what is the mechanism?  
*rf*  
DOT C, EL CHEHAB H, LE CORRE A, RACT-MADOUX G, COSTE O, SALVANY P, MOURGUES G, SWALDUZ B, GIRAUD JM—Lyon
- 337 Intravitreal bevacizumab (Avastin®) in treating macular oedema associated with central retinal vein occlusion  
ADEPEGBA O, GEORGE S—London
- 338 The dexamethasone drug delivery system for the treatment of retinal venous occlusion with cystoid macular edema  
EGEA ESTOPINAN C, IDOPE M, PRIETO CALVO E, FERNANDEZ LARRIPA S, FERRERAS A, PABLO L, ABECIA MARTINEZ E—Zaragoza
- 339 Retinal vein occlusion: treatment by series of 3 ranibizumab IVT  
GONZALEZ C—Toulouse
- 340 Responce to intravitreal bevacizumab for macular edema following central retinal vein occlusion in patients with pseudoexfoliation syndrome  
  
STECH S, JURKUTE N, JUSKIENE D, CIMBALAS A, ASOKLIS R—Vilnius
- 341 Design and rationale of COMO, a 12-month study that compares the safety and efficacy of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion  
LOEWENSTEIN A, BANDELLO F, KAMPIK A, SOUIED E, FIGUEROA M, TUFAIL A, HEYWOOD A, FULFORD-SMITH A—Tel Aviv, Milano, Munich, Paris, Madrid, London, Marlow
- 342 Analysis of gene expression in ischemic neuroretinas: genome-wide screen discriminating occlusion versus laser effects in rats  
GEKA A, OROPESA C, POURNARAS CJ—Geneva
- 343 Central retinal vein occlusion: visual acuity correlates with focal electroretinogram but not with optical coherence tomography  
RUBERTO G, TINELLI C, LIZZANO M, PICCININI P, CALMA F, DISPINSERI J—Pavia
- 344 Intravitreal ranibizumab for retrofoveal neovascular age related macular degeneration, in pseudovitelliform and/or drusenoid pigment epithelium detachment shape  
GONZALEZ C—Toulouse
- 345 Effect of subtenon injection of natural leucocytic interferon- $\alpha$  for treatment of age-related choroidal neovascularization  
CELLINI M, STROBBE E, BALDUCCI N, CAMPOS E—Bologna
- 346 Idebenone prevents retinal pigment epithelial cells from oxidative stress and apoptotic cell death by stabilizing BAX/Bcl-2 ratio  
ARENDE N, LAUBICHLER P, WOLF A, HARITOGLOU C, ULBIG MW, KAMPIK A, KERNT M—Munich
- 347 Long – term results of intravitreal bevacizumab (Avastin®) injection for choroidal neovascularisation secondary to angioid streaks  
LEVINAITE G, CIMBALAS A, SVALBONAITE E, ASOKLIS R—Vilnius
- 348 Premacular haemorrhage in a patient with leukaemia  
PRIETO CALVO E, EGEA ESTOPINAN C, IDOPE CORTA M, DE LA MATA G, ABECIA MARTINEZ E, FERNANDEZ LARRIPA S, GARCIA MARTIN E—Zaragoza
- 349 Association between retinal vessel diameters and different types of diet  
DROBNJAK D, VEIBY N, KESSEL L, JORGENSEN T, TOFT U, LARSEN M—Oslo, Copenhagen
- 350 Clinical manifestations of reticular pseudodrusen in Korean patients  
KIM SM, LEE MY, HAM DI—Seoul
- 351 Correlation between exudative age-related macular degeneration and pseudoexfoliation syndrome  
SIRTAUTIENE R, ASOKLIS R, LIUTVINAITE R, BABRAUSKAITE E—Vilnius
- 352 Subtenon injection of natural leucocytic interferon- $\alpha$  for treatment of diabetic macular edema  
CELLINI M, STROBBE E, BALDUCCI N, CAMPOS E—Bologna
- 353 Increased IL-6 levels in the vitreous of proliferative diabetic retinopathy (PDR)  
ARJAMAA O, PÖLLÖNEN M—Turku
- 354 Proliferative diabetic retinopathy: from screening to treatment  
TADROS C, MANSOUR T, PETO T—London
- 355 Combined cataract surgery with anti-VEGF agents in patients with quiescent proliferative diabetic retinopathy with no macular edema  
  
SOKOLAKIS THOMA, SPAI SOFIA, GOURGOULI IOANA—Athens
- 356 Intrasession reproducibility of retinal nerve fibre and macular thickness measurements using Cirrus® Fourier-domain OCT in DM patients without retinopathy  
IDOPE M, PRIETO E, EGEA MC, FERNANDEZ-PEREZ S, GARCIA MARTIN E, PINILLA I, BORQUE E—Zaragoza
- 357 Diabetic retinopathy screening with computational support  
  
CSUTAK A, ANTAL B, LAZAR I, PETO T, TOROK Z, BIRO A, HAJDU A—Debrecen, London
- 358 Cytokines and adhesion molecules in proliferative diabetic retinopathy: high vitreous concentration of IL-6 and IL-8, but not of adhesion molecules in relation to plasma concentrations  
LIINAMAA MJ, KOSKELA UE, KUUSISTO SM, NISSINEN AE—Oulu
- 359 Retinal phototoxicity related to xenon light  
★  
GARCIA M, CASTRO J—Oviedo (Asturias)
- 360 Changes in the retinal vessel diameter, retinal nerve fiber layer thickness, and optic disc after vitrectomy  
LEE SU, KIM SJ, LEE JE, KIM SY, LEE SJ—Busan
- 361 Aspirin® is not a risk factor of haemorrhagic complications during or after surgery of primary rhegmatogenous retinal detachment  
ZARATZIAN BRILLAT ZB, ALBALADEJO A, ROMANET R, CHIQUET C—Grenoble

- 362 Intravitreal ranibizumab in the treatment of subretinal neovascularization in a case of punctate inner choroidopathy  
PEREZ GARCIA D, PINILLA I, JIMENEZ DEL RIO B, IBANEZ J, PEIRO EMBID C, CABEZON L, CRISTOBAL JA—Zaragoza
- 363 Pivotal role for SD-OCT in the diagnosis of acute zonal occult outer retinopathy  
DE ZAEYTIJD J, KESTELYN P, LEROY BP—Ghent
- 364 Diabetic retinopathy and type 2 macular telangiectasia  
TADROS C, MANSOUR T, LEUNG I, SALLO F, CLEMONS T, PETO T, MACTEL GROUP—London, Washington
- 365 OCT as sensitive indicator of geometric fundus deformities  
KRSTEL H, BEUTELSPACHER SC, STEINMETZ PH, DRINGS A, ZAHN TH, JONAS JB—Mannheim
- 366 Reproducibility and differences between Cirrus® and Spectralis® Fourier-domain OCT in epiretinal membranes  
PINILLA I, GARCIA-MARTIN E, IDOIBE M, PEREZ-GARCIA D, JIMENEZ B, RAMIRO P, PEIRO C, ASCASO J, ABECIA E—Zaragoza
- 367 Reproducibility of retinal thickness measurements in patients with age-related macular degeneration using Fourier-domain optical coherence tomography  
RAMIRO P, PINILLA I, CABEZON L, PEREZ D, IBANEZ J, MATEO A, CRISTOBAL JA—Zaragoza
- 368 Retinal manifestations in catastrophic antiphospholipid syndrome  
VILLAFRUELA I, COLAS T, PRIETO M, CLARIANA A, RIVAS O, FERNANDEZ A, BORREGO R, DE PABLO P—Madrid
- 369 Presence of contracting cellular elements at the border of stage III and IV macular holes  
MENDRINOS E, BOCHATON-PIALLAT ML, GILODI N, TSILIMBARIS MK, POURNARAS CJ—Geneva, Crete
- 370 Laser and surgery treatment of retinoschisis  
BAGDASAROVA T—Moscow
- 371 Fluorescein angiography based classification of retinopathy of prematurity  
SUZANI M, TRAVERSA E, BARILLÀ D, GUAGLIANO R, BERTONE C, ANSELMETTI G, BIANCHI PE—Pavia, Torino



*Science for Sight*



# Saturday Oct 8



FP  
RV

## RETINA

Eberhart ZRENNER, Irene BARBAZETTO

Zeus

08:15	4111	Adaptive optics imaging in age-related macular degeneration GOCHO-NAKASHIMA K, BENCHABOUNE M, ULLERN M, LAMORY B, CHATEAU N, SAHEL JA, PAQUES M—Paris, Orsay
08:27	4112	The effect of anti-VEGF treatment and triamcinolone in experimental retinal vein occlusion REHAK M, HOLLBORN M, WIEDEMANN P, BRINGMANN A—Leipzig
08:39	★ 4113	Technical and topographical variability in automatic retinal oximetry PALSSON O, HARDARSON SH, STEFANSSON E—Reykjavik
08:51	★ 4114	Daily skills performed by previously blind RP patients with subretinal electronic implant Alpha IMS ZRENNER E, BARTZ-SCHMIDT U, BESCH D, BRUCKMANN A, GREPPMAIER U, GEKELER F, KOITSCHEV A, SACHS H, SLIESORAITYTE I, STINGL K, WILHELM B—Tuebingen, Reutlingen, Stuttgart, Dresden
09:03	4115	Blood-retinal barrier function status from OCT data BERNARDES R, SERRANHO P, RODRIGUES P, GONÇALVES V, CUNHA-VAZ J—Coimbra
09:15	4116	Calculation of central retinal artery diameters in patients with type 1 diabetes using non-invasive measurements PEMP B, GARHOFER G, SCHMETTERER L—Vienna
09:27	4117	Retinal vascular profiles MACKAY FREITAS A—Lisbon

FP  
PBP

## BLOOD FLOW

Leopold SCHMETTERER, Gerhard GARHOFER

Artemis

08:15	4121	Comparison of optic nerve head and choroidal blood flow regulation during isometric exercise SCHMIDL D, BOLTZ A, LASTA M, PEMP B, KAYA S, GARHOFER G, SCHMETTERER L—Vienna
08:27	4122	Measurement of retinal oxygen saturation in patients with chronic obstructive pulmonary disease PALKOVITS S, LASTA M, SCHMIDL D, BOLTZ A, TOLD R, KAYA S, GARHOFER G, SCHMETTERER L—Vienna
08:39	4123	Effects of increased neutrophil count on ET1 – induced changes in erythrocyte and leukocyte movements TOLD R, FUCHSJAGER-MAYRL G, GARHOFER G, SCHMETTERER L—Vienna
08:51	4124	Complex regulation of optic nerve head blood flow during combined isometric exercise and elevation of intraocular pressure BOLTZ A, SCHMIDL D, LASTA M, PALKOVITS S, KAYA S, GARHOFER G, SCHMETTERER L—Vienna
09:03	4125	A randomized, placebo-controlled study investigating the effects of moxaverine on ocular blood flow after oral administration in healthy subjects LASTA M, SCHMIDL D, BOLTZ A, PALKOVITS S, TOLD R, KAYA S, GARHOFER G, SCHMETTERER L—Vienna
09:15	4126	Characterization of retinal blood flow in healthy subjects FUCHSJAGER-MAYRL G, SCHMETTERER L—Vienna

**COURSE 13 OPTICAL COHERENCE TOMOGRAPHY APPLICATIONS IN ANTERIOR SEGMENT EYE DISEASES**

Athena

COS

Edward WYLEGALA

Intermediate

Optical coherence tomography has changed ophthalmology practice and approach to ocular diseases. There are many available OCT devices, using the same technology but with distinct differences among them. It is crucial for clinicians to be able to determine which OCT scans provide clinically useful data and to know their basic clinical applications.

This course consists of two parts:

1. To describe OCT technical principles and basic differences among time-domain, spectral-domain and swept-source OCT. To present time-domain and spectral-domain OCT devices and describe their scan parameters and available software:

- Visante® OCT (Carl Zeiss Meditec, Inc.USA)
- Cirrus® OCT (Carl Zeiss Meditec, Inc. USA)
- 3D OCT – 2000 (Topcon Medical Systems,Japan)
- RTVue® - 100 (Optovue, Inc.USA)
- Copernicus® HR (Optopol Technology, Poland)
- SS-1000 CASIA (Tomey, Japan)

2. To present OCT applications based on clinical cases: anterior eye segment photo, clinical details, TD OCT, SD OCT and SS OCT scans, diagnosis and conclusion.

- Corneal dystrophies and hereditary anterior eye segment disorders
- Lamellar and penetrating keratoplasties
- Cataract surgery
- Refractive surgery
- Ocular injuries
- Glaucoma


08:15	4131	Technical principles of optical coherence tomography and basic differences among time-domain, spectral-domain and swept-source OCT WYLEGALA E-Katowice
08:30	4132	Important factors determining reliability and reproducibility of OCT scans; Advantages and disadvantages of commercially available OCT devices WYLEGALA E-Katowice
08:45	4133	Lamellar and penetrating keratoplasties WYLEGALA E-Katowice
09:00	4134	Corneal dystrophies and hereditary anterior eye segment disorders NOWINSKA A-Katowice
09:15	4135	Cataract, refractive and glaucoma surgery WYLEGALA E-Katowice
09:30	4136	Ocular injuries WYLEGALA E-Katowice



**SIS** **PEDIATRIC UVEITIS AND ARTHRITIS: IMPACT ON VISION AND LIFE -** **Europa**  
**LIFE LONG!**  
**IM** Friederike MACKENSEN

08:15	4141	Risk factors in JIA associated uveitis MACKENSEN F, HEILIGENHAUS A–Heidelberg, Muenster
08:33	4142	Living with juvenile idiopathic arthritis LANDGRAFF OESTLIE I, JOHANSSON I, MÖLLER A–Gjøvik, Gothenburg
08:51	4143	Outcome measures in JIA associated uveitis FOELDVARI I–Hamburg
09:09	4144	Long-term follow-up of patients with uveitis associated with juvenile idiopathic arthritis: a cohort study of three centers BARISANI-ASENBAUER T–Vienna

**FP** **SURGERY** **Minos 1**  
**G** Alain BRON, K. Sheng LIM

08:15	 4151	Outcomes of trabeculectomy with transconjunctival application of mitomycin C MAHROO O, SCOPPETTUOLO L, ANSARI E–Maidstone
08:27	4152	Patients with advanced glaucoma with controlled intraocular pressure and visually significant cataract: phacoemulsification vs combined surgery LIASKA A, CHATZISTEPHANOU K, PAPAKONSTANTINO D, THEODOSIADIS P–Lamia, Athens
08:39	4153	Glaucoma and retinal detachment surgery MANGOURITSAS G–Athens
08:51	4154	Lens phacoemulsification in treatment primary angle closure glaucoma with block induced lens after laser peripheral iridotomy FAYZIEVA UMIDA, EGOROVA ELYA–Tashkent, Moscow
09:03	4155 <i>rf</i>	Evaluation of the efficacy of patterned laser trabeculoplasty: pilot study DENEYER J, POURJAVAN S, DETRY-MOREL M–Brussels
09:09	4156 <i>rf</i>	Outcome of trabeculectomy in uveitis patients with secondary glaucoma LEWKOWICZ D, WILLERMAIN F, JANSSENS S, MAKHOUL D, CASPERS L, JANSSENS X–Brussels

FP PO	PATHOLOGY/ONCOLOGY 2		Danae
	Steffen HEEGAARD, Karin LOEFFLER		
08:15	4161	Photodynamic therapy for symptomatic high risk choroidal melanocytic lesions AMSELEM L, GARCÍA-ARUMÍ J, BADAL J, GÜNDÜZ K, ADAN A, ZAPATA MA, VALLDEPERAS X, CORCOSTEGUI B, HUSTE F—Barcelona, Ankara, Badalona	
08:27	4162 <i>rf</i>	Juvenile xanthogranuloma of the iris treated with proton beam radiotherapy DAMATO EM, COUPLAND SE, DAMATO BE—Liverpool	
08:39	4163	Supraselective intraarterial melphalan as the primary treatment for advanced retinoblastoma in older children DE FRANCESCO S, BRACCO S, GENNARI P, GALLUZZI P, CERASE A, D'AMBROSIO A, CAINI M, GALIMBERTI D, TOTI P, VENTURI C, HADJISTILIANOU T—Siena	
08:51	4164 <i>rf</i>	Superselective intra-arterial chemotherapy complications in advanced retinoblastoma HADJISTILIANOU D, DE FRANCESCO S, DE LUCA M, BORRI M, MENICACCI C, MICHELI L, BRACCO S, GENNARI P—Siena	
08:57	4165	Follicular lymphoma of the ocular adnexal region in Denmark RASMUSSEN PK, RALFKIAER E, PRAUSE JU, SJÖ LD, HEEGAARD S—Copenhagen	
09:09	4166 <i>rf</i>	Anterior segment OCT and histopathologic data in conjunctival, limbal and subconjunctival tumours PAJAUJIS M, PETROSKA D, SVALBONAITE E, ASOKLIS R—Vilnius	
09:15	4167 <i>rf</i>	Squamous cell carcinoma (SCC) of the caruncle, with clinical presentation of an inflammatory mass DE KEIZER RJW, VAN DE PUT MAJ, DE WOLFF ROUENDAAL D, HAESEKER BI—Leiden, Leiden/ Groningen	
09:21	4168 <i>rf</i>	Adenocarcinoma of the retinal pigment epithelium: clinicopathological case report GKARAGKANI E, SCHALENBOURG A, ZOGRAFOS L—Lausanne	
09:27	4169 <i>rf</i>	Unexpected ectopic thyroid tissue in the orbit: a clinical case report ASOKLIS R, RUZGYS R, PAJAUJIS M, PETROSKA D—Vilnius	

FP COS	CORNEA AND OCULAR SURFACE - INFLAMMATION 1		Minos 2
	Dominique BREMOND-GIGNAC, Anthony J. BRON		
08:15	4171 <i>rf</i>	Ocular surface evaluation in children presenting ongoing ocular allergy BREMOND-GIGNAC D, COPIN H, MILAZZO S—Amiens	
08:21	★ 4172	The correlation between ocular surface inflammation and corneal fluorescein staining (CFS) in patients with moderate to severe dry eye disease (DED) participating in a randomized clinical trial BUGGAGE R, AMRANE M, ISMAIL D, LEMP M, BAUDOUIN C, BAUDOUIN F—Evry, Washington D.C., Paris	
08:33	4173	Response of the lipid and aqueous layers of the precorneal tear film to horizontal saccades. Novel findings and a new paradigm BRON AJ, YOKOI N, GEORGIEV GA, TIFFANY JM—Oxford, Kyoto, Sofia	
08:45	★ 4174	Efficacy of wet chamber warming goggles (Blephasteam®) in patients with posterior blepharitis DOAN S, CHIAMBARETTA F, CORTEVAL F, SEMBEIL J, BAUDOUIN C—Paris, Clermont Ferrand	
08:57	4175 <i>rf</i>	High resolution images of the tear film lipid layer: effect of the blink cycle KING-SMITH PE, BRAUN RJ, NICHOLS JJ, NICHOLS KK—Columbus, Ohio, Newark, Delaware	
09:03	4176 <i>rf</i>	Altered corneal nerve morphology and epithelial wound healing in experimental lacrime-deficient dry eye GALLAR J, LUNA C, FERNANDEZ-SANCHEZ L, BERBEL D, SESMA J, MIZERSKA K, QUIRCE S, KOVACS I, BELMONTE C, CUENCA N, ACOSTA MC—Sant Joan d'Alacant, Alicante	



**KEYNOTE LECTURE - Rando ALLIKMETS****Zeus**

- |       |   |
|-------|---|
| 10:00 | Introduction by Bart LEROY  |
| 10:10 | Genetics and treatment of Stargardt disease<br><b>ALLIKMETS R</b> –New York |
| 10:40 | Award of the EVER certificate of honour                                     |

**SIS  
RV****RETINAL DETACHMENT SURGERY**

Constantin POURNARAS, Efstratios MENDRINOS

**Zeus**

11:00	4211	Pneumatic retinopexy for uncomplicated rhegmatogenous retinal detachment KISS S–New York
11:15	4212	Prognostic factors for anatomical and functional results after retinal detachment surgery. The SPR study HEIMANN H–Liverpool
11:30	4213	Subretinal fluid lavage: a novel concept in retinal detachment surgery VECKENEER M–Rotterdam
11:45	4214	Rhegmatogenous retinal detachment associated to vitreous hemorrhage. Role of primary vitrectomy? POURNARAS CJ–Geneva
12:00	4215	Primary vitrectomy alone for pseudophakic retinal detachment MENDRINOS E–Geneva
12:15	4216	20-gauge pars plana vitrectomy vs 23G, 25G in the management of primary and recurrent retinal detachment: pros and cons BRAZITIKOS P–Thessaloniki

**WS  
VEP****DOCTOR I CAN'T SEE IN THE DARK**

Graham HOLDER

**Artemis**

11:00	4221	The first consultation SPILEERS W–Leuven
11:22	4222	Causes of night blindness LEROY BP–Ghent
11:44	4223	Electrophysiology of patients with nyctalopia HOLDER GE–London
12:06	4224	What limits normal visual performance in the dark? RAUSCHER F–Leipzig

**COURSE 14 ANGIOGRAPHY AND FUNDUS IMAGING IN UVEITIS: PRINCIPLES & PRACTICE**

Athena

IM Carl P HERBORT, Moncef KHAIRALLAH

Intermediate

Imaging in Ophthalmology has drastically improved in the last two decades with the availability of indocyanine green angiography (ICGA), optical coherence tomography (OCT) and fundus autofluorescence (FAF) to name the most important modalities. These new methodologies have improved management of posterior uveitis, not only by enhancing diagnostic capacity but especially by allowing precise monitoring of disease evolution and assessing the result of therapeutic intervention. The course will emphasize practical situations and issues. After a first section dealing with the basic principles of the main imaging techniques, the whole second part is devoted to quiz cases coming from several parts of Europe and the Middle East.

11:00	4231	Fluorescein angiography in uveitis KHAIRALLAH M, JELLITI B—Monastir
11:10	4232	Indocyanine green angiography in uveitis HERBORT C—Lausanne
11:20	4233	OCT in uveitis NERI P, ARAPI I—Ancona
11:30	4234	Fundus autofluorescence (FAF) in uveitis MANTOVANI A, HERBORT C—Como, Lausanne
11:40	4235	Cxcl chemokine expression profiles in aqueous humor of patients with different ABU EL ASRAR A, AL-OBEIDAN S, KANGAVE D, GEBOES K, OPDENAKKER G, VAN DAMME J, STRUYF S—Riyadh, Leuven
11:50	4236	Practical & quiz cases II MARKOMICHELAKIS N—Athens
12:00	4237	Practical & quiz cases III BODAGHI B—Paris
12:10	4238	Practical & quiz cases IV PAPADIA M—Genova
12:20	4239	Practical & quiz cases V HERBORT C, KHAIRALLAH M, NERI P—Lausanne, Monastir, Torrette-Ancona

**WS HOW TO GET YOUR WORK PUBLISHED ?**

Europa

IM Uwe PLEYER, Harminder S DUA

11:00	4241	What do we (authors, reader, publisher) need ? DUA H—Nottingham
11:22	4242	Characteristics of a good paper WEGENER A—Bonn
11:44	4243	How can we improve the review process (view of the Editor and beyond..) STEFANSSON E—Reykjavik
12:06	4244	The reviewer: friend or foe? PLEYER U—Berlin



**SIS G**      **CATARACT AND GLAUCOMA SURGERY, COMBINED OR NOT?**      **Minos 1**  
 Thierry ZEYEN

11:00	4251	Cataract and glaucoma surgery, combined or consecutive, where do we stand? SUNARIC MEGEVAND G—Geneva
11:30	4252	Combined approach, the yield of microincisions for cataract surgery BRON AM—Dijon
12:00	4253	Staging: glaucoma first or cataract first? ZEYEN T—Leuven

**JOINT M. OOG PRESENTATIONS 1**      **Danae**  
 RJW DE KEIZER, Nikolaos E. BECHRAKIS



11:00	4261	TRPM1 and MITF expression in conjunctival melanocytic proliferations MOULIN AP, ZOGRAFOS L—Lausanne
11:10	4262	Strontium brachytherapy in conjunctival melanoma MISSOTTEN G, DE KEIZER RJW, SPILEERS W, BLANK L—Leuven, University, Amsterdam
11:20	4263	Chromosomal alterations in iris melanoma COUPLAND SE, BAUDO MM, LAKE SL, KALIRAI H, DAMATO BE—Liverpool
11:30	4264	Role of 3.0 Tesla MRI in diagnosis and treatment planning of iridociliary and choroidal melanocytic tumours DE KEIZER RJW, RAZZAQ L, MARINKOVIC M, VERBIST B, VERSLUIS M, VAN DUINEN SG, LUYTEN GPM—Leiden
11:40	4265	Autophagic activity in uveal melanomas BECHRAKIS NE, GIATROMANOLAKI A, SIVRIDIS E, CHARITOU DIS G—Innsbruck, Alexandroupolis, Berlin
11:50	★ 4266	Percentage of aberrant cells in uveal melanoma correlates with the patient's prognosis VAN DEN BOSCH T, VAN BEEK J, VAARWATER J, VERDIJK R, NAUS N, PARIDAENS D, DE KLEIN A, KILIC E—Rotterdam
12:00	4267	Genetic and histological heterogeneity in uveal melanoma: a peculiar case ANGI M, KALIRAI H, BAUDO MM, BIDDOLPH S, COUPLAND SE, DAMATO BE—Liverpool
12:08	4268	Are liver function tests relevant for early detection of liver metastasis of uveal melanoma? MOURIAUX F, DIORIO C, BERGERON D, BERCHI C, ROUSSEAU A—Québec, Caen

**SIS COS**      **KERATOPROSTHESIS UPDATE**      **Minos 2**  
 Christopher LIU



11:00	4271	An update on patient selection for OOKP surgery: psychosocial assessment BUSUTTIL A, TURTON E, HEROLD J, LIU C—Brighton
11:15	4272	An update on glaucoma in OOKP eyes LAM FC, HEROLD J, LIU C—Glasgow, Brighton
11:30	4273	An update on imaging and strengthening of the OOKP lamina QASHOU A, FRANCIS I, HEROLD J, LIU C—Brighton
11:45	4274	An update on the Boston Type 1 KPro CORTINA S—USA
12:00	4275	An update on the use of the Boston Type 1 KPro outside the USA LAKE D, ALDAVE T, BELIN M—East Grinstead
12:15	4276	Collagen-based bioengineered corneas: a material development update RAFAT M, FAGERHOLM P, MERRETT K, LAGALI N, GRIFFITH M—Linköping



**JOINT M. IM UVEITIS AWARD CEREMONY**  
Manfred ZIERHUT

Europa



12:35	Introduction by Manfred Zierhut
12:40	Activation of OX40 Augments Th17 Cytokine Expression and Antigen Specific Uveitis ZHANG Z–Portland
12:50	Aquaporin expression in blood-retinal barrier cells during experimental autoimmune uveitis MOTULSKY E, KOCH P, JANSSENS S, LIENART M, VANBELLINGHEN AM, BOLAKY N, CHAN CC, CASPERS L, MARTIN-MARTINEZ MD, XU H, DELPORTE C, WILLERMAIN F–Brussels, Bethesda, Belfast
13:00	Inhibition of the alternative pathway of complement activation reduces inflammation in experimental autoimmune uveoretinitis CHEN M, MUCKERSIE E, LUO C, FORRESTER JV, XU H–Belfast, Aberdeen
13:10	Long-term remission after cessation of interferon- $\alpha$ treatment in patients with severe uveitis due to Behçet's disease DEUTER CME, ZIERHUT M, MÖHLE A, VONTHEIN R, STÜBIGER N, KÖTTER I–Tübingen
13:20	New scale for photographic grading of vitreous haze in uveitis DAVIES J–Miami
13:30	Award ceremony

## Lunchtime CIS



### NEW ADVANCED TECHNOLOGIES FOR OPHTHALMIC APPLICATIONS

Zeus

The symposium will present data of pre-clinical and clinical studies which were performed to study the safety and efficacy of a novel thiolated biopolymer, namely *chitosan-N-acetylcysteine*.

In addition bromfenac's mechanism of action, recent clinical data of pivotal/other bromfenac trials and bromfenac's safety, tolerability and use in combination with corticosteroids will be reviewed.

- |       |  |
|-------|--|
| 12:35 | Bromfenac – a new standard in NSAID efficacy<br>FINDL O–Vienna                         |
| 12:55 | Innovative thimer technology - application to dry eye syndrome<br>SCHMETTERER L–Vienna |
| 13:35 | End of session   |

**SIS  
RV****CME: PATHOGENESIS AND MANAGEMENT**

Gabriel COSCAS, Gisèle SOUBRANE

Zeus



13:45	4311	Blood-ocular barriers and macular edema CUNHA-VAZ J—Coimbra
13:57	4312	Macular edema: clinical pattern and imaging GANI A, PELLEGRINI M, INVERNIZZI A, STAURENGHI G—Milan
14:09	4313	General pathophysiology AUGUSTIN A—Karlsruhe
14:21	4314	Retinal vein occlusion COSCAS G—Creteil
14:33	4315	Diabetic retinopathy BANDELLO F—Milano
14:45	4316	Macular edema of choroidal origin SOUBRANE G—Creteil
14:57	4317	Postsurgical cystoid macular edema LOEWENSTEIN A—Tel Aviv

**FP  
VEP****FREE PAPERS**

Werner SPILEERS, Miguel CASTELO-BRANCO

Artemis

13:45		4321	Spatio-temporal responses in the visual cortex evoked from first- and higher order thalamic nuclei in tree shrews: a voltage sensitive dyes study CASANOVA C, ABBAS FR, VANNI M—Montreal
13:57		4322	Quantifying end-stage electrophysiological function in progressive retinal degenerative disorders (PRDD) LACHAPPELLE P, GAUVIN M, TRANG N, LINA JM, RACINE J—Montréal, Québec
14:09		4323	Windows-based software for recording clinical electroretinograms SANDBERG M—Boston
14:21		4324	Clinical significance of red target increment perimetry KRASTEL H, BEUTELSPACHER SC, ENGLER CH, KAHLERT CH, JONAS JB, JAGLE H—Mannheim, Regensburg
14:33		4325	Assessing the wavelength dependence of intraocular scattering by a new optical approach PEREZ G, GINIS H, BUENO J, ARTAL P—Murcia, Crete
14:45		4326	The optical integration technique for the measurement of light scatter in the human eye GINIS H, PEREZ G, BUENO J, ARTAL P—Heraklion, Murcia
14:57	★	4327	Intracorneal lenses using femtosecond laser for the treatment of presbyopia PALLIKARIS IG, BOUZOUKIS D, LIMNOPOULOU A, PANAGOPOULOU S, PALLIKARIS AI, KYMIONIS G—Heraklion
15:09		4328	ELVisWeb: an interactive web-application for the visualization of ERG recordings based on the Electrophysiology of Vision Markup Language STRASSER T, GOLDINA A, LANG S, LOTTER M, ODER M, OSTERTAG T, ULRICH M, WALTER M, YILDIZ D, PETERS T, ZRENNER E—Tuebingen, Augsburg

**SIS** **RESTORATION OF ACCOMMODATION** **Athena**  
**LC** Rafael I. BARRAQUER, Ralph MICHAEL

13:45		4331	Accommodative IOL' s and pseudo accommodation PALLIKARIS IG–Heraklion
14:03	★	4332	Small aperture keratophakia for correction of presbyopia RIHA W, GRABNER G–Salzburg
14:21	★	4333	Lens refilling (Phaco-Ersatz) PAREL JM, HOLDEN BA–Miami, Sydney
14:39		4334	The use of electro-optical materials to restore accommodation MICHAEL R, BARRAQUER RI–Barcelona
14:57		4335	Experimental femtosecond laser lens surgery BARRAQUER RI, LOZA-ALVAREZ P, OLARTE OE, MERINO D, MONTENEGRO G, MICHAEL R–Barcelona, Castelldefels

**FP** **OCULAR IMMUNO-INFECTIOLOGY FROM BASIC SCIENCE TO** **Europa**  
**IM** **CLINICAL CHALLENGES**  
Piergiorgio NERI, Carl P HERBORT

13:45		4341	Histopathology of Behçet's uveitis DAMATO EM, DICK A, COUPLAND SE–Liverpool, Bristol
13:57		4342	Vitreo-retinal interactions and optical coherence tomography study in Fuchs' uveitis BOUCHENAKI N, HERBORT C–Geneva, Lausanne
14:09	★	4343 <i>rf</i>	Anti-inflammatory mechanisms of mapracorat, a novel selective glucocorticoid receptor agonist, in human conjunctival fibroblasts ZHANG JZ, VOLHEJN SM, WARD KW–Rochester
14:15		4344 <i>rf</i>	Skin tattoos and the development of uveitis VAN CALSTER J, VANDER HULST K, GOOSSENS A, VAN DEN OORD J, JACOB J, VAN GINDERDEUREN R–Leuven
14:21		4345 <i>rf</i>	Acute retinal necrosis. 3 case reports CIMBALAS A, KOVALIUNAS E, KARALIUTE Z, LIVEIKIENE A, ASOKLIS R–Vilnius
14:27		4346 <i>rf</i>	Slowly progressive corneal opacification in a patient with known mucocutaneous leishmaniasis and HIV VAN OS L, TASSIGNON MJ, VLIEGHE E, DE KEIZER RJW–Antwerp

FP  
G

## IMAGING

Jost B JONAS, Fotis TOPOUZIS

Minos 1

13:45	4351	Anterior segment optical coherence tomography study of the surgical outcome of the filtering surgery in glaucoma YANI A, MERCIE M, DJABAROUTI M, BADAT I, BOISSONNOT M, DIGHIRO P, GICQUEL JJ–Poitiers
13:57	4352	The effect of cataract surgery on imaging optic nerve head topography with the Heidelberg Retina Tomograph® FALCK AAK, SAARELA V–Oulu
14:09	4353	Is choroidal thickness different between glaucoma patients and healthy subjects? BRON AM, FRANCOZ A, BEYNAT J, NICOT F, CATTANEO A, CREUZOT C–Dijon
14:21	4354	Evaluation of the corneal pachymetry and biomechanical parameter changes in patients treated by prostaglandin topical medication VANTOMME M, POURJAVAN S, DETRY-MOREL M–Brussels
14:33	★ 4355 <i>rf</i>	Optic disc assessment using confocal scanning laser ophthalmoscope in normal tension glaucoma with disc hemorrhage LIM S–Seoul
14:39	4356 <i>rf</i>	GDx-VCC vs GDx-ECC in glaucoma diagnosis MILANO G, LOMBARDO S, BORDIN M, BOSSOLESI L, RAIMONDI M, LANTERI S, ROSSI GCM–Pavia
14:45	4357 <i>rf</i>	Anterior segment optical coherence tomography changes post laser peripheral iridotomy in primary angle closure suspects in an Asian population HOW A, AUNG T–Singapore

## JOINT M. OOG PRESENTATIONS 2

Edoardo MIDENA, Nathalie CASSOUX

Danae





13:45	4361	PCR-based circulating melanoma cells detection in uveal melanoma PARROZZANI R, PILOTTO E, DARIO A, MIGLIONICO G, MIDENA E–Roma, Padova
13:55	4362	Adjuvant intravenous therapy by fotemustine in uveal melanoma: a randomised study DESJARDINS L, LEVY C, LUMBROSO LE ROUC L, CASSOUX N, PIPERNO-NEUMANN S, MARIANI P, SERVOIS V, DENDALE R, PLANCHER C, ASSELAIN B–Paris
14:05	4363	Quality of life after treatment of uveal melanoma DAMATO BE, HOPE-STONE L, SALMON P–Liverpool
14:15	4364	Verteporfin photodynamic therapy of retinal optic disc haemangioma HEIMANN H, KENAWY N, DAMATO BE–Liverpool
14:25	4365	Development of new models of orthotopic primary human retinoblastoma xenografts CASSOUX N, ASSAYAG F, NEMATI F, FONTAINE JJ, AERTS I–Paris, Maison Alfort
14:35	4366	CNS abnormalities in retinoblastoma patients HADJISTILIANOU D, DE FRANCESCO S, RENIERI A, MENCARELLI MA, MAROZZA A, DE LUCA M, MICHELI L, MENICACCI C, CERASE A, GALLUZZI P–Siena
14:45	4367	Propranolol in the management of orbital and periocular pediatric hemangioma MIDENA E, PARROZZANI R, DARIO A, MIGLIONICO G, BISOGNO G, FLORA GP–Padova, Roma, San Donà di Piave
14:55	4368	Puzzling case of choroidal tumour: paraganglioma or neuroendocrine carcinoma, diagnosis and treatment options VAN GINDERDEUREN R, MISSOTTEN G, VAN DEN OORD J–Leuven

FP  
COS**CORNEA AND OCULAR SURFACE, INFLAMMATION 2**

Minos 2

Harinder S DUA, Mario NUBILE

13:45	4371	S100 expression in normal and pathological sclerocorneal limbus CALIENNO R, CURCIO C, LANZINI M, NUBILE M, COLASANTE M, MASTROPASQUA L–Chieti
13:57	 4372	CREB is involved in growth of pterygia CURCIO C, CALIENNO R, LANZINI M, NUBILE M, MASTROPASQUA L–Chieti
14:09	4373	Meganuclease targeting herpes simplex virus protects against viral endothelitis: an organ culture model CHAPELLIER BC, LABETOULLE M, ARNOULD S, SMITH J, SAHEL JA, GABISON EE–Paris, Romainville
14:21	 4374	Cultivated oral mucosa epithelium transplantation (COMET) in bilateral limbal stem cell deficiency DOBROWOLSKI D, WYLEGALA E, WOWRA B, ORZECZOWSKA-WYLEGALA B–Katowice
14:33	4375	Documentation of distribution of normal conjunctival vessels and their changes by mild irritation of photography using automated algorithm BANAEI T, POURREZA HR, KHAJEH DALOUEE M, DANESHVAR KAKHKI R, BASIRI M, ABRISHAMI M–Mashhad
14:45	4376 <i>rf</i>	Topical application of autologous adipose-derived mesenchymal stem cells (AdMSCs) for persistent sterile corneal epithelial defect AGOROGIANNIS GI, KYMIONIS G, ALEXAKI VI, CASTANA O, CASTANAS E, PALLIKARIS IG–Heraklion, Athens

**SIS  
RV****RETINAL DETACHMENT COMPLICATIONS**

Elias FERETIS

Zeus

16:30	4411	Optical coherence tomography in retinal detachment cases KAMPANAROU SA–Athens
16:45	4412	Epiretinal membranes following retinal detachment surgery KOURENTIS C–Athens
17:00	4413	Macular holes after retinal detachment surgery XIROU T–Athens
17:15	4414	Glaucoma and retinal detachment MAGURITSAS G–Athens
17:30	4415	Pneumatic retinopexy complications PARIKAKIS EA–Athens
17:45	4416	Silicone oil complications PAPPAS G–Heraklion

**JOINT M.  
VEP****ISCEV SESSION**

Graham HOLDER

Artemis



16:30	★	4421	ELVisML: A little less conversation. Experiences with the Electrophysiology of Vision Markup Language in clinical routine and in a multi-center trial STRASSER T, PETERS T, ZRENNER E–Tuebingen
16:45		4422	Progression of electroretinogram responses in Stargardt-fundus flavimaculatus: a longitudinal study FUJINAMI K, MICHAELIDES M, LOIS N, WEBSTER AR, HOLDER GE–London
17:00		4423	The importance of dark adapted cone function in ERG interpretation HOLDER GE–London
17:15		4424	Electroretinogram and patterned visual evoked potentials as detectors of retinal dystrophy in children affected by Joubert syndrome: a longitudinal survey RUBERTO G, SUZANI M, SIGNORINI S, FAZZI E, ANTONINI M, BERTONE C, GUAGLIANO R, TINELLI C, BIANCHI PE–Pavia, Brescia
17:30		4425	Colour vision in Stargardt disease VANDENBROUCKE T, BUYL R, DE ZAEYTIJD J, UVIJLS A, DE BAERE E, LEROY BP–Ghent, Brussels
17:45		4426	AZoor defined (Acute Zonal Occult Outer Retinopathy) HECKENLIVELY JR, WANG A–Ann Arbor

**JOINT M. THE EVER *f* - HOW TO PROMOTE IT, HOW TO WORK FOR IT****Athena**

Harminder S DUA



The EVER *f* is an independent incorporated organization with its own board of trustees. Its aim is to support the EVER mission and to facilitate the attainment of EVER's objectives. 'Science for Sight' also represents the statement of intent of the EVER Foundation.

EVER *f* recognizes the enormous contribution made by the pharmaceutical trade and industry towards supporting science and education. It will consolidate and build on this platform such that EVER *f*, EVER and the Industry can work together to alleviate blindness and vision disorders, for our mutual beneficiaries – our patients.

[www.ever-f.eu](http://www.ever-f.eu)

**JOINT M. VIRUS AND ANTERIOR UVEITIS****Europa**

Manfred ZIERHUT, Sofia ANDROUDI



16:30	4441	Herpes simplex virus KHAIRALLAH M, ATTIA S, NAHDI I—Monastir
16:45	4442	Varicella zoster virus ANDROUDI S—Thessaloniki
17:00	4443	Cytomegalovirus BODAGHI B—Paris
17:15	4444	Anterior uveitis with intraocular fluid analysis positive for rubella virus WILLERMAIN F, WENSING B, JUDICE RELVAS L, VIDOVIC VALENTINCIC N, STUNF S, DE GROOT-MIJNES J, ROTHOVA A, CASPERS L—Brussels
17:30	4445	Diagnostics of virus-induced anterior uveitis GARWEG JG—Bern
17:45	4446	The project of "virus-induced anterior uveitis" ZIERHUT M—Tuebingen

**WS THE VISION SCREENS IN THE EUROPEAN MOUSE CLINICS****Minos 1**

Jochen GRAW

16:30	4451	The Sanger Mouse Genetics Programme: high throughput characterisation of knockout mice GARDIN A, WHITE J—Hinxton
16:48	4452	Scheimpflug analysis and OCT as new and rapid screening tools in the mouse PUK O, FAVOR J, GRAW J—Neuherberg
17:06	4453	Visual phenotyping at the "Institut Clinique de la Souris" ROUX M—Illkirch
17:24	4454	Rete mirabile in mouse retina? RUBERTE J, MENDES-JORGE L, RAMOS D, LOPEZ-LUPPO M, NACHER V, NAVARRO M, CARRETERO A—Barcelona, Lisbon
17:42	4455	Optic disc coloboma in the mouse JACKSON I—Edinburgh





**JOINT M. OOG : BUSINESS MEETING**

Danae

Sarah COUPLAND



## Agenda

1. Minutes of previous Business Meeting (Copenhagen, April 2011)
2. OOG elections
3. Financial report
4. OOG Website update
5. Nominations for membership to OOG
6. Update on current collaborative studies/new proposals
7. Details of next OOG Meetings
8. Any Other Business (AOB)
9. Closure of Business Meeting

**SIS  
COS****THE OPTICS OF THE TEAR FILM**

Jean-Jacques GICQUEL

**Minos 2**

16:30	4471	Tear film topography NOCHEZ Y, HABAY T, PISELLA PJ—Tours
16:48	4472	Measurements of the dynamic aberrations induced by the tear film GICQUEL JJ—Poitiers
17:06	★ 4473	Straylight as measure for quality of vision and the tear film VAN DEN BERG TJTP—Amsterdam
17:24	4474	The implications of the Meibomian glands dysfunction in the quality of vision DIGHIERO P—Poitiers
17:42	4475	Chronic ocular surface inflammation and vision quality PISELLA PJ—Tours





## EVER GENERAL ASSEMBLY AND PRIZE GIVING



### AGENDA

1. President's address, Lene MARTIN
2. Minutes of the General Assembly 2010
3. Report of the Secretary General, Bahram BODAGHI
4. Report of the Programme Secretary, Tero KIVELÄ
5. Report of the Treasurer, approval of the accounts 2010, discharge to the directors, budget for 2011, Jean-Jacques GICQUEL
6. Proposal, deliberation and decision regarding the amendment of the purpose (aim) of EVER inpa by adding: "the financing, support and subsidizing of projects and people concerning the eye and vision in general";
7. Proposal, deliberation and decision regarding the granting of a special power of attorney
8. Results of the elections
9. Presentation of the board 2011-2012
10. President Elect, Vice President Elect
11. Acta Board members
12. Presentation and report of the Scientific Sections meetings
13. Future congresses
14. Prize giving
15. Miscellanea
16. Acknowledgments
17. Handover of chain of office

20:00 - 23:00

EVER Farewell Dinner with musical entertainment in Creta Maris




**Cornea / Ocular Surface****Moderators:****Jean-Jacques GICQUEL, Mario NUBILE**

- 401 *rf* Ocular surface evaluation in children presenting ongoing ocular allergy  
BREMOND-GIGNAC D, COPIN H, MILAZZO S—Amiens
- 402 *rf* High resolution images of the tear film lipid layer: effect of the blink cycle  
KING-SMITH PE, BRAUN RJ, NICHOLS JJ, NICHOLS KK—Columbus, Ohio, Newark, Delaware
- 403 *rf* Altered corneal nerve morphology and epithelial wound healing in experimental lacrimodeficient dry eye  
GALLAR J, LUNA C, FERNANDEZ-SANCHEZ L, BERBEL D, SESMA J, MIZERSKA K, QUIRCE S, KOVACS I, BELMONTE C, CUENCA N, ACOSTA MC—Sant Joan d'Alacant, Alicante
- 404 *rf* Mechanical reinforcement of the cornea with an intrastromal in-situ photo-polymerised implant  
PENNOS A, PENTARI IG, GINIS H, KARIOTAKIS N, KYMIONIS G, PALLIKARIS IG—Heraklion
- 405 *rf* Long-term results of simultaneous topo-guided photorefractive keratectomy followed by corneal collagen cross-linking for keratoconus  
DIAKONIS V, GRENTZELOS M, PORTALIOU D, KOUNIS G, LIMNOPOULOU A, KYMIONIS G—Heraklion
- 406 *rf* Topical application of autologous adipose-derived mesenchymal stem cells (AdMSCs) for persistent sterile corneal epithelial defect  
AGOROGIANNIS GI, KYMIONIS G, ALEXAKI VI, CASTANA O, CASTANAS E, PALLIKARIS IG—Heraklion, Athens
- 407 Late-onset diffuse lamellar keratitis associated with cataract phacoemulsification  
PRIETO CALVO E, IDOPE CORTA M, EGEA ESTOPINAN C, SANCHEZ PEREZ A—Zaragoza
- 408 Ligneous conjunctivitis. Response to topical cyclosporine and mitomycin  
DE LA MATA G, FERNANDEZ-PEREZ S, FERNANDEZ TIRADO J, PRIETO E—Zaragoza
- 409 Fourier-domain OCT and keratoconus  
IDOPE M, EGEA MC, PRIETO E, HERRERO LATORRE R, FERNANDEZ-PEREZ S, SANCHEZ PEREZ A, BRITO C—Zaragoza
- 410 Topical treatment with 0.05% cyclosporine for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis  
KONTADAKIS G, PLAKA A, LIMNOPOULOU A, DIAKONIS V, KYMIONIS G—Heraklion
- 411 Corneal biomechanical properties in myopic LASIK  
DEL BUEY MA, LAVILLA L, CRISTOBAL JA, LANCHARES E, MATEO J, ASCASO FJ, RODRIGUEZ A, PEIRO C, MATEO A, RUIZ DE GOPEGUI E—Zaragoza, Valencia
- 412 Peripheral corneal ulceration associated with rheumatoid arthritis  
ALMALIOTIS D, KONIDARIS V, STAMOULAS K, GEORGALA A, KARAMPATAKIS V—Thessaloniki
- 413 Clinical and ultrastructural feature of a cornea with pellucid marginal degeneration  
AKHTAR S, KIRAT O, KATAN H, ALMUBRAD T—Riyadh
- 414 Analysis of factors affecting corneal endothelial cell loss after penetrating keratoplasty  
HOSIK H, KIM MS, KIM EC, KIM TK—Seoul

- 415 Use of hypo-osmolar riboflavin for corneal cross-linking in thin keratoconic corneas  
FRUSCHELLI M, BATISTI C, MOTOLESE I, SANGIUOLO M, MENICACCI F, MENICACCI C, MOTOLESE E—Siena, Genova
- 416 Protective antioxidant system disorders in myopic patients  
BOYCHUK IM, KOLOMIYCHUK SG, SUROVAYA EI—Odessa
- 417 Ocular surface epithelial thickness evaluation with spectral-domain optical coherence tomography in patients with dry eye syndrome  
FRANCOZ M, KARAMOKO I, BAUDOUIN C, LABBE A—Paris
- 418 Analysis of factors affecting the decrease of endothelial cell density of imported donor corneas  
HOSIK H, MAN SOO K, EUN CHUL K, SEOK JOON K—Seoul
- 419 Efficacy of amnion membrane transplantation (AMT) on corneal surface in annular abscess and anterior uveitis  
KOEV K, GEORGIEV R—Sofia
- 420 A retrospective comparison of enhancement rate between low myopic astigmatism and high myopic astigmatism in patients treated with femtosecond LASIK  
CANADAS SUAREZ P, IGLESIAS M, GIMENEZ P, CANONES R, TEUS M—Madrid
- 421 Ocular surface changes and corneal sensitivity in keratoconus  
CHO KJ, MOK JW, CHOI MY, JOO CK—Cheonan, Seoul
- 422 A case of lattice corneal dystrophy due to the L527R mutation in the TGFBI gene in Korea  
CHO KJ, MOK JW, JOO CK—Cheonan, Seoul
- 423 Changes in expression of matrix metalloproteinases 12 and 19 in corneal epithelial cells after UV irradiation  
ARDAN T, CEJKOVA J—Prague

**Immunology / Microbiology****Moderators:****Piergiorgio NERI, François WILLERMAIN**

- 424 *rf* ★ Anti-inflammatory mechanisms of mapracorat, a novel selective glucocorticoid receptor agonist, in human conjunctival fibroblasts  
ZHANG JZ, VOLHEJN SM, WARD KW—Rochester
- 425 *rf* Skin tattoos and the development of uveitis  
VAN CALSTER J, VANDER HULST K, GOOSSENS A, VAN DEN OORD J, JACOB J, VAN GINDERDEUREN R—Leuven
- 426 *rf* Acute retinal necrosis. 3 case reports  
CIMBALAS A, KOVALIUNAS E, KARALIUTE Z, LIVEIKIENE A, ASOKLIS R—Vilnius
- 427 *rf* Slowly progressive corneal opacification in a patient with known mucocutaneous leishmaniasis and HIV  
VAN OS L, TASSIGNON MJ, Vlieghe E, DE KEIZER RJW—Antwerp
- 428 ★ Meganuclease-mediated inhibition of HSV1 infection  
LABETOULLE M, HUOT N, SMITH J, GROSSE S, BARRADEAU S, ARNOULD S, MAHIET C, DESSEAUX C, CEDRONE F, PAQUES F, CHAPPELLIER BC, GABISON EE, ERGANI A—Le Kremlin-Bicêtre, Gif sur Yvette, Romainville, Paris

429 Effect of SOCS1 overexpression on RPE cells activated by cytokines  
  
 BAZEWCZ M, MAKHOUL M, DRAGANOVA D, CHTARTO A, TENENBAUM L, EL MALEH V, CASPERS L, BRUYNS C, WILLERMAIN F—Brussels

430 Loiasis: approach to a form of ocular parasitosis  
 CABEZON L, CASAS P, RAMIRO P, JIMENEZ B, MINGUEZ E, IBANEZ J, PEIRO C, CRISTOBAL JA—Zaragoza


431 Demodex infestation in the normal population, blepharitis patients and among people who work with microscopes  
 UDZIELA M, SZAFLIK JP, GARBACEWICZ A, GRYTNER-ZIECINA B, SZAFLIK J—Warsaw


432 ICAM-1 and HLADR expression on conjunctival epithelial cells in patients with Graves' orbitopathy and Graves' disease - preliminary report  
 PAWLOWSKI P, MYSLIWIEC J, MRUGACZ M, BAKUNOWICZ-LAZARCZYK A, ZAK J, WYSOCKA J, GORSKA M—Bialystok


## Pathology / Oncology


### Moderators:



Alexandre MOULIN, Rita VAN GINDERDEUREN


433 Mutations in the BAP1 gene in uveal melanoma  
  
 KOOPMANS AE, VAN DEN BOSCH T, VAARWATER J, KILIC E, PARIDAENS D, NAUS N, DE KLEIN A—Rotterdam


434 Preclinical study of a glycoengineered anti-human CD20 antibody in murine models of primary cerebral and intraocular B-cell lymphomas  
  
 BAGGA RYM—Courbevoie


435 Juvenile xanthogranuloma of the iris treated with proton beam radiotherapy.  
  
 DAMATO EM, COUPLAND SE, DAMATO BE—Liverpool

436 Superselective intra-arterial chemotherapy complications in advanced retinoblastoma  
  
 HADJISTILIANOU D, DE FRANCESCO S, DE LUCA M, BORRI M, MENICACCI C, MICHELI L, BRACCO S, GENNARI P—Siena

437 Anterior segment OCT and histopathologic data in conjunctival, limbal and subconjunctival tumours  
  
  
 PAJAUJIS M, PETROSKA D, SVALBONAITE E, ASOKLIS R—Vilnius

438 Squamous cell carcinoma (SCC) of the caruncle, with clinical presentation of an inflammatory mass.  
  
 DE KEIZER RJW, VAN DE PUT MAJ, DE WOLFF ROUENDAAL D, HAESEKER BI—Leiden, Leiden/ Groningen

439 Adenocarcinoma of the retinal pigment epithelium: clinicopathological case report  
  
 GKARAGKANI E, SCHALENBOURG A, ZOGRAFOS L—Lausanne

440 Unexpected ectopic thyroid tissue in the orbit: a clinical case report  
  
 ASOKLIS R, RUZGYS R, PAJAUJIS M, PETROSKA D—Vilnius

441 Epiretinal membranes in a patient with Scheie's syndrome diagnosed using a high-resolution SD-OCT  
 STRATOS A, PATSEA E, XALKIADAKIS I, PARIKAKIS EA, STERGIOPOULOS G, PEPONIS V, MITROPOULOS P—Athens

442 Initial experience of a nationwide ruthenium-106 and iodine-125 ocular brachytherapy service in Ireland  
 WALKER C, LANGAN B, HORGAN N, CUNNINGHAM M, GRUNNER E, MCCLEAN B

443 Orbital involvement in multiple myeloma  
 FERNANDEZ-PEREZ S, SATUE M, HERRERO LATORRE R, DE LA MATA G, IDOPE M, GARCIA-MARTIN E, PABLO L—Zaragoza

444 Atypical inflammatory myofibroblastic pseudotumour of the ethmoidal sinus extending into the orbit  
 DE KEIZER RJW, LAUWERS N, DE GROOT V, CLAES J—Edegem Antwerp

445 Extraskeletal chondroma of the palpebral conjunctiva: a case report  
 JUNGJIN L, HYOJEONG K, SANGWROUL S—Seoul

446 Incidence of eyelid cancers in Singapore - a 13-year review  
 LIM VSY, AMRITH S—Singapore


447 Treatment of an infantile hemangioma with propranolol  
 PEREZ GARCIA D, IBANEZ J, REMON L, RAMIRO P, PEIRO C, PINILLA I, CRISTOBAL JA—Zaragoza

448 Treatment and visual outcome in orbital and palpebral hemangiomas of infancy  
 PINELLO L, MAZZAROLO M, DE CORTI F, LUZZATTO C—Padua

## Physiology / Biochemistry / Pharmacology

### Moderators:

Neville OSBORNE, Miltiadis TSILIMBARIS

449 Cationic oil-in-water emulsions protect and restore function of the injured ocular surface  
 ★  
  
 DAULL P, LIANG H, BAUDOIN C, GARRIGUE JS, BUGGAGE R, BRIGNOLE-BAUDOIN F—Evry, Paris

450 Ghrelin expression in the rat's eye  
 ROCHA DE SOUSA AA, PEREIRA-SILVA P, AZEVEDO-PINTO S, PINHO S—Porto

451 Cystoid macular oedema in a phakic eye treated with bimatoprost for presumed normal tension glaucoma  
 COUTTS SJ, GHAZI-NOURI S—Chelmsford

452 Cyclosporine A-loaded and limbal stem cell-seeded nanofibers for the local suppression of inflammatory and transplantation reactions  
 HOLAN V, ZAJICOVA A, CHUDICKOVA M, LENCOVA A, TROSNAN P, SVOBODOVA E, KRULOVA M—Prague

453 Axitinib modulates hypoxia-induced blood-retina barrier permeability and expression of growth factors  
 KERNT M, THIELE S, LIEGL RG, HARITOGLOU C, ULBIG MW, KAMPIK A—Munich

454 Gangliosides of the retina  
 MASSON E, BRETILLON L—Dijon

455 Pasireotide (SOM230) protects the retina from ischemia induced retinopathies  
 KOKONA D, MASTRODIMOU N, PEDIADITAKIS S, CHARALAMPOPOULOS I, SCHMID HA—Heraklion, Basel

456 Investigation of the liquid in- and outflow parameters of the human eye using a modified strategy of the mechanical loading test  
 MOISEEVA IN, LYUBIMOV GA, STEIN AA, IOMDINA EN, NAZARENKO LA—Moscow

- 457 Optic nerve head blood flow response to increase of arterial blood pressure in humans  
LACHARME T, GEISER M, ALMANJOURI A, KHAYI H, ARNOL N, ROMANET JP, CHIQUET C—Grenoble, Sion
- 458 A novel device for the measurement of intraocular pressure, ocular rigidity and pulsatile blood flow.  
KARYOTAKIS NG, GINIS H, TSILIMBARIS MK, SIGGELAKI EM, PALLIKARIS IG—Heraklion
- 459 Effects of benzalkonium chloride on antigen presenting cells in vitro  
MICHEE S, ROSTENE W, BRIGNOLE-BAUDOIN F, BAUDOIN C, LABBE A—Paris
- 460 Effect of lacritin, a novel glycoprotein, on ocular surface and tear film integrity  
★ SAMUDRE S, LATTANZIO F, WILLIAMS P, MCKOWN R, LAURIE G—Norfolk, Harrisonburg, Charlottesville

## Vision Sciences / Electrophysiology / Physiology Optic

### Moderators:

Guillermo PEREZ, Werner SPILEERS,

Miguel CASTELO-BRANCO

- 461 ElVisWeb: an interactive web-application for the visualization of ERG recordings based on the Electrophysiology of Vision Markup Language  
*rf* STRASSER T, GOLDINA A, LANG S, LOTTER M, ODER M, OSTERTAG T, ULRICH M, WALTER M, YILDIZ D, PETERS T, ZRENNER E—Tuebingen, Augsburg
- 462 Asymmetric color perception in the shopping aisle: some implications for merchandising  
PINNA A, PUGLIATTI M, PORCHEDDU D—Sassari
- 463 Glare visual performance in young subjects under night driving conditions  
PEREZ CARRASCO MJ, PUELL MC, PALOMO-ALVAREZ C, BARRIO AR, GONZALEZ-RUGARCIA A, LOPEZ-SERRANO T—Madrid
- 464 Electrophysiological assessment of fundus albipunctatus  
🌀 PAWLOWSKI P, SUWALA M, BAKUNOWICZ-LAZARCZYK A—Bialystok
- 465 Colour vision in adult amblyopia  
BLACK JM, LUN V, PHILLIPS G, THOMPSON B—Auckland
- 466 Prevalence of uncorrected refractive errors among schoolchildren in northeast of Iran  
YEKTA AA, KHABAZKHOOB M, AZIZI E, OSTADI MOGHADDAM H, HERAVIAN J, AZIMI A, YEKTA R—Mashhad, Tehran
- 467 How does Bangerter filter affect the normal visual perception?  
LI J, DING Z, DENG D, CHAN YLL, BENJAMIN T, CHEN X, HESS RF, YU M—Guangzhou, Hong Kong SAR, Auckland, Montreal
- 468 Halo size in healthy subjects  
PUELL MC, RODRIGUEZ-ORTEGA J, PEREZ-CARRASCO MJ, PALOMO-ALVAREZ C, BARRIO AR—Madrid
- 469 A new method for assessing central and peripheral visual acuity  
CHUNG H, LEE YW, SEO JM—Seoul, Pohang









**Save the Dates**

**ARVO 2012**  
Translational Research: Seeing the Possibilities

**ARVO**  
The Association for Research  
in Vision and Ophthalmology


May 6 – 10  
Fort Lauderdale, Florida  
[www.arvo.org/am](http://www.arvo.org/am)



**Optic Nerve Degeneration,  
Protection and Autoimmunity**

December 6 – 9, 2011  
Hotel Edelweiss & Gurgl  
Obergurgl, Austria  
[www.arvo.org/austria11](http://www.arvo.org/austria11)

**ARVO**  
The Association for Research  
in Vision and Ophthalmology



**Acta  
Ophthalmologica**

Edited by: Einar Stefánsson

**EVER**  
The Association for Research  
in Vision and Ophthalmology

**Why should you be reading?**

- Impact – our impact factor continues to increase and now stands at 2.809\*, placing us amongst the most highly-cited ophthalmology journals.
- Coverage that's relevant to you – encompassing all aspects of the anatomy, function and diseases of the eye.
- Official publication of EVER and all five Nordic Ophthalmological Societies.

Members of  
EVER receive FREE  
online access to  
*Acta Ophthalmologica*  
as part of their  
membership.

Visit [www.actaophthalmologica.com](http://www.actaophthalmologica.com)  
for more information

\*2010 JCR, Thomson Reuters

**EVER**



[www.ever-f.eu](http://www.ever-f.eu)

*European Association for Vision and  
Eye Research Foundation*

# WORLD OPHTHALMOLOGY CONGRESS® 2012

XXXIII International Congress of Ophthalmology ® 2012

12<sup>th</sup> International Congress of the Middle East Africa Council of Ophthalmology (MEACO)

## HIGHLIGHTS

- More than **500 scientific sessions**, including symposia, case studies, courses and interactive programs.
- New special sessions, including the ICO Quiz, 3-D Stereotactic Anatomy Course, Ophthalmic Premier League and much more!
- A subspecialty day for Cataract, Refractive Surgery, Glaucoma, Retina, Pediatric Ophthalmology, Oculoplasty.
- More than **2000** internationally recognized speakers.

JOIN US  
[www.woc2012.org](http://www.woc2012.org)



Sponsor



Host & Organizer



Supporter





## KEYNOTE LECTURES

HOLDER G	> Wednesday, 17:20
PALLIKARIS I	> Wednesday, 18:05
COCHENER B	> Wednesday, 18:25
TRABOULSI E	> Thursday, 10:00
BELMONTE C	> Thursday, 15:30
SÖDERBERG P	> Friday, 10:00
DICK D	> Friday, 15:30
ALLIKMETS R	> Saturday, 10:00

Four digit numbers refer to oral presentations



Day | Timeslot | Hall | Order in session

Three digit numbers refer to posters



Day | Order in the postersession

ABU EL ASRAR A: 1345, 2211, 4235

ACAR N: 2212

ADEPEGBA O: 337

AGOROGIANNIS GI: 406, 4376

AHMADI-LARI S: 3473

AKHTAR S: 214, 413, 3131

AKKOYUN I: 3325

ALBERT R: 3136

ALIBRAHIM A: 215

ALMALIOTIS D: 212, 412, 2263

AMRANE M: 3123

AMSELEM L: 4161

ANASTASAKIS A: 271

ANDROUDI S: 1242, 4442

ANGI M: 4267

ANSARI E: 222

ARAGONA P: 3125

ARDAN T: 423

AREND N: 346

ARIJAMAA O: 353

ARNDT C: 2315

ARTIGAS VERDE JM: 256

ASCASO FJ: 268, 308

ASOKLIS R: 440, 4169

ATHERTON S: 2144

AUGUSTIN A: 4313

BAGDASAROVA T: 370

BAGGA RYM: 434, 3367

BALASUBRAMANIAN SIVA: 2374

BANAEE T: 4375

BANDELLO F: 4315

BARBAZETTO I: 3316

BARISANI-ASENBAUER T: 4144

BARRAQUER RI: 4335

BARRETT BT: 3251

BAZEWICZ M: 429, 3331

BECHRAKIS NE: 1266, 4265

BEHRENS R: 2162

BERNARDES R: 4115

BERTRAND V: 2252

BEUERMAN RW: 1222, 3231

BEUTELSPACHER SC: 2262

BLACK GCM: 2323

BLACK JM: 465

BOBORIDIS K: 1313

BODAGHI B: 1343, 2342, 3442, 4237, 4443

BOGDANICI C: 302, 2267

BOLSHUNOV A: 2172

BOLTZ A: 4124

BORRUAT FX: 3343

BOSCHI A: 3342, 3452

BOUCHENAKI N: 2245, 4342

BOURCIER T: 2153

BOURGES JL: 2371

BOUZIKA PS: 3324

BOYCHUK IM: 305, 416

BRAZITIKOS P: 4216

BREMOND-GIGNAC D: 401, 2446, 4171

BRETILLON L: 2112

BRON AJ: 4173

BRON AM: 2451, 4252, 4353

BRONKHORST IHG: 3364

BUGGAGE R: 4172

BUSHUYEVA NN: 307, 321

BUSUTTIL A: 1333, 4271

CABEZON L: 315, 430

CALIENNO R: 4371

CALIPEL A: 213

CALVO P: 236

CANADAS SUAREZ P: 420, 2175

CARR A: 2231

CARZOLI A: 303, 2268

CASANOVA C: 4321

CASAS P: 313, 318

CASSOUX N: 3461, 4365

CELLINI M: 345, 352

CHALKIA A: 2314

CHALVATZIS N: 1314

CHAPELLIER BC: 4373

CHATEAU N: 3175

CHIQUET C: 2344

CHO H: 234

CHO KJ: 421, 422

CHOI HJ: 211

CHUNG H: 469

CHUPROV AD: 3212

CIMBALAS A: 426, 4345

CLAERHOUT I: 2474, 3454

COCHENER B: 2271

COLLIGNON NJ: 2353

CORDEIRO MF: 3356

CORTINA S: 1336, 4274

COSCAS G: 4314

COUPLAND SE: 2461, 2465, 3462, 4263

COUTTS SJ: 451

CREMERS FPM: 2421

CRETU I: 304, 331

CREUZOT C: 2312, 2414

CSUTAK A: 357

CUNHA-VAZ J: 4311

CURCIO C: 4372

DAMATO BE: 1263, 3262, 3465, 4363

DAMATO EM: 435, 4162, 4341

DASTIRIDOU A: 3153

DATSERIS I: 3111

## PRESENTING FIRST AUTHORS

- DAULL P: 449, 3126  
DE BAERE E: 2322  
DE FRANCESCO S: 4163  
DE GROEF L: 3332  
DE KEIZER RJW: 438, 444, 4167, 4264  
DE LA MATA G: 270, 408  
DELAMERE NA: 3121  
DEL BUEY MA: 249, 411  
DENEYER J: 221, 4155  
DEN HOLLANDER AI: 2423  
DENOYER A: 2176  
DE POTTER P: 3344, 3451  
DESJARDINS L: 1265, 3264, 3466, 4362  
DETORAKIS ET: 1311, 3154  
DETRY-MOREL M: 3453  
DEWISPELAERE R: 3333  
DE ZAEYTIJD J: 363  
DIAKONIS V: 405, 2177, 2372  
DICK A: 1241, 1348, 2141, 3441  
DIGHIERO P: 1233, 1324, 3173, 4474  
DILLON JP: 3312  
DJABAROUTI M: 2363  
DOAN S: 2152, 4174  
DOBROWOLSKI D: 4374  
DODI PL: 247  
DOT C: 336, 2318  
DROBNJAK D: 349  
DUA H: 1231, 1235, 1325, 2473, 3272, 3371, 3472, 4241  
EGEA ESTOPINAN C: 251, 338  
EL CHEHAB H: 263  
ENGELHORN T: 3353  
ETXEARRIA J: 1337  
FALCK AAK: 4352  
FAVARD A: 202  
FAYZIEVA UMIDA: 4154  
FELIPE MARCET A: 255  
FENOLLAND JR: 242  
FERNANDEZ-PEREZ S: 443, 3214  
FERRANDEZ ARENAS B: 311  
FLATAU A: 2256  
FOELDVARI I: 4143  
FRANCOZ M: 417  
FRUSCHELLI M: 415  
FUCHSJAGER-MAYRL G: 4126  
FUCHSLUGER T: 203, 3145, 3373, 3475  
FUJINAMI K: 4422  
GABISON EE: 2155  
GAILLARD E: 3311  
GALICHANIN K: 2361  
GALLAR J: 403, 4176  
GALLEGO BI: 2134  
GARCIA M: 359  
GARCIA MARTIN E: 237, 325  
GARDIN A: 4451  
GARHOFER G: 3223, 3421  
GARWEG JG: 4445  
GEKA A: 342  
GEORGET M: 330  
GHERGHEL DOINA: 3352  
GANI A: 4312  
GICQUEL JJ: 1232, 1321, 2272, 2471, 3171, 3271, 4472  
GIL ARRIBAS L: 240  
GILLNER M: 258  
GINIS H: 3152, 4326  
GKARAGKANI E: 439, 4168  
GOCHO-NAKASHIMA K: 4111  
GOLDSCHMIDT P: 2343  
GOLNIK K: 1212  
GONZALEZ C: 339, 344, 2215  
GRAGOUDAS E: 3261  
GRAW J: 2221  
GRIFFITH M: 3374  
GRZYBOWSKI A: 2261, 2352, 2443, 2445  
GÜERRI N: 243  
GUPTA N: 3351  
HADJISTILIANOU D: 436, 4164, 4366  
HALDAR S: 332, 2216  
HALL G: 2321  
HAMEL C: 2424  
HAMMER M: 3315, 3422  
HAWLINA M: 2125  
HECKENLIVELY JR: 4426  
HEEGAARD S: 2464, 2466  
HEIMANN H: 4212, 4364  
HERBORT C: 1246, 1346, 2246, 4232, 4239  
HERMANS K: 3334  
HERRERO LATORRE R: 312, 329  
HOLAN V: 452  
HOLDER GE: 2324, 2441, 4223, 4423  
HOLLANDERS K: 3335  
HORWATH-WINTER J: 2334  
HOSIK H: 414, 418  
HOW A: 220, 4357  
HUGUET P: 2434  
IBANEZ J: 225, 233  
IDOIPE M: 356, 409  
ILMARINEN T: 2232, 3233  
ISMAIL D: 227  
JACKSON I: 4455  
JACOB S: 2164  
JAGER MJ: 2142  
JANBAZ CC: 3122  
JANKOWSKA-LECH I: 301, 316, 317, 2266  
JIMENEZ DEL RIO B: 250, 314  
JING W: 245  
JONAS JB: 333, 2126, 2217, 2351, 2413, 3221  
JUNG KI: 2253  
JUNGGIN L: 445  
JUUTI-UUSITALO K: 1224  
KAARNIRANTA K: 206, 1223, 2136  
KALFERTOVA M: 254  
KALOUDA P: 3213  
KAMMA-LORGER CS: 2171  
KAMPANAROU SA: 4411  
KAPETANIOS A: 3112  
KARYOTAKIS NG: 458  
KATSANOS A: 2257  
KAWASAKI A: 259, 1211, 2124, 3345  
KAYA S: 2316  
KERNT M: 453, 2214  
KESTELYN P: 1323  
KHAIRALLAH M: 1244, 2242, 4231, 4441  
KHAYI H: 306  
KIM NR: 210, 238  
KIM SJ: 228  
KIM SM: 350  
KING-SMITH PE: 402, 2335, 4175  
KISS S: 4211  
KIVELÄ T: 1261, 2163, 3463  
KLEIMAN N: 2161  
KLEIN JO: 239  
KLETTNER A: 2233  
KLING S: 2373

KNOP E: 2331, 2431, 3132	LUCAS RS: 2265	OBROSOVA IG: 3162
KNOP N: 2332, 3133	MACHALINSKA A: 3216	OCHIAI H: 246
KOEV K: 266, 419	MACKAY FREITAS A: 4117	OGBUEHI K: 231
KOHANDANI TAFRESHI M: 2365	MACKENSEN F: 4141	ONAL S: 2241
KOKONA D: 455	MAGURITSAS G: 4414	ORGIAZZI J: 3341
KONTADAKIS G: 410, 2174	MAHROO O: 4151	ORGUL S: 3222
KOOPMANS AE: 433, 3366	MAJSTEREK I: 264, 265	OSBORNE N: 2131
KOURENTIS C: 4412	MANGOURITSAS G: 4153	OSTADIMOGHADDAM H: 262, 322
KRASTEL H: 365, 4324	MANTOVANI A: 4234	OTIN S: 2251
KRESS C: 3255	MARKOMICHELAKIS N: 1342, 2243, 4236	PAIMELA T: 3135
KUDRYAVTSEVA YV: 2366	MASSON E: 454	PAJAUJIS M: 437, 4166
LABETOULLE M: 428, 1322, 2154, 2341	MATEUS C: 2123	PALKOVITS S: 4122
LACHAPELLE P: 4322	MAUGET-FAYASSE M: 3215	PALLIKARIS I: 252, 2367, 3151, 4327, 4331
LACHARME T: 457	MAVRIKAKIS I: 1312	PALSSON O: 4113
LAGALI N: 3474	MAY F: 230	PANTELIDIS E: 1315
LAGREZE W: 3445	MCGRAW P: 3252	PAPADIA M: 2244, 4238
LAKE D: 1335, 4275	MCNAUGHT A: 3423	PAPPAS G: 4416
LAM FC: 1332, 4272	MENASHI S: 2151	PAREL JM: 4333
LANDGRAFF OESTLIE I: 4142	MENCUCCI R: 3124, 3273	PARIKAKIS EA: 4415
LANGENBUCHER A: 257	MENDES-JORGE L: 209	PARK JH: 248
LANZINI M: 3274	MENDRINOS E: 369, 3114, 4215	PARROZZANI R: 4361
LASTA M: 4125	MENICACCI F: 2173	PAULSEN F: 3142
LAUBICHLER P: 335, 2317	MICHAEL R: 4334	PAWLOWSKI P: 432, 464
LECERF JM: 2111	MICHEE S: 459	PEIRO C: 269, 328
LEE AG: 1213	MICHELI L: 3361	PEMP B: 4116
LEE A: 2442, 2444	MICHELSON G: 3354	PENNOS A: 404, 2377
LEE MK: 241	MIDENA E: 4367	PEREZ G: 4325
LEE SU: 360	MILANO G: 219, 4356	PEREZ CARRASCO MJ: 463
LENCOVA A: 3144	MISSOTTEN G: 4262	PEREZ GARCIA D: 362, 447
LEONARDI A: 2433, 3443	MOE MC: 2311	PETROSKA D: 235
LEROY BP: 2422, 4222	MOISEEVA IN: 456	PETROVSKI G: 2132
LEVINAITE G: 347	MONNIER VM: 3165	PFRIEGER FW: 2114
LEWKOWICZ D: 217, 4156	MORGAN I: 2223	PINELLO L: 448
LI J: 319, 467	MOTULSKY E: 3431	PINILLA I: 201, 366
LIASKA A: 4152	MOULIN AP: 4261	PINNA A: 462
LIINAMAA MJ: 358	MOURIAUX F: 4268	PISELLA PJ: 2273, 3172, 4475
LIM KS: 3455	NAVEA TEJERINA A: 2313	PLEYER U: 1245, 1341, 2432, 3141, 3444, 4244
LIM S: 218, 4355	NEPP J: 2333	PODRACKA L: 208, 2137
LIM VSY: 446	NERI P: 1243, 1347, 2247, 4233	POSSEMIERS T: 3432
LIU CS: 1331, 1334, 3471	NIEDERKORN J: 2143	POURJAVAN S: 2254
LOCATELLI A: 267	NISSSEN C: 2264	POURNARAS CJ: 4214
LOEFFLER K: 2462, 2463	NOCHEZ Y: 2274, 4471	POURNARAS JAC: 2412, 3113
LOEWENSTEIN A: 341, 4317	NOWAK DM: 260, 2224	PRIETO CALVO E: 348, 407
LOSONCZY G: 261, 2225	NOWINSKA A: 4134	PUELL MC: 468
LOU M: 3161	NUBILE M: 1234, 2472, 3276	PUK O: 4452



- PURANEN J: 207  
QASHOU A: 4273  
RABENSTEINER DF: 2336  
RAFAT M: 4276  
RAMIRO P: 327, 367  
RASMUSSEN PK: 4165  
RAUSCHER F: 4224  
REHAK M: 4112  
REICHL S: 3372  
REIS A: 2122  
RIHA W: 4332  
RITTER T: 3143  
ROBIN A: 324  
ROCHA DE SOUSA AA: 450, 3326  
ROJAS B: 2133  
ROUSSEAU A: 223  
ROUVAS A: 3115  
ROUX M: 4453  
RUBERTE J: 4454  
RUBERTO G: 343, 4424  
RUDOLF M: 2113  
SACK RA: 2435  
SAMUDRE S: 460  
SANDBERG M: 4323  
SANDERSON J: 2255  
SATUE M: 226, 323  
SAW SM: 2222  
SCHALENBOURG A: 3265  
SCHMETTERER L: 3224  
SCHMIDL D: 4121  
SCHWEITZER D: 3313  
SCORCIA V: 3275  
SEREGARD S: 1264  
SIJNAVE D: 3433  
SIRTAUTIENE R: 351  
SIVAK JG: 3163  
SJÖSTRAND J: 216  
SMITH RT: 3314  
SÖDERBERG P: 3111, 3164  
SOKOLAKIS THOMA: 355  
SOUBRANE G: 4316  
SPILEERS W: 4221  
SRIVASTAVA GK: 204, 205  
STECH S: 340  
STEFANSSON E: 2411, 4243  
STEIN AA: 2375  
STRANG NC: 3254  
STRASSER T: 461, 4328, 4421  
STRATOS A: 253, 441  
SUNARIC MEGEVAND G: 2453, 4251  
SUZANI M: 371  
SUZUKI N: 334, 2218  
TADROS C: 354, 364, 2213  
TALEBIZADEH N: 244  
THEOCHARIS IP: 2135  
TOLD R: 4123  
TOTH-KOVACS K: 3211  
TRAUSTASON S: 3424  
TRECHOT F: 326  
TSIKA C: 3322  
TSILIMBARIS MK: 3155  
TSOKA PA: 3321  
UDZIELA M: 431  
URTTI A: 3232  
UUSITALO H: 1221  
VAAJANEN A: 224  
VAKROU C: 3253  
VAN BERGEN T: 3134, 3434  
VAN CALSTER J: 425, 4344  
VAN DEN BERG TJTP: 3174, 4473  
VAN DEN BOSCH T: 4266  
VANDENBROUCKE T: 4425  
VAN DER VELDEN PA: 3363  
VAN DE VELDE S: 3323, 3435  
VAN ESSEN TH: 2376  
VAN GINDERDEUREN R: 4368  
VAN OS L: 427, 4346  
VANTOMME M: 4354  
VASSILEVA P: 229  
VECKENEER M: 4213  
VERSLUIS M: 3362  
VILLAFRUELA I: 232, 368  
VISWANATHAN A: 2355, 2452  
VU THK: 3365  
WALKER C: 442  
WASIK M: 309, 310  
WEGENER A: 2364, 4242  
WILLERMAIN F: 1344, 4444  
WILLIAMS P: 2121  
WYLEGALA E: 4131, 4132, 4133, 4135, 4136  
XIROU T: 4413  
YANI A: 4351  
YEKTA AA: 320, 466  
YU Z: 2362  
ZANGWILL L: 3355  
ZARATZIAN BRILLAT ZB: 361  
ZEYEN T: 2354, 4253  
ZHANG JZ: 424, 4343  
ZIERHUT M: 4446  
ZIYATDINOVA O: 3217  
ZOGRAFOS L: 1262, 3116, 3263, 3464  
ZRENNER E: 4114

# AUTHORS BY COUNTRY

Australia .....	2
Austria.....	18
Belgium .....	35
Bulgaria .....	2
Canada.....	4
China.....	2
Czech Republic.....	4
Denmark.....	4
Finland.....	13
France.....	65
Germany.....	34
Greece .....	41
Hungary.....	5
Iceland.....	2
Iran.....	3
Ireland.....	2
Israel.....	1
Italy .....	28
Japan.....	2
Lithuania.....	7
Netherlands .....	12
New Zealand.....	1
Norway .....	3
Poland .....	11
Portugal .....	7
Romania .....	1
Russia.....	7
Saudi Arabia.....	3
Singapore .....	4
Slovenia .....	1
South Korea .....	13
Spain .....	43
Sweden.....	9
Switzerland.....	14
Tunisia .....	1
Turkey .....	2
Ukraine.....	3
United Kingdom.....	41
United States .....	31
United States Minor Outlying Islands .....	1
Uzbekistan.....	1

	Zeus	Artemis	Athens	Europa	Minos 1	Danae	Minos 2
<b>Monday October 3 / Tuesday October 4, 2011</b>							
ICO Residency Program Directos Course							
<b>Wednesday October 5, 2011</b>							
12:00 - 14:45	NSPH: The swollen optic disc: is it true swelling. What causes it and how to investigate it Aki KAWASAKI	ACB: In vitro techniques for ocular cell biology and tissue engineering Hannu UUSITALO Ulla AAPOLA	COS: Common corneal procedures Harminder S DUA Jean-Jacques GICQUEL	IM: EBO review course: Intraocular inflammation and infection (Part I) Bahram BODAGHI Carl P. HERBERT	PO: EBO review course: Diagnostics of ophthalmic tumours Laurence DESJARDINS Bertili DAMATO		
14:30 - 16:45	COS: Facial nerve palsy: anatomy, etiology, evaluation, and management Ioannis MAVRIKAKIS	COS: Corneal infectious diseases update Jean-Jacques GICQUEL Harminder S DUA	COS: Basic keratoprostheses Christopher LIU	IM: EBO review course: Intraocular inflammation and infection (Part II) Bahram BODAGHI Carl P. HERBERT			
Welcome Ceremony in ZEUS							
17:00 - 17:15	Welcome by the President EVER 2011 - Lene MARTIN						
17:20 - 18:00	EVER Lecture: Spot the difference! The electrophysiological differentiation of retinal fleck and spot disorders - Graham HOLDER						
18:05 - 18:20	European Ophthalmologic Heritage Lecture: The development of microkeratomes from the very early ages, with handmade and mechanical systems, until the fempto - laser technology today - Ioannis PALLIKARIS						
18:25 - 19:00	Keynote Lecture 1: Ocular surface and refractive surgery - Béatrice COCHENER						
19:00 - 21:00	EVER Welcome Reception						
<b>Thursday October 6, 2011</b>							
08:15 - 09:45	RV: Cholesterol and retina: news and views Lionel BRETILLON	MBGE: Functional studies of cellular & molecular dysfunction Seang-Mei SAW Graeme C M BLACK	ACB: Retinal cell growth, death and survival Airo URTTI Neville OSBORNE	IM: EVER/ARVO : Antigen presenting cells in the eye in health and disease Sally ATHON	COS: Corneal ulcerations: from bench to slit lamp Eric GABISON Serge DOAN	LC: Ionizing radiation and cataract Jochen GRAW	COS: Refractive surgery and quality of vision Ioannis G. PALLIKARIS Beatrice COCHENER
10:00 - 10:45	Keynote Lecture 2: Clinical and molecular genetic aspects of optic nerve hypoplasia - Elias TRABOULSI						
11:00 - 12:30	RV: Diabetic retinopathy Jost B JONAS Anat LOEWENSTEIN	MBGE: New disease genes & mutations Bart LEROY Marcela VOTRUBA	ACB: Cell biology of retinal pigment epithelium Hannu UUSITALO Kai KAARNIRANTA	IM: Uveitis: from practice to principles Carl P. HERBERT	G: Visual field and risk factors Anarith VISWANATHAN Thierry ZEYEN	NSPH: Free Papers Andrzej GRZYBOWSKI Aki KAWASAKI	COS: Refractive surgery for EVER Beatrice COCHENER Jean-Jacques GICQUEL
12:35 - 13:35	Lunchtime CIS - THEA - What's new in 2011 in antibiotherapy?						
13:45 - 15:15	RV: Surgical retina Catherine CREUZOT Constantin POURNARAS	MBGE: Update on ocular genetics - part 1 Bart LEROY Graeme CM BLACK	ACB: The eyelid margin – a fresh view on an important structure Erich KNOP Nadja KNOP Johannes NEPP	IM: Applications of PCR in infectious ocular disease Christophe CHIQUET Marc LABETOUILLE	G: Controversies in glaucoma Sayeh POURJAVAN Veva DE GROOT Andrzej GRZYBOWSKI	LC: Free Papers Lens Alfred WEGENER Ralph MICHAEL	COS: Keratoconus and corneal grafting Jean-Jacques GICQUEL Jean-Louis BOURGES
15:30 - 16:10	European Vision Award 2011 lecture: From comfort to pain: neural basis of ocular surface sensations - Carlos BELMONTE						
16:15 - 17:25	Poster Session 1: Anatomy/Cell Biology - Glaucoma - Lens and Cataract - Molecular Biology / Genetics / Epidemiology						
17:30 - 19:00	RV: Macular edema in vein occlusion Catherine CREUZOT	MBGE: Update on ocular genetics - part 2 Bart LEROY Graeme C M BLACK	ACB: immunology and inflammation at the ocular surface Erich KNOP Robert A SACK Nadja KNOP	NSPH: Controversies in neuro-ophthalmology and pediatrics Andrzej GRZYBOWSKI Dominique BREMOND-GIGNAC	G: EBO review course: How to begin with the glaucomas? Alain BRON	PO: Crash course in ophthalmic pathology Sarah COUPLAND Karin LOEFFLER Steffen HEEGAARD	COS: Management of conjunctival cicatrizing diseases and severe ocular surface dysfunction Harminder S DUA Jean-Jacques GICQUEL

	Zeus	Artemis	Athens	Europa	Minos 1	Danae	Minos 2
<b>Friday October 7, 2011</b>							
08:15 - 09:45	RV: Anti-VEGF agents for various ocular pathologies Constantin POURNARAS Efstratios MENDRINOS	PBP: Anterior chamber Nicholas DELAMERE Gerhard GARHOFER	ACB: Anterior segment anatomy and therapy possibilities Erich KNOP Tanja ILMARINEN	IM: Immune modulation in corneal transplantation Thomas FUCHSLUGER Uwe PLEYER	G: Ocular rigidity and hydrodynamics of the human eye Anna DASTRIDOU Ioannis G. PALLIKARIS	LC: Ocular oxidative stress Per SÖDERBERG Marjorie F LOU	COS: Wavefront aberrometry and quality of vision symposium Jean-Jacques GICQUEL Pierre Jean PISELLA  ZEUS
10:00 - 10:45	EVER-Acta Lecture: Clouding lens, swap or stop? - Per SÖDERBERG						
11:00 - 12:30	RV: AMD Anita LEYS Gisele SOUBRANE	PBP: Vascular aspects of glaucoma - what to look at? Leopold SCHMETTERER	ACB: Cell biology of ocular surface Hannu UUSITALO Roger BEURMAN	CONCORDIA: Standards and criteria in academic ophthalmology in Europe Marko HAWLINA	VEP: Binocular vision & stereopsis: Why two eyes are better than one! Franziska RAUSCHER	PO: Complications of intra irradiation treatment of intra ocular tumours Leonidas ZOGRAFOS	COS: Update on techniques in corneal and ocular surface surgery Mario NUBILE Jean-Jacques GICQUEL
12:35 - 13:35	RV Irene BARBAZETTO	MBGE/ PBP PBP: Intravitreal treatment Miltiadis TSILIMBARIS Neville OSBORNE	ACB/ VEP FRO - Belgian Fund for Research in Ophthalmology 1 Philippe KESTELYN	IM/ NSPH NSPH: Update in Management of Graves' orbitopathy Antonella BOSCHI Aki KAWASAKI	G G: Eye and brain in glaucoma Georg MICHELSON Doina GHERGHEL	LC/ PO Theodora HADJISTILIANOU Martine J JAGER	COS COS: Cell therapy in cornea - Moving towards individualized treatment Thomas FUCHSLUGER Harminder S DUJA  ZEUS
13:45 - 15:15	RV: Imaging retinal fluorophores: autofluorescence and beyond Irene BARBAZETTO						
15:30 - 16:10	Ophthalmic Research Lecture: Road to fulfillment (not perdition): taming immune response to restore vision - Andrew D DICK						
16:15 - 17:25	Poster Session 2: Neuro-ophthalmology / Strabismology / Paediatric / History / Retina / Vitreous						
17:30 - 19:00	PBP: Retinal oxygenation and blood flow Sveinn HARDARSON Gerhard GARHOFER			IM: The new decade: immune modulation in eye diseases Uwe PLEYER Andrew DICK	G: Secondary glaucomas Sayeh POURAVAN K. Sheng LIM	PO: Management of small choroidal melanocytic lesions Laurence DESJARDINS Tero KIVELÄ	COS: Corneal bioengineering Thomas FUCHSLUGER Christopher LIU
<b>Saturday October 8, 2011</b>							
08:15 - 09:45	RV: Retina Eberhart ZRENNER Irene BARBAZETTO	PBP: Blood flow Leopold SCHMETTERER Gerhard GARHOFER	COS: Optical coherence tomography applications in anterior segment eye diseases Edward WYLEGALA	IM: Pediatric uveitis and arthritis: impact on vision and life - life long! Friederike WACKENSEN	G: Surgery Alain BRON K. Sheng LIM	PO: Pathology/Oncology 2 Steffen HEEGAARD Karin LOEFFLER	COS: Cornea and ocular surface - inflammation 1 Dominique BREMOND-GIGNAC Anthony J. BRON  ZEUS
10:00 - 10:45	Keynote Lecture 3: Genetics and treatment of Stargardt disease - Rando ALLIKMETS						
11:00 - 12:30	RV: Retinal detachment surgery Constantin POURNARAS Efstratios MENDRINOS	VEP: Doctor I can't see in the dark Graham HOLDER	IM: Angiography and fundus imaging in uveitis: principles & practice Carl P HERBERT Moncef KHAIRALLAH	IM: How to get your work published? Uwe PLEYER Harminder S DUJA  IM: Uveitis Award Ceremony Manfred ZIERHUT	G: Cataract and glaucoma surgery, combined or not? Thierry ZEYEN	OOG Presentations 1 RWJ DE KEIZER Nikolaos E. BECHRAKIS	COS: Keratoprosthesis update Christopher LIU
12:35 - 13:35	Lunchtime CIS - CROMA: New advanced technologies for ophthalmic applications RV: CME: Pathogenesis and management Gabriel COSCAS Gisele SOUBRANE	VEP: Free Papers Werner SPILLEERS Miguel CASTELO-BRANCO	LC: Restoration of accommodation Rafael I. BARRAQUER Ralph MICHAEL	IM: Ocular immuno-infectiology from basic science to clinical challenges Piergiorgio NERI Carl P HERBERT	G: Imaging Jost B JONAS Fotis TOPOUZIS	OOG Presentations 2 Eduardo MIDENA Nathalie CASSOUX	COS: Cornea and ocular surface, inflammation 2 Harminder S DUJA Mario NUBILE
15:20 - 16:25	Poster Session 3: Cornea / Ocular Surface - Immunology / Microbiology / Pathology / Oncology - Physiology / Biochemistry / Pharmacology - Vision Sciences / Electrophysiology / Physiology Optic						
16:30 - 18:00	RV: Retinal detachment complications Elias FERETIS EVER General Assembly and Prize Giving	VEP: ISCEV Session Graham HOLDER	The EVER f - How to promote it, how to work for it Harminder S DUJA	IM: Virus and anterior uveitis Manfred ZIERHUT Sofia ANDROUDI	The Vision Screens in the European Mouse Clinics Jochen GRAW	OOG : Business meeting Sarah COUPLAND	COS: The optics of the tear film Jean-Jacques GICQUEL
18:00 - 19:30	EVER Farewell Dinner						
20:00 - 23:00							

# THANK YOU SPONSORS

EVER wishes everyone of its past and present sponsors good future for the coming years and thanks especially the following companies, many of which are our long-term supporters, for their generous sponsorship in 2011. Thanks to their kind support EVER can continue to encourage research and dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information.

## SIS sponsors



## CIS sponsors



## Exhibitors

